var title_f41_24_42368="Hypercalcemia tutorial";
var content_f41_24_42368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypercalcemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 107px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A short QT interval (&lt;0.36 seconds), primarily secondary to a decrease in the ST segment duration, is characteristic of hypercalcemia. The initial portion of the T wave has an abrupt upslope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42368=[""].join("\n");
var outline_f41_24_42368=null;
var title_f41_24_42369="Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)";
var content_f41_24_42369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/49/12051\">",
"         Patient information: Vasculitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/54/42852\">",
"         Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Polymyalgia rheumatica and giant cell arteritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/polymyalgia-rheumatica-and-giant-cell-arteritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H561015492\">",
"      <span class=\"h1\">",
"       What are polymyalgia rheumatica and giant cell arteritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Polymyalgia rheumatica is a condition that can cause stiffness and aching in the shoulders, neck, and hips. Sometimes it also causes swelling in joints such as the knees, hands, and feet. It usually occurs in people age 50 and older.",
"     </p>",
"     <p>",
"      Giant cell arteritis is a condition that can cause headaches, trouble seeing, and jaw or arm pain. This condition affects blood vessels, usually in the head and sometimes in the neck. Blood vessels in the brain are",
"      <strong>",
"       not",
"      </strong>",
"      affected. Giant cell arteritis is sometimes called &ldquo;temporal arteritis&rdquo; because it often affects a blood vessel in the temple on the side of the head.",
"     </p>",
"     <p>",
"      Polymyalgia rheumatica and giant cell arteritis are two different conditions. But they often occur together. Usually, these conditions last between one and three years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H561015499\">",
"      <span class=\"h1\">",
"       What are the symptoms of polymyalgia rheumatica and giant cell arteritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms of polymyalgia rheumatica are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain and stiffness in the shoulders, hips, neck, or upper part of the body that is usually worse in the morning &ndash; These symptoms occur on both sides of the body and last 30 minutes or longer after getting up.",
"       </li>",
"       <li>",
"        Swelling and stiffness in the knees, hands, wrists, ankles, or feet",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The most common symptoms of giant cell arteritis are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headaches &ndash; The pain is often over the temples (sides of the forehead) but can also be in the front or back of the head. Some people also have pain in the scalp when it is touched.",
"       </li>",
"       <li>",
"        Pain in the jaw, especially after chewing or talking",
"       </li>",
"       <li>",
"        Pain or weakness in the arm, especially when you move your arm",
"       </li>",
"       <li>",
"        Trouble seeing clearly, or trouble seeing out of one eye",
"       </li>",
"       <li>",
"        Cough (that is new) or sore throat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms of giant cell arteritis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H561015506\">",
"      <span class=\"h1\">",
"       Are there tests for polymyalgia rheumatica and giant cell arteritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects that you have polymyalgia rheumatica or giant cell arteritis, he or she will do an exam and order blood tests. He or she might also order an X-ray, MRI, or other imaging test. Imaging tests create pictures of the inside of your body.",
"     </p>",
"     <p>",
"      To check for giant cell arteritis, your doctor might order a test called a biopsy. During a biopsy, a doctor takes a small piece of a blood vessel from under your skin on the side of the head. He or she then looks at the tissue under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H561015513\">",
"      <span class=\"h1\">",
"       How are polymyalgia rheumatica and giant cell arteritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Both polymyalgia rheumatica and giant cell arteritis are treated with medicines called steroids. (These are not the same steroids that athletes take to build muscle. These steroids reduce swelling and ease pain.) Many people feel better after taking their first dose. But most people need to take steroids for one to two years.",
"     </p>",
"     <p>",
"      Steroids can have side effects, so your doctor will want to make sure you are on the lowest dose possible for the shortest amount of time possible.",
"     </p>",
"     <p>",
"      Doctors might also prescribe other types of medicines for people with giant cell arteritis. For example, most people with giant cell arteritis also take a low dose of",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      every day to prevent vision loss or a stroke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H561015520\">",
"      <span class=\"h1\">",
"       What else can I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all of your doctor&rsquo;s instructions about treatment and follow-up. For example, if you have giant cell arteritis, your doctor might order a test called a chest X-ray every year to check the blood vessels in your chest.",
"     </p>",
"     <p>",
"      It&rsquo;s also important to let your doctor know if you have side effects from the treatment or if you develop new symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H561015527\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=see_link\">",
"       Patient information: Vasculitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=see_link\">",
"       Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/24/42369?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15532 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.243-7F1A92C927-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42369=[""].join("\n");
var outline_f41_24_42369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015492\">",
"      What are polymyalgia rheumatica and giant cell arteritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015499\">",
"      What are the symptoms of polymyalgia rheumatica and giant cell arteritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015506\">",
"      Are there tests for polymyalgia rheumatica and giant cell arteritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015513\">",
"      How are polymyalgia rheumatica and giant cell arteritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015520\">",
"      What else can I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561015527\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/54/42852?source=related_link\">",
"      Patient information: Polymyalgia rheumatica and giant cell (temporal) arteritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/49/12051?source=related_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42370="Patient information: Allergy skin testing (The Basics)";
var content_f41_24_42370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86636\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/23/20860\">",
"         Causes and symptoms of common allergies",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/31/41457\">",
"         Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/57/29586\">",
"         Patient information: Epinephrine auto-injectors (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/42/25250\">",
"         Patient information: Insect allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/38/37474\">",
"         Patient information: Seasonal allergies in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/10/13475\">",
"         Patient information: Seasonal allergies in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/27/5553\">",
"         Patient information: Allergic conjunctivitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/8/41092\">",
"         Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/37/22098\">",
"         Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/38/32354\">",
"         Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/47/29429\">",
"         Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/35/35379\">",
"         Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/40/5764\">",
"         Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/30/28134\">",
"         Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Allergy skin testing (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H553618799\">",
"      <span class=\"h1\">",
"       What is allergy skin testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Allergy skin testing is testing that helps your doctor figure out what you are allergic to. Doctors use 2 main types of allergy skin tests. The most common is called a skin prick test. The doctor puts a drop of the substance you might be allergic to on your skin and makes a tiny prick in your skin. He or she then watches your skin to see if it turns red and bumpy. If that happens, it usually means you are allergic to the substance.",
"     </p>",
"     <p>",
"      If your skin does NOT turn red and bumpy, your doctor might still think you could be allergic to the substance. If that happens, he or she might inject a tiny amount of the substance under your skin. This is called an &ldquo;intradermal&rdquo; test.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H553618814\">",
"      <span class=\"h1\">",
"       Why do I need allergy skin testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might recommend allergy skin testing if you have symptoms that seem to be caused by an allergy. The Table shows common types of allergies and their symptoms (",
"      <a class=\"graphic graphic_table graphicRef86626 \" href=\"mobipreview.htm?20/23/20860\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      If you know exactly what is causing your allergies, you can avoid the substances and choose the best treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H553618848\">",
"      <span class=\"h1\">",
"       What happens during skin allergy testing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might tell you to stop taking certain medicines (such as allergy medicines) for up to 1 week before you get an allergy skin test.",
"     </p>",
"     <p>",
"      The pricks or injections are done on your arms and sometimes on the upper part of your back. This is not painful, but small children might find it upsetting. You might get tested for a few different substances at the same time.",
"     </p>",
"     <p>",
"      If you are allergic to any of the substances, itchy red bumps usually show up in 15 to 20 minutes. The bumps go away within an hour or so.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H553618863\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/38/37474?source=see_link\">",
"       Patient information: Seasonal allergies in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/42/25250?source=see_link\">",
"       Patient information: Insect allergy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/31/41457?source=see_link\">",
"       Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=see_link\">",
"       Patient information: Epinephrine auto-injectors (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=see_link\">",
"       Patient information: Seasonal allergies in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=see_link\">",
"       Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=see_link\">",
"       Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=see_link\">",
"       Patient information: Allergic conjunctivitis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/37/22098?source=see_link\">",
"       Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/38/32354?source=see_link\">",
"       Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"       Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/24/42370?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86636 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-1E1E8CC54B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42370=[""].join("\n");
var outline_f41_24_42370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553618799\">",
"      What is allergy skin testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553618814\">",
"      Why do I need allergy skin testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553618848\">",
"      What happens during skin allergy testing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H553618863\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/23/20860\">",
"      Causes and symptoms of common allergies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/31/41457?source=related_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/27/5553?source=related_link\">",
"      Patient information: Allergic conjunctivitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/8/41092?source=related_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/38/32354?source=related_link\">",
"      Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/42/25250?source=related_link\">",
"      Patient information: Insect allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/38/37474?source=related_link\">",
"      Patient information: Seasonal allergies in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/10/13475?source=related_link\">",
"      Patient information: Seasonal allergies in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/40/5764?source=related_link\">",
"      Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42371="EUS microcystic lesion";
var content_f41_24_42371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS image of pancreatic serous cystadenoma (microcystic variety)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WooooAKKKKACiiigAooooAKKKKACiiruj6Zf6vei00qyub26Ks4ht4zIxVRknA5wAKAKVPjRpHCxqzt6KMn8qFXfnAzgZrqPDtpHPqNvHGfJmjw6f7aEc5/GgDmViIJL8FTypHNOw5SIKoHUD3zXRa5p6PfTtgxyLlXA4wR0P41kRQlIBMVBcNgxt6LycUAZ7KVYhuD/ADpv1rprvTjd6batZxo/lLyeckehrKbTJtjybVCqx3LnkDHWgCvZW4uJRGzbC/CHtn0pl3by2s7wzptkXqKv3VjJZSRg7pISQ5we/rU6XNteyBNRLmFE2rOo/eIc9T/eFAGHRWrqejXNlH5yAXFmwBE8XK47Z9DWVQAUUUUAFFFFABRRRQAUUv8ADWxY6bEsQu9XdoLVeVQffm/2VHb6mgChZ2c11vMafukGXkb7qj61WYAMQDkDjI71ta5q51DZBaQR2ljGCIreAED6sf4m9/yrIWCU5Plvgd9tAEdKCR9O9OKEthR1q/pNis80ck5zApzIF6gCgDOIwORg9fwpK1rmB7rVD0UtllTHAUdBWcwZn3bQD6dAKAIqKeEJB657YpGG0sB0oAbVhXDKA3QVLrGmX2kXn2TVbK4sroKrmG4jKNtYZBwexBzVZelABJjOcVHUrjA5qM0AJRRRQAUUUooASilxSYoAKKD0pKAFooooAKKKKACiiigAooooABRg+lSW0ZmnjjUgMxwCegrat7O3jlUlTLG0DNlz/EDzigDFEDmMuVwoxn1rUikl0m+jk0y8ube5KY3RSGNsHgruU5wQTmpLspc3A2sGztfbjHy/SpLS3iuNRkgl+WUZ8s9Ny9etAFibTs2tre20GAwMUyY6ehHtSQrNaz6fLIABC6qWXqR71f067Frb3O3zJYUOxgw6jtj6VHZxy3N1dxOcAISiPxkEcUAdTdWRu7d2kEIuHYmKYfxjrtNcnPFbxanGWiM8Mn31XrHkc8UttrYt7ZY7rzWtydvBwYXXpxTZWtP+EgTzNyrIu9pI3xuP9AaAN/RdRi0bUHm014Z7SSLMtrJwQq8Ej8P1rd1PTrC7sNT1fTvs4WRg01g64Ozb98Ec1gfZjo9lK8saG2mXfazxuHdSx6H2rU0+4OqWtzcySLHexxqhhwB+66FuKAMUW0l5pDm0mj2udogc4Dg9ByM9axdStbRbOCzltGj1BSd823aoI/g9xXVRD7fcCzjVdrEsjyfdIC54IqKwsDLqrC4VJV2CUK0mA204Kgn1IHuaAOYiXUtBEcjSNDBMgw7HfH9MCtQQeHNdtjLNG2mXa/K8sY/cM3qMfnzVq8SytL3bHZzbZJQ/ks+RFk9j0/Cqmp6XdW1nJPpkpVJLgpLAxVlGemF7UAZN14O1AMTYNFew43CSJs5FYVxYXdszLPbTIV65Q11WmaTqMqAaZbt9oCbxMsrRK3PO0HhsZGcdO9aFjqOq27T22pT6gbtePLa2WRfxPp70Aeec9xSqjN91WP0Ga9BFrrN3MHn0/TmC/cE1ttLA9DxUFtqd5aytHcppdlChwTHbE5PsaAOTtdJ1C5ZVgsp2JOAdhAP4mtYeGfsoMmtX9tZRg/cDeZIfoBWjrOq6pevFAtzcDBJjKsqLn1OO2K565llVoYAqSuuSXI3b2PXmgDUjns7Vlj0ayYyjhru8HP1C9uKzbiF5L2RtRug2w/PJnccH0wamSymuVmIadpkAWQnlQdp447Vcv7eyVVWJEMluMyIo4kyvagChDDaSyr9mWQTmXCDO1VA7n3NaE9pcPfxR3MciQBiIeC7FcdBjgjvV/SIBb2cd3cQLGjxKshMZZF+bhj711uj2ontElurwQW8OUtxIFDyZ7AZ4GO9AHnMFnDDcmK+jkFqS0i4U75ccAYHSrvh7w9d6xceTYny2d90mW+VEHY1qXtmU1WS1sreZpCWHm+YfKYjk/Tt+VdRrV1pXh7wfBoem3AXVZV33k4bqSD8oPp2oA88u1Ed3qcqIojgzDC+cDINY9xbSW4jMhy0iE4PGPeui1NAmmabbxBg07ruyucgex649az9UiN9Jd3BR8Qt5a88YHfP9KAKccCpbRzbt20E8d6qCPCv5xwwxhT/Fz609XaJHjZzvbA+XkFe9WIrUS20QJ4LE7j+lAFfUr24v75pr+6nu5cBPNnlMjYAwBk84A4FQRMobLdPSmOhV2U9jimUATuyl/vYQHpjmoT1o60UAFFFFACrgsATgetHHFJRQAtFN5o5oAccYpKSloAKKKKACiiigAHJpwQnuMfWmjqK2fDmsnRrqaaO0sLtpraS22X1uJkUOMblB6OOx7UAY+04z2p0S/MO+ePxqV4yLcPjodpNLFubzF243jcD6GgCSLCXEDvjbu9OhFbenRPNYXMNuoM6yEpnoVb/9VY8LpIkChsTebgg9Dk81t2MoivHETgsh+UA8jnpQAmgwBtTR7siKaEmNkx94Y7VpXVnbPII3fybiCUGNx1IPY+1TXn2Wa+W6VWYhssMcj1rQeTT7W8eabElvIFLMBlo27H3HrQBnwwPC97byw7LaZS0cpORn1rH1GO5VIlHNzHgEqOWA5B+nNdXdhlt91pGswY5ZV6MD3HpUNvZXM4S6higEwQrCkj4JI6qD2+lAHPX5guoUjnULPODsZF4LVPoOi2d611aXkzR39vh41ZSFkGOmD3p2qSPdW4umjW1vbT948CnGQDgkV1vhtnnhe7uU+1wXMO2RgPnhORgjPtQAlpp8MUJstVtIpAqlIpVyvlD+Ele/NV0W98O2zTQNi4FubffMFdHUnPQiruuWNvCZmkQTNMi7DvPJHPHPFVdQuxNarEbOe4ZVDmMuWMa99vrmgCPRNWlvLu2crFZXpJSOTy9oA7jbjj61orpmm3guFvYvNmgmZ9+8hGzj7nq2a5i6E0Vs97a3k8Ns7BYIZyu7B689eMVU0i8N3qaw3Es8axx/I24gMfUdgaANO9hgfTrtrKC5S5BDNuA+Vs/zqtDE4s5LmXV1jlTcitjl2x1x61Y0m+ijkNtfzyi5jPnZX5gTnHzYrode0mGylQX0X2m6kQMXVQgUMcqAOgoAfqHimHWvCelQLo8VoVBzHt8uGx/eBiLIhiwMwz52/PJ4rmTDYSH7ZJJf6ZcZCb4mLO3bBHpWtJo1tEZ8TS+ezeYgiYFVHHHtyTz7VM3grUdTvwsV7BPAp2q0sgBBI+8GHXHoaAMKe8+ytJcT3V6Sr7A4XdhQcZUE8dahnulurhVh+z3PykKxGHIPcjoTmtfVdAe2QW00zSyQru3o23cN3VvY8/lWrZWdu0ckMzw2m1wzMkO8lQM5VvQ0AcTa6O11eRpHaXKqUaMvuIDnnJGewqjBpHlP5TI+8Njy5CQMjk4PXkV6nHbTTaXBdW6peSIZGW1kBDtGT2x09c1NLZ6DIg1K7W1u9QlHlpawhiMg/d9uCaAPPNG8L3xkuN2+0KDzU29DkdD61HpdlLPcrHC/ki3UqzsAAw5zzjJ6GvQNRsZ9RuUmlhhsmjwsNqxJQjpwaofYYmheNbq1WYZRfKJMr446HoOvI9aAKFlpF7a6aVPyafLIPLPmfNIOpIHORTLrT7JLwX9xMJ4hjbEpIYrjnHYGn2kbfZJWmlFuwk8tH80ssQHGCD0NPh0bUZ95IdtNjALvkbpCehoAzYIEvdXFjaPcIRFl1jO7Yh5wSce3Nb1lpOnWEkJ1K2BTyt0RZxI7v6Z7Cnw3un6c81ppVncM1ymJZ5MA7sY2qew+tZum23/EyeD91OwjxsEv+pwOSQev8qAOb8QQ3FxqMEtjuReUBdgSoz0B9Kxby4YsLVC0du3Lbj94jr+deg2+iwzTtBNGiyeWZQxYkhM557CsjXLiwFzCbSJOeI8IPkC/xfnQBy1pa5vooXtpIpCN20jJxVfVswq4zzvKKF4CY7fWttZ/7Mur27lZhdSKVXec4Y9xXLzOJkYPMcKcnI5ZiTzQBVz1ycn1plTYMnOCAFyOOtRHJ980AKoyetAODSdDRQAUUUUAKRg44/A0la3iPW3126gnks7GzMNvHbBLKAQowQYDMB1Y9z3rJoAKKKKACiiigAopWXaRmm0ALRRRQAU7dxjGOcikVc9OtWIYHmJjCjeozg+lAFu1j8ybynOY7heGHTdUH2WaGcRyMVIO3r0pbWYxoYyvKNk+oq1dO1zi4jAIGNwzyce1AFa5tfLCMCS+Svy9j2NbDxRo0dy64EpVSynBVu+fSn3Fgk0VzHE5DlRPEegbjkZo8qQ20MiF1jbAlXb8repoA1mma1v4ngXec7gCM71x6f1q3NEs9huVTBC8mYXX70bdx+NN8L211LqccDRtJCmfILNzt/u1systvqStBsks94BjbqrZ6H0POaAMSxdYJU8p3lfzNriM/c+o9K6jwnHaTre2OqsDvffFIhOEYnA+nSsi40e3bVprqxw1zGxH2djgsO4+tW9KH265jkihAZ2McsSf6xcdM/SgCnqnhgpdSXSyyXjxv5bQtwyKe2f4geuaZY3qxQyN5aR2sq+UYMk47E+3rWvcJIfECWzJM87oPljzHIcdOO/FacBure2MdisFxZykh5JFAkgfptdeo+tAGPqMcVvHHHDaKfsoEqucuSpHWoIPOvFe6unLW0afJGp2kccnjk/StO6ttSUTht7ztHtjFvyHTOf0qneyJ/YlqmoW7x3cDg+ZbSYZ1JxhvegDmNVtrISzfZNSiuFZjuQqcxnsAM1mSX7LGmn3iPErHcZRgMp7AH0roTpF9G0x077K9tbhnDzjDMD6n2rFk0q7uNZNtdQwbZVDqqSfKwx2PegC++v3C2FvbW0Nn9tgBWRwNrSxnoCe56Vrw6jfae7xyvHeSSqFQSyAuwxx1Hbp1rnrKJbe/d3sw9r5nlMVGTHt7c/zqKR4EuJcRSXVo5DeYwP7g5/OgC9NqQtIla5gMaTNtmQEEBe4z7kipbjWljgs5rWKSK2UFYxGpQB+y57/AFpYbe1nmgWcqjRsFkRDjd3DYPUVqabb2ctxLZavc3qbJi8KqAQB2bHpQBmzalBHrCNcy3USSRqgkJJyuPu46YyWFa2nOzIFaaR3875ADjC9gc+vpWodD0cXTKdUe7tSudsihSvGQRn3zTdP07w/FLEHu5FZJDI6NISkh7MD7elAFPTbr7Vrtythe3k155LbYoG3YHPQD+VadzqWr6TDZmee2jQnmTycENt75wcnvUFvPpOnXb29vHPAFlLC5QkP8w4Ckc461UvfE1rc6gkF9pRWbG6S5uMjODgEA9T7igDKOtNqM08t1eStcyuFWBfkyAeuD2966iL+ytNgF1qFqLW7t7cCOR5NwdmwMbxxj2rIu1sUnEkkKT3tweSF3KOcjCjnHFULS2TVdSjsVv5DFKxIQE4THTjHFAGpHL9qmuL5YrWSJ/kjUA4cjrxn9aXUZ7aJYZ/PEaDcZ7dn4yPujBNbevaHo3hGzgh+1XFzqkkZaNc52Z71xQW01A4e+lN2DulBjK9Oy+tAGjPcb7mNoYEuTMeCgH47z2AqNp47C3lkigh85WKfKjFmJ7Zx0qLyzZXELvEltCcsEnyd2TyzY6fSpzex3+ppBp0iywzuJLg7TtQDptJ7UAWZdXMulSaPFHJc3E21ZWQDCr3Bb+lYMOmzz6ul9NF5NraqUMQU7VUZwAe5Ndvp9lEzz2FvqMFhaxEtPd+Tt3Z5K7mrK1WaSaKS10KMy28cnmLPL/y3YcgKPqKAOH1lAkEwMU0tyJdzMUOAx7D8KxZLaOWMTAFlxtGB99vau91PQbk6fBd6ndzYmYLKFGAGzk8+vasHTtOTU9WnSEOunRkhpMYVB6A+poA5SeTzHwwKrEmwhTnmqnQBuma6jVLW1F4Y7W18qyhTq2cyN71lSQEGWWVBuC/JGB0oAznQgKxIy3OBTKnaMxn51xKRkL9e9QUAFFHaigAooooAKKKKACiilRQx5OKAHSMWbk5I7+tMooxxQAU+KPzHCjgnpmmVInO3Bww6UASRR7lkjGBIORz1qa0ZwzXCN88Y+ZT3FJAqteBThWByDnvVi8tJobxti8SKSmOjD2oAdKFlv454cFJU3EenqKk1C3hRvMt2ZZtu7C96r2dlMVeVOJY23NHjtWpGkjXtqylT5ZyV9QeooAuaTZNd28rFiYjENuOqccirOnNLb6DNHGySRNkqDyRjqB6Vev7U2rRTWLmNXyjK3FUPsreQXlCwzRtgqGwJKAOr0eG6j0Oy1G02eZGwLCU7Tt74PrVLxNNPa6lLNGu+1uyMqF6nv9Grp9NlXTtGhslAnilXDRzcZz1571yuos2kXTzRhrjTZhh4yclMf1oAki1uOV3ubd4pJVQKzEYZlHG4+hA4xV67JsWXVtskN04HkyQx7lk9M+hrnrqW2aS0uLC1yJmIEg+RkbHQg8fnXTWsmonTrSKa1L2yMTLMFJKj3A5H1oA0NX8STeILXT7e7s0XUogGjvYQVI98/wBKxRrA/t9HmvA8zL5c0TJjzMdx612MOpW1pYW0cs6TWrNgOkQyxz90N3rF8a2OnQ3kUXluYV2zQXgTLJ7HFAF/U47Sc2r6Pc3KvNHtSOQH90R1we1ZlxHFPOZLJwzcedC5O6NwOTz1BqlYeJLqKb7E8iyqZCfNyAVXsRVyS3vMzm5vIJIj+8jZZQZh9MDBAoAwb6x1FLee6uUuJ3GQ3lxn5k3fxAegq/ZnSdZt2gTT9tzGgkjvQ21k45G3tUlzFcS6XLe2mqXM8smQI0fYrgDHzZ71yVtevDIWMz20rKEMO4BmYd/egC3rd9dpfIlujSQ52uyLuRzjv6GpLcW5kN5a27x79qOi8MR/EMHjFOm1sXMaR3aRu8RVyM+UXyODWtod7Hp0slrewSjzAZVfZv257BuhFAGY9pbmFZY7WW4jEuBK+AUXP3MDnjPWujsNCt5khktNTjRyAZt0Rl2oOxPbiop5rNp0ls4llkcbFmkbapPUhlH86j1K7kit28iyiieRAQ1vKAFX3U8UAaMumtdQzTJf2EwgOIUhQBWTHAIbk5/CkS+sVsQrW72cxxE8LhVjJ7nPbjNZ1nHc36XF7fQWUUIjC4T72RjBx39zU9hNZyiST7fYNN5m1reS3JJ4xkE9aAIor2KSRxZW+J0BU3LPvXg8EnGKy9RW9urfzri7kuYLckN8mSq+v09KuvNFdzXFpYXMbrMf3sSI2Ex3OB7VattO1Cazna/mWO2t9qgBfkcZzjb+XWgDO0y5uYtl/GksFo6+WZlKl5MegIyPwqxp2oyxC6s1lGnRyAvmJPMmc57t2qXVYEicHEskjKPLO3Zsb0HPFc/DqNzFaSxafbTSsozIY49zD6noKAGy2mo3EkN5JACIwSzXMvzdflxz1p9td3cmo21vHZILhVwwQ5IY9Gz0FY8kkgvYWnupl3D96GG7d7YFdXaLDC8cMO+KJhzGRvZz6luuPagCr/ZVpbu/9qX832uc/LGp3F3PoOf6VL4esdXkWVLWIHT7Zy0k+NinHO3J647gUt9pNtpkTTGO2HzeaH3nLAf3e9Wr3WLnUUjhkkuFsVj/AHccGR1HQAd/egBieIJNduTJcQvNDFwuI9sDdsn1q1qWnRJbJPazshnc7rmVtuFwMhF9KxJN+n3kS6ghjhgh3G3LZMa9t2OAx9KSGxvbgJfXN1IbGEbgWXIK9QCe9AGpq2rWmqQwRXENxFp1kQsSnP75v7x9apa74otbKCDT7PTpF06MEuVXAml6qD7VPrWpNf6HDHbqsVnGd0l0U5I7BR61T0CxQxT3WsvPHasN488AMEHoPU0AcncXlzqtyskgJZ5ARDH2A/oKybySdZ5neRRuJGV9q0GvoZNRup7C2McCgrbxjsD/AFpj2qW06PeOj3W0yyRgZCjsOO9AGfbTNGZzIpaaReM/rVMKSM4OB1Nakpa3tzNIoM9xzjH3R6VTSKWWUptIZhkAHtQBCg6kkAfWmgEg4B461bazZSsagNI5x9PerWp2/wBlgCKVAAAO3ue9AGTRR057UUAFFFFABT4zgHFMpQSOlACUoPFJSUAPC7hn2pADnjr7U5G2sAelOgfy5lbHyZwc+lACp8vly8HDcg/zrdSB5LFVhlJwd9u7fqvtWbHEpw0BGQScDkY9DV3SbnyQsbqwgkfBz0RvWgDW062upomUlY75F3LkcSD0qe7jF9Zx3VqFikj/AHc8LcNG2cj8D2q06XRUsnyXVn82c/LIntWr5cep2iT2zGKZzzuHDZ7MPT0PagB+hH+07WWxvCguE5jJPDDFaM/htZdKhnRXkgLbCG5+f09vrWUukxpqVuHuGtmX5XXGQmf4lPcV2GkzapoUctlqEC39jcIRKFbAdezqeze1AGZY2ct3oqRafAZ4/mjEUzYeFvTPt29a5/x5p2oeHYIZpo3mhuFBVwuDu7hh2rvZJNNsLdJ7e4lSHgkgkOPZh61T8Q+IEbRz9ue31TSZGCNs/wBfbk9DigDxaYyyrFPbyzeUTuZJBwJPSvSfA/i1rmxkg1KIGKI+W0kMg82MeuD1Ws2TS4ZLW8m0q/S7tGYMsQGSG7j/AOtWPYRXemaiNQ0+SHZIQk0LoSM98jtQB21y8ui6lHNZFbjTLhyyIxAAI/iHocda0bC1m1CRooHnMBjMp6MM9cr6isrS7yHUrq1S3aNZQ7bYZ4iAGH8P0IrVuNHvrRvtcYlhIfLxwA+V1/2TkUAZE/h+2e6n+2NLFMCGQou3I7g5q0lnNpURS9sbmSxH7y2ukGGj9jWzaa+2nS3MepaM+o2Ey5KSsCysfQ4zVLVtWXTzbqRfR2MgXYSxYgH+EnuPegDGtL6SVbm11C3Z7aV8JdDAAPYkAcH3rnZpJLHVYbe4mtZ4yGMUzxhnj/H6V09z9j1eQWtlMkVsDkvBljI3qRWLHpNzEZoVhXEb4aeRDkj3oA0mFtc6P5xWJ2CmJZDCHGM9CabpjyafoE1n9osxIjbk86XLGPqdo7VS1SXT1tPONlPYXIjbiFsqWHqvv1zVVhYRaeL8XSsGA3RTx52SY4IPWgDS03ULEzzI1rY3SS/K8Xm4dccZKg962rmPww0MarMtl5aEG3WTgD8ax4HhvvDmnW2oTi8trJZpIAoCi2aV90u3ADNuOD85OOg71qWOpafYyWkI0Zb0ohIwgQsMfxZ6mgBdK0rS9UuVVLi7mEanBaQJ8uOg/vVinQJrrWYEs7l7a7Dl8OOBGO2fXFakfilprua0XTFgDNmOVnCsB3HHNSS2tubsXV6bi2hj+YSWittkbHAZutAEU2my6Pa3epT6+8VuzYEaqPmb0Hen6N4hAt5P7RtTOLnG0ITJtB7kdqj0/VLSG4ElvIbvA3PHdsAw+lXtZ1eWFWfTEsxLJHmRLdR39WoAxvEty66navp6RSSuMNsUqVQd2zxmucvvFDWS3UOlFcTDMiwKCh/3j/hWhaWbQf8AE0u5fOkKHbbK+5i3uT2roF1e1v7WIT2iWoiKh3gjVfwPr+FAHG+ReG0sbqKSBLyfASNI2Z2B967HStLn0y0N411G090NvmMnKD0VfWtO4t7Ke7ii02+gj8uP5m83kE+ij+dc7La6hZ3k5iuHujFgLucrHg9ce9AFS+04nF3q808oiJ8pPLAD49cdBT59a1S3cS26xRxFQgZo9pXjIwOwOOtdQFuI4ku7eH5duB5qh9revPWsjxDdPYxQRXEIurqYZdmTbn0+mPSgDlWvFcTahqNtNLEBvK4/1j9i30po8Q311BFat5Njp+wuIyhbd9cV0Ph+zs3M76srmSQnzJ2GyKPPYDuaw9bsNEDg6WLnyY3wZZScOfYelAEGpeLdSEcNnDaxxwRDMQCYDH+8Qe1Ymta/fahbNFNIZEmwWkYcuR2Ht7VeXTr28nkuEwYYx+8c54HtVXV457HyZmhbI4WV1xGP91e/1oAi0ixeXUre2WRkkZQ3zrjbx0A9a3dWgsLMyW+ngyiL95c3L8lj6A1jaLa6jK008OIEcYku5hgID1I96va5q+nQ2S6XpayzwRgPJO3Bmbvz1AoAybcpql40tw3kWduoY56nHQfU1ejvLSCSSby9skqbhuXonp9a7nQPAXh7UfDngH7U+rR6n4ukvIUmhnj8i1lil8uMmEx5dSSu75wRyRnpTLrwhpuoeAfFet6jqsZ1fRJIYl06xB8uIG5EDPKxTksQ5VRggBSc5xQB57a2rMp1W+lWGDPygdX9gKqXU0urXWIhtQDp2AFaH2W51TZLKPKt4wFhixwB61Wvp49PiltLU75W/wBdL/QUAZPyjdnop496jNHUk0DjtmgAoHWlA+XNIpI6UAB60UEk9aKADHFOweabT41LZ56DNABkFQNnTqRV22j3GJZYiYpOCfQ1SiyHyBnHUetWlka3YS27Fov7p7UAaOnWcazuN+xwflB6HFbH2OC1AkC/6HcMN694m9ax7ON76eSby8QNjI/2h0raluHgSB5VCwOQkjfe+mR6UAdDp0dzD5sUm2ZRH5kEo5DL6GrdrBC+mBrJSZSc+Weo9CKztPll0bUUCnzbcpuEe7KkH0NdrcW1lNoks8DeQeH44KHrQBVvLdL+GzF9C1vcYHzuvBPofY1tX1rcaJa4jkNzZOu9YmbLoO+1vT2rR0C6uZ9JuZrWG21KWOAyC2dseYccZP1xVO4sdKudK05tLuLq6v55ZWmtVRgWAlUN5iFyLbygSEIz5uOc9aAPONR1lA8RZiweTDBhjAz/ADpdQgvINRWazVJ4JgGUooyp9CKi8SaPIs8xAlkMbb94i++Mnh17Eetdl4Fa01S1hiudkdyFxHPuyjH+6RQBx8UVpbBJZIZI/Nf765Qxv6MBxj3q8dasDqQikspJmdNk0aH5sZGHHqPeu2ufCVzp4kuPLefTpvklhDAmJifvj1A7ivMvFXh++015XimM8e7fE8K470Aa9vZNNqJVJGj8wboS/AJHTLdjXaeHhrmg3cd9d2r3dq8YErRgu6j3X+tcX4f1mxjiWS7guC8SgTopyQP7wH1rWtvE1xYapb3en61uiU/Jlc8/3WFAHb6hp8U002q6ZKbm2dfnjOSi+xH3kb61laBPNeXVxZnTVutHdctDdMAV7nYTz2rVtPHS3nkT6jaRy3TLH5l1DAbYxSNnzIiu4+ai4XEh+9k8cc6V1ItyUjhsxLAhLtJanDqD/s0Aeaz6PBpevRz+HLoSWzlwbeTAaP1UnsfSodOupoNQvGNrdpby/wCsUvvX65rT8R2EV3fG2sbhrdX+Z1mBWV/YVz19YX2mzv5XmC1C8vN/rIvx/iHsaAHPHLqtktxbT2ck0MhVEMTDI989TSW8AW4Vb+IwfKQ0axZLgjvnqPetiPU7SGwh+x3mCcbyI8I3+1z0rtrZJJQsr6tYTFY8KrIN0i49ep/CgDzGabQ7qNZWilXecL5b/OG6ZI9OK6dL7TNWaztFsLkLEvlGdMZRjxn9K349MtZTcDTYLOR1IMhWEq208ORFkbyFyQuRuIAyM5qZtP1N0e5i0tre46PLEQnmqOEZlycMRglQeMkc4zQBk6b4Jskkaexs5NQmGWMs0wOD/ugURrdXby2moWhtYowSAjeXk/7prfj/ALZtLUNb2i2jlMOzDIJ+orm4/C+pTyj7XJbXM8zeYUe4bGO5oAz7yyks1iY6TZDk7XLqC49OOtZFvPaq9yqiI3Ui5kjgGQvOMY7V28fgrTnj33msQRXK5aONlaRfpv7fhSaXpekwKkdi9soDEyz+QFyfTdQBz+kad9hC3GoxxXEECHML7Q7g/wAIakl1CPULCeDTdAW2nlOQJIyxX/gVd1pcekWt9Ov9gQ38TDdMVO4u/aq+q22rhftOmaX/AGZZYb/UwiV92PkVUYj5WPBb+Ec0AcjpWhGzgR59G33qg+XulCEk+x5Iqu/w+1Oa7juvEV68Ecp3xQo+Pu+uO1ek6dqN3ouktc69FYC4mAzJHKJHVjjIHHPpmq0viC18m5lsjK2EO47dzn2Bbt9KAMy01K0h09kWDEFqP3s8mCXPtXLXk9rrGrveWZSQRja5lTYi+y+tT63fmS4hghmNveTrvYCH5QuO59fpWORDBbrYXixzPcNlmTJcjPUf3RQBBe2q3bCKWG4NupLeWh/dg+4rm9Qt7y680LFO9svynEeFQd8eprpL+5tbOaOzs7mKS3jbLwhixY+jGpn1/UdeR9N/0HT9Jj5eVFKqB7epoAzdC+x2Eccd1dSxwp8xRBlVHt6n1qHXDN4lvRPFZutlbqSTJwWx0C0uqXOnaHE5triS7vFdIoYFh3iWNl+aUyZ+Rw3ATuMH0xVs7owXMMeqX08ayAM1uj5kPoB6GgCxrUF7P4bjRobeGDg+Sen+8w78VwF0wmuGtopcF8BpGx82OAoA/lXU6zrP/CR63b6YRNYaFHKq3BhXzZFTPzOe7MFyQoPNegTWHhZvh3o9m/iDUk8NQajNLZaklgXnmuiv7yMw5+VVXaQ2eSTxxQByFj8RZ9F0jQtMg0Owup/Dpuf7L1GYyF7d5nLlzHu2MykjbuGPlBxWXoOv30ejeI9LhS2nj10Qtd3MpYuphlMu7PGSzE5yOlZ08Fzc2yiK3GwE7ju27h6k/wAxWVf3MhJs7RlKEYcRDAY/3aANDUtSE0S2tlNiMt+9m9fp/wDWrn7kDOFz5QOMnqT611MmhtpOjW32mIf2re/6mE/eUd2I/hHvXP6jYm3uPJBeebADMvQN6CgDO4z7dqAMkDj8asXduLfanmB5MZYD+GoI1Z3Cr1PSgCe1tjcSsA2EQbnY9Ki8olwBzu+79Kus+23+yQBh3mbFPTZZ2hmIzcyjEYP8C+tAGa4KuQRgim0H86KAFONo9aVCwJ29SMU0AmpFT5AcDDcZoAfbpuuFV22461pQ2TI5hlxsl+ZG9/SsyLiYb1LFOorTkunMYWJjsPKP6H0oA0NLae2dvKjDxH5ZYz2PqK6LSLJZIpbd4nMDglSwzx2B/GsnRpJJHZ9q+bj74H3j6Gu18NXFpPIImcRSlcbGPU+tADtKtbbyIIrpdsR/dgN1jf6+lbXh24sLXUJdO1WUxkNgNIOGX196esEN7ptzCIxOq5WQAYZT657fWtDRPCzXljBc3MpeJRsSWTk49GPcUAdgvhpNCt47uzQLbn5o5Iz91T29wa5tAn9qyXltvhaRhvaLHDDgZ4z/APrrs9ElvNOi/su5kRomH7tZDlSP9k9qw9VtoLZXE6CAqT5csZyI/bPcexoA5u68QahbX1xdWtnDqEkfyzW5G2Rl9QP4q5rWJLWTOr6HbNp7n5pLRxtRm9vStrX71bQK2qQhpAu6K+tz+pHp7Vws/iK3YyLKPMjD5XeOCf8A69AHYaDrLwWv2i6uTGkrcxhiyqcelbdtdxaiw+2S2pLjyjH5RGR2PtXEINF1qzFxYzTWN8hBktZWJV8dxXValf2tzp1pKy2t7cxgLujIjkYD+EjuMUAYuv8Ag3VNN8y+0q2gLv8Ad2SZDiucs7Sa3uDPdabJbXvSWNuVf3x2r0Jp7GZl+xX0qWMnMkakny2HXKn+dYmrTw3moBUvbW+SIZj+YpIn+yR3oAo2F7pk6yNB5SOp2XMbMeF/vCr899qljcwLpN6vlouVZFPI7ZNV49L0+W6jv9NvRDPjbcpGodh9R1/Sn+Zq/h4b9PvtP1W0kbL28w2kg+h9aAN/RPHSA3Q8Qw2kt/EOA0O9gPVSKy9Q8T6Xfzxm4xHHn50ki6r/AI1y+r67oZ1aO9n02bT5iuyVYjkMfUGqul65Gs00VjFFJaTsQBKpdhQB2mm+HtKmu5n0XUgUkU4gbaiHPb5v6VrW3h7VLC5SHUbE28cxJhkjYSheOPpXF2ds13FMtvEiMvOEkMZ+oGMV0mja1qNhboIJLyR/uiO6RmK/Q5xQB1GmJ4xtsK0FpeSRNyXbbIY/TpzVu8sXv/OSEiw3DdJIsoCRH3Gc1zw13WLxvst1NdyITxDPFtP0Vl7Vf86+uYHs44LaKMjHkyRZyfc55oAe8MlpZLanVLT7NtI8xZHBB9QD1+lc5b6TqBlD6bctNA2Q8/mAT59Bu6L9K3IfL0m4RtZuLe1kcgIY7fckf0DGjVNU0mObebuW5mzkbQsYb0yBQBraa13FbRwarc2s0MacxrEz7fqTWHHeacNZgWLULK0syzAmXGwH3WoLfRbq5sryXVdVj0+2lw21Q7s6/wB1SO/1rOtbDwnBp+bpZZdpPlhxl1x1JHvQB6Brn2C9lj/sXU0luIQGMsI2If8AgPVq51Bf61PctfGdVVNiKx2MD3IHpXH3HjmxjjVNNtZFSNwFeUYIA9farieLJNVtnA8mCUKdkqnDLntnvQBp6bDp8epOsbmQwjDtKxfB/wBn3q4qR2/2mW6TUmaVt6RlFc4HbA6CsW1u4dOjU2sUEmoRqGklMmxUB7hT1NXdP8SwwvHJZRXV7qU7Ykld/wB2g9loAxr6S9ur83dwsVnGD8s1+GUgeiqKjtzFbzzXd9dJcRhcs8LfKn+6O5Na3jOXS9Z8tLvUnm1JcgjbhIfrmuW8PWOk2kgW7uXki3/KFXJkPsO9AEX9iC6j+1RgwQkl0MvG1T1B/vGqt/aJa6SYTcu7yEoI3UM5U+w+7XU6vcSandxQLazwsnMYlOSB2Jx0HtWemkx3s7wxSfPEN81wTtQn/e7igDH0+4MlzHpWj2RS62hi5QEqe/8A+s1raj4c03TYDearcJ53/PCFt7u/bzD6Z9KpRW9rp6ytDqEk8rHJEJ2iT2+lZ8k1xqFxsgMdmfu5RDIwPsO596AKcsNr9oaEzvGJF8ydI0IG0dBu6gc449Se1QC/u5TFYQxXQsYWaS3tCSVLEYMgQ4VWI6knkdq1YYxZTLZwCZpW/wBbLcEFyf6D2qe31YCWe1sIvOkA/ezxjJHtnoBQBi2bNJM1luAmLYlwSWye3sPbrXRf8Ixa+FYk1S8ltoJvvxxycsfeszTNY06B1miQLMr8gfMzn69qvf2TdeNNWZrrdHZoR5r7ug9BQBh6cb/xLrxufLlup5s7W6BE/oKreKrVLKRoo3Es4G1ynCrnqB6mu1Yz2t3Lp+iPHb2v3DIOW2+grG8R2EdvbvDYkS3f8Ttz5fuaAPPpovsyLHMB5ijLIP4D2z7+1LAFQ732+fIMKgH3a130aOy09p7gkSN/y1c9B6/WqKaUJVgdd6CQ7st3UfxfjQAt1b/2fpyb13zTnJPrVG9xFEFk+a5k+Zj2UdgK3r+2murmABhFBtxGO+B3rG1x4/OMduQ0Ufys/q1AGZjgY70r7doAHPrSlSE3duwpSqLFknLnkY7UANTG4ZJweOKmLhVaF+Y85B9PeothbcQCQBk/T1qUW8hTJwMDK57g0ATRxyIylceagyvoy1dtBG8jLGwVZBkoemfUVBZzRjFteAFc4RxwVp62brd+TI4WQDML9N9AG9ocsUMrRTK6Jna4Hr2auu06zjt7vbfBXcjdHKBg49K4sNPLLFPDCHlC7XVeQ+PX0Nde12l/pkSyiRjDgqycPEfcdxQB11jCGWSfTZQl3GNxAP8ArF9CK7XwJ4jtHt5rW9jRfMP7yA8Bz6j0Ned6TojyW41awnIfHzAH5Gb0x2NWdNT+0hNNZ482NsTW7dVPcigDudUt59NdmBa70lTui4Jlg56e4+lc3qGtfa79o4rWOVZF2kCT5ZCPQHo1aen6xJp6QpepcLaNwjdQh/2W649qzdRijm1GSRbaGUMd4ePClmH8Y56+1AHD67eR3CS6fZTSQFSWMNwPmQ9xnuKzo5Z9EhW41PTlvdMm4ldI8x49+6mus1W/tJ79FvrEi5HyiUrtdx9Kp6Ss+nas9qbmR7CfOIiM/oeKAK8P9kzIEtlBsrhS0SSc7R6Kw/ka5V7N4bmQwzwEo+VWQ7XA9z/Wurmsr/S555dMs4JLd23NA6Exyfp8prmvEttZ30aXE0L6fdE7TG5JRvbPpQBtW2h/bIzImoJZ3LD5og/LA9we9FxazeF7IR3LWF3IxJjugTuz9RXM6FbXVn5UFxJG6ZPlkn7v+6e/0r0OzntLjRza3OjJqMgHzbDtf8QaAOLWG5a+j1HUlZWfjz4ZhkD1A70zXvtYAuLbe8fTzY8up+oHQ1pt4et5yywWWo2iA4e1vEyn4EdKowm90JZUtC1nHn7plD7l9gT/ADoA5qF1ukWGeR3uo3yu47gw9MVqXOly2ZilNpL5TqceWhyD+Fbkc1tq9mzyDT7ho/4yNsu78K7LwTqOiwWaQXU5s36PHMwYfgT0oA5nwxf2EdqCHmFzwrRTJ8uR+or0XRJI59PL3l28EWcCKU/qM9qg1zUG0+UbdKs760IzHdCIMyj8OtU7DQdN18pKmoT29wMusKxmOPPr8wIFAG7ZRa5bIZLTXrGSDcSkBQK+Pq1S+IJnmkslullgkzu3kD5j9a53VzewmKzu1M9s0k8cEyuuydoHCS7cZYbWIHzABuq5HNLcnR3gWW/vLuDUIj/HLlQO2MCgBkml/wBr6kGttF1e+cNiTypQoGO4Vhz+FXF0GwkvpZLy2v7WJECg3CkEMOxwKj0m81BrkT2WsTKOi+ZKBuH+yO9amm6Rda758smtGHa5EglkJJP0zQBmX+urPZy2MF1bRCPkNLIY8j6Ec15dqmspaXrymSaYN1KcJ+VeieKfDkNlFOnnR6huX5pFXG36E15drfhWCOTFreMxb5zlidv6UAY+s+Ipbq6JBjZP7rpgV1HgrSoLy3e5mtmaYdAzFY1rhrm1b7QIxK0hDFQPLycjnpXp/gnwpqerWURigm2MBmPlCPc5I4oAmN/YRhbS2sLR74Es88jnbj0Oe1a9vqaKq3d7FZRmMbQ24gN/uqOtbWofDzRtGsVuteu7UT9UieYE5+mTXPX1tEl6ocWp+T5JFAZUHZRnvQBLcLp980k9zc28IcAkKu6TPpis6G3iE0NrpliYlGWkvAQJPz6D8Kamox6LMu6ztZlJLHOGKn1JFO06afxDqYc3MNrp6tkwQqS0v1PpQBest9rNceTeN503ymSUlwo9fesa6JiBt3drqDJbC/L5h9T/AIVo+N9TjmENhYRBCPvpE2Bj3PBrJt7N2s0kEe2KIZzCCQD7k9aAGy2t2R9nglBlbDTTsAqxr2Uepx6VpPBFp+kSzaNtaRP9ZIq7WkP1PSsjS9UaOZ8RO8r5VHnOAvuBWdq+qLDEbS2eW825Mki52E+lAC6RFNem5urxhaxMx3lm3Mw74NEEr6vG+maVHJZacMjbGP3k3qWb0qlp1ytw0cFzbzIshwQxJ+X+ldXPrllZ6cbLTjFawbcPKozI2Ow70Ac/p+n2FpqDqlkWkjXIO44yOzelWNV8R6g9n9j0wANKwjCRjjJ+nWobOGbXJ2trVWt9NHzyyueCB3Y9z6CtFNc03TryG00+JTHGBulYYaT6f/WoAuDTpfC2hC81WaSfUphiC1i4Yn1PtWZdwN9itkY7TI3mMiN80jHsT6VneI9QbUtRWa6neJU5GW+c/T0pbezu7m0E8PnRwTZXzH+9Keyj2+lAEOsvC7o93KJRGQqxp90v/dA7/WpIQdQkiXB8s8yPjqo/gH09a1YdEstLihN863F+0eFjUfLAvoB6+/Wsm61NLaCVhH5RdtkEY6lfQfU8kmgDM1FpZtWkVf8AXkbQq9IUHTn1rAv4ysoRF2xjhF7n3PvXU2yyxKqOuJ5vmdz6fX0rnrm5UXs8wUZB2hie/tQBUmiEQUk5bHK+lV2OTnGKlaV3VicHJyTUJOcUATRF0YOoDFeo9RV+2nhXETAm3lzjd/A3tWbGSGGDgnuKuRqDEBJ9z+LjoaAESE72X7zjOVPR19R71KqT/YDvQy2u7G7qYz6imyp5QXZn5TnryPTFdLaBkjS4KF7aUbZQv8J9cUAV/DUotblZ9xaGX5W2nhPQkV6FHo0OoPFLZyqlzjcCjYWUen1rjrKOLT7px5aywScg4wa7DTY43t4r3TiSjfLLAxx+I9DQBZsRf6TcmS3V5LZjtnhHOD/tDt9altrwWmoSXEcTIZMlbhRw3+yw9vWori5mNyJ4Gdnj4Eo4kA9GHf61ZvLkhV1K2MbRMNt5DGMc9m2+tAFxdWm1OMmz2wTKf31sWzG47lfQ4qpri3UsQa0dHAIeIN8jf7rD+tV9Nnt7e9QThDFKd1reIOAD/BJW6yQaos0RRra7TIG0g7h6g9x7UAcbrE73GmSx3UoWdRlra5bbJGfVH71k+GtXM10lvrEc08KgrHPEcsnv68Vv/arG+vG0fXRFcNHxHLKuwj6MP5VWj8F3Njr8d14fuAJTz9nlHX/gXQ0AdXpPi+C0hENlLHdSRnDGXhJV/wBoHvVXVnsdSlldPKgikI3xqu8ITUfiHS3ubSQ3OnSafqarl8KCknuMda43w1c3MN8bSWZGRjg+Y2P/ANVAHX6hoWp6LAqLFZX2lSgeWXiztPsw6Vymt2niHT5hdizvlt2XKSQAOrD/AHhXc2ulS6Tab7PVr1rYEl7V2EseD12n+lQ67fppViJ9N1WKa2Zcvby/umH4HigDzbS/F2sm68oaxKoAx5V1Hu21s3l7BNaCfVtPNwM8SWrDn6g859qgPhw+KIZdS00eZcLyEVwp/IVzC6HqdtJ5+prcQPbnLJMpBxnqp70AaOtOourW4gtL6OL+9sCn6EVrzWc93YxtYQeZPP8AIwkIH86ia4uNYghbT5oZwq4aGQbCx9iadpGk6m1yU+xi1zwWkuc8+1AFrRYtR0a8itPEDXNlZvxFM0jPED746V6jYanq2n6S/wDZt/Jq8WDsaCANGnsWrgJodSsARrkkUdqp5jyTvX2IOK6zwxrWhnTZbXRop7C7cElfPyje5FAE+ia3pNtqL3ev2XlyXGFlukj+bgYG5gOcdvQCqfiuSxvdUY6Nqn2izIz5IUjtXJnVZrfUpLWLVFjlDHEcyhkJ9s1fka/tpUe+8kzTDA5AT8MGgDa8NDTIrFpnaeORTwJY9xX6HtWtN4osI7KUaej3PZ5UbAU98gjmvM9YsLxL2N7bUrWFm/5ZbnH4ZNc1rc/2PbEZbwSscu0U42H8AMmgD3K28Z+B7RUOqR3M92RhRE2Pm+nSrHiXxz4ZvbSK3sPDUhDgAzMyiT64r5rkvEc/MRIoP+qA2ufxxW9pE7lgAsdrHt53N83/AAIkUAe02/hjRrb7Pf3N5b2MCt57bYC77vc9qyvGvxLSSM2nhU3TAjy/O27UA+mKwdBvrzUZlhh1RLhUPEaHIA9sEV0C/bNQ32sEcMdxjaJlVRj8KAPN11S4GoAzWq3koIdnnJJLeldONSvp7VrnU7EzwIBsigIUfie9Ld+F1Q3AudShjlXlwoHmOaw9JsY7y7Um4m+zxnHls5RSaANuHWdLktdk9hLEAd5hgXLMf9o9Kntdb/smOWKxWRDdZ2xhA7J+PatfU1ij09LSOWzt4cZZVbd+fGTXNa5q+k6fapJJKzyOMRxwLt3H34zQBz+oQNZ3jXf2a5vJpG3APIFX8R3roH1HVtR0qO2L/Z1kGPLVAD9AB/OuV09ReKbptMffuPlBmOMe5NdRoGsRaVZzSww2y3GCpupjkIf7q0AZ95ZPaytFdSynCDezJkJ7KO5NZFzbTvBnUU+x2TcwxPwzDsxA6Vpal4j1JYzLFtEL8mXZl298dqXR5EuLSTUpgbud/vvMflX6g0AcwbKXUIJpvOWC3i4/uiSoIA9tAhhhExznHTaPXNbv9m6jqN0ZFjH9nqSFeQ7Uz/srVPVba9hhFpaMJZJTh9i8hf8ACgCjfa7ezAW4ZFgU/NEgwm7sSR1NSWJminad3jVwMyXE/OPZR2NQ2dhcWc4+0xLI6j5QDkj3/wDr1r2MNtbtHdX1uJolfdtc8Ofc+n4UAa+k+GLVkTV9ZaW7jk/1dueDOewz2UV1UMdxeyh1KSXgXbFHHxHAOnHpgdfWuM8RatqGs4EB8mKMfwfKEX0Wq667I1gtra3SwWyDEki/ek9Ru/pQBs+Jb/TtGt5bWxuUutRfi7vyNwB/uqPUVythGDeLdyZcoPkMvTH95vStOyTSpII3URtEjYRCfvt6mtP7Jbw3EC3eZJp/3hhUZyB0B9vrQBhXpmET390H8gghARjeO34Vyt7HO4Fw8flofujpxXf6pBc6ndpNMu2yi+4nTJHt6Dmue1C3/tC62FhsXq2cKAO31oA51rcGJPLZmY8kAcD3qIx4iDdCTgD1rqtRtVSzEVqCoK4AA5b61zggmluNm394BjHZRQAxIiZCrrgn5gAeT9KlQMqNt/eRdGA6/jUphTKxBwFY5UHqreopbW3laRu0qn1+99aAJ4YzHGqSKJYT88bjsf7orZs5ra53JbyvBN/Ep/wqJUhuU3LmCdeJYccMfUelOSPy50fIWdf7w+9QBcvILhoY5Q674mG5kPBrqNGu48CNyAJhkof7w7isYWxMayWoRXfkpu+V/dTV9Y4pdPWOSLyZAcAOMc+uexoA2ciGeNzIFzyrk/Kx/u5rVlu7KeMTQ7Ip2+W4hdMb/oe4965fRLa5kimt7mWNiG3COQ8sPUGtDTtPaHVIo7TyZVYnzLS4fbJ/wFjwR7UAb+paCJ9PVtPgiWfHMefklHt7153rEmsabfKh82zmjUiNZQTx7GvY9L0lCqWglmsX6wRy8ofUBvWpNZ0W6mtPI1NY5B91HkH3T2BPbNAHk+krceIUW4leK31dBtKSr8k4/pUNnql5omsYv4J9tueUVzwO+0elXvEui3kTmOS3ktTH1kBIVffI7e+Kk0HSXvphZalcFi4+Q3B7f7LjrQB0fiO+k17SYdQ8O6rBcTQr/wAetzhHC91ya5fwtHZarqJh1C1/srVMnILErIPoev1rK8Q+HZvDWohry0uJLHduWeJ+U9sd66cW/wDa+mQta3dvMq4YC5Qxyr7bh1oAn1vwo2kIZI768so36PGS0Wfr0/Gse+uYl0trS5WGacjapmw6S+4I71Q1rUdQ0e6RDqDJDP8AIYzJvjb8MnFYeuaRcbUummjkt5OP3MgO0/TtQBTilXS7wgPPYs3zD7O3ytV258U6rNAYJLiS/tsdXUMVHpz3rnbiPAxcSPMUPyxkHdioHmtnKLDbeW4PLFyDQB1+kappwlji1exRI2+7PCT19x2rr5LTTlijlivJpLJj/q3ORivONL0qPUkmkN5PCOgJGVJ+oqC8S6slMEcikJ/y0ickEfSgD0seGf7USePTbkMiDPlfaecduDWZY6ReCUW8sSFYj80hGHH41yfh65u7CZZrXferkEtCcbT6HNerw614UvrTN1pup22o4A3wnIJ96AJ7DVfAdlB9n1nT4b65PyrLCC53e/cVgNfWL6q6JZmNGP7pGU4A9z2rptC0W08QxPDqerW+jrnCM1vhmHuwFVNS8OP4ReSKz1aO6gYE+aiCUAfUmgDGvTNPayQWb2tuVGG+62fzrk7fwzJqsjR3Wu2sYj6Dbt3c9jV220y4v72S40yzF+WyDKZFyvrxn9Kx73T9YtL0NfabuwfkycKB7gUAdDo/guH+0Iso8lsrYe4jYOAPf0rstWm8O6TCLWwt7O6jwQ0s9uSQfr3rjfCem+INWaVIB5Nsr7j5Em0AehPevQbPRzPEbQpvkQZYGRSPxx1oA8t3JPfTsd0Vhj5WtFERq/d+J9K0zThFDoU7z4/4+WmP559a9YsNA05bORtVntLdI1wNsO7H14rJ1Hxd4RsNLlhs7KzvXxgztFhvwB4oA8g0P7VrN+90t4sEjsDiV/uqPT1r0rS9c0O1aO0lkjllRcyTOCQprKPi3w3DbOLDQYYLqQHN1MV2rn2rzvWbiYXRlS8ErynjbhIx68d6APRr4aZqepyzx6iEtBwWBxms6GG3fVsho7hegnlYsQvsOmK5fRk1G7ZFgu4WRTjYMYY+nHNdhc6fLFiTVNRggbaAsEIPH+96UAGqNYWV+nnu92DgCNmYj6ACs69hs7q8zeKIrUH5beNMn68cVd+w3bxC4SR/ILYMnlknHouavXOnxvaLFbafdw245kfH7yX2oA5rVb6z1KF/sZ+yabB8rbhzIR9as6Zon2myXUtQLfYowDFBHlVx6n1p2s3FvYLbRNp0cYDDbA7ZY1qS6zHNEW11oTGi/urSNuMdsgUAc3qviKa+ugluI0sYRgkDke/FYjvcCUuWnSOTkru/eOPXPYe1dEdNutWUXV7PFpunqS0dvbr8xHrTX09rvfFaKYbLHDN/rZj6sT0HtQAzToIDbiUCOGI8nc255D359KztRu4ftX2mZ/NiT5YyfuqfRVq7HbrZ28kchG88Kqj5V9cVmoSbl2hgFxPGPl3cJEfU0AMvdVCW5GwpERj5hgsfYVzbDzpiAAq5zg/4Vt32m3lyPtE7+fcP90Dpj29KseGfC7ardNFkySeoOEj9y1AFvwjpYe7W5EKbI8FTKeFPrjvXoFrbQWpmvLtTlhlnlGGl9Bt/u1v6H4TsvDuheZAyy3JXJu5hwD6Ivc1wHimK7MpczyG4fkROcso/vN6fSgDP8Vao88jruMcQICxr95/r7VRsIkCCW9/fXDkGO3QYC+n4/WqUduFIlk3ysTgSf3j7Vrxq9nb7IAFnYZklbsPQe9ACXEHlK1xeMBcOcLGD0+tZ/wBiFvatd3fyBz8qfxOfSrUCR2we/wBScyv/AMsoup+p9/aqN7dNc3H2q9+/wIYhyE/D1oAwFRJvkB/eY4JPIpyyXNs6u2Q6HqehqCGA3CkwhhKvPXtWxpStdxtDcDzIGBAf+JGHrQBqW09tqQSURhLhPlZf73uD3rS8q3jRU1Dd9nb7lyvBi9mrnrexmR2ifMdwg/d9gw9jWzZ3LXVhLDIMnodwyQ3v7UASz2N1bssUcivBL86eWcq/uvo1belSyXVq8Uq+Yyr+8U/ez6+5+lcjpN3JaNNahSIWywjOeG9V9M1sWepLcIzbXW8iOQgOGK+o9aANeeyu2hilhMc8SnAZgdw9m9PrT4LufzYUmtv3YbEsNyM4HrG44I+tM0vUjKhuraRgudrkcE/Vf512GiaxaxyKt4iBJhjcFyjfh2oA63TJJtT0oWqTi6jCjjI8+LHT/e/CpdP1FI5BFcah5wQeW5kX5sejKev1qjb6BaR6hHeWNwYGHzoUP8vatGWX7XfBWhjac/K0yxh429nHUD3oAh8Q2Tw5FrcRSRMu5Ff54yD2UjlT+NcnYabpWo20kC3aWUinHXIRvXHb6iu2uPDFxZTCaSKW0tm6zWj+ZH+KHoK4/wAeeGJFgN5YPbGXqssR2Bx7igDN1jSdfktm03VVtL+3IzHKrf6wdsH1rkdKtNW0czR6ba3MgQ5a3K/MB9OjCqGpeKZIYPszRXFrdoeWBJz7iq9r4q1GOWO8TVLhpYvuuQN2PQ0AakmraGZ2GsaTh+hhYeW6nuQDUcp0JCUs0l8mX5hBMMH6Kela0HjXSvF/+ieKtKiujjalxEAHHvkc1maloVlYAnRNXlezJ3fZLxM7fo3agDn72xEZMkMkvkk5MU68r9CKw/7KW7uCIJxHcZz5c/y7voe9bNzdKRJBdS3VtkY8zbvjzWXLcJtS3uZ7eZkYMjKeMfX1oA6Hw/Lptuhs9ZtLq3lzgzWvzK31Wrup+Go44nu9OmlngPOxvlJ9sdRW74Znt9VtPLurSFioAWUHBH4itq38PtMxiNxbzwZyIZZhk+2etAHmFjp1zLOJdN8yCTvH5xDD8Ohre0Sz1SbUUj1C6GC3IZB092713d14Q+Gtxan7R9t0fVx1eOclN3t2rkIbWIag9nbma9tIjjzmYgkfUUAeo2cllYWP2OHVgwcY8ppwQPXGQaypon0tHDpBeQP93ODt/LFGhr4btrZbWa0MjsfvPCzlT9e9bay6XZWjAaWl6FyQ7IyYH8qANjwzaeHbrSU+TS473rmAhD+IrN8ZeFr66tXTTlsPJZSDiQeYfoK4LWNciuY5oLSztI1OQBGmGX8RXQfD3XW8PWYWK8061mdtzHUAZGP0z0oAg8PfC27s9Maa9uriyc5KpISN35Vi32nNbrJHZ3N/cTI37xojnNek638Q77XIhZ6ffW2pyr9421r8qfia5G61G402LKRrCxPztHCzH8cDFAHn3ia+1M25tT9vkVRyTuVT9a5ES3F3AY7y3VVDdW+8fxxXuTaFD4ktYlv/ABLLp6PgmQW+Tz9adrfgDwJ4RsVvLnxRe6tcgZWAOoDH3AoA8+8KeA5Y4lvL7SjNbvgoZblVVfeuvt9H8Hxzxv4nghniiO4RWzbkHqCe9QzeM/DVvaoJNKmuJTxFFJJ+79iRXDeLdf1XUJfOhms7C3B+W2hA+QUAeq+IfiH4M03Q1tvBOg2ts54WQwjevuM1wOieHNX8RXbXPm+RE53s0gBZvf0FcRp8eoX919smiDhThXZfLLV6h4f0z+04EXV7yS1sf4orQnJ+rjvQBcfw42m3MU+pa0LiCPH7hJsnjsSP5CuqiudS1eJV0zSJra1+6spGXf6DsPesmVNFtGVfDrvJcBcPIybtv+8zf0rQi8U6npNsqQmWWd/lNwFPloPb3oAzNV8GzWpNxqVjbQMnI+fzJGJ9T2+lc/IbTTWLXWlwGaRsIvG9j2HrW34nt73UYUuNS1e6ZG5KgiMn8O1YMqadZWRupWMlwQfLUvvkJ9j2oAdeanLFGZbuK3E23K28K58sejN2Ncld28s80lzJdukkoxzkIB6cck/hV9tZi+zmPyjcXTfMsCnHPqxqppthfXEzyG5WOQ/eeJfuj+7uPT8KAHWekwQuFkkeU8APM2Bk9lH+NR3NpDG0sUEiMyn5oYDyD/tt0qaaw06F5ZJnuZmVcKASWOeuKr6dYOuZVhS3swciBm5c/wC1QBv+F/DovZDNq1zHBajuvUewrtzrHhrw7bGKwtUmYclcD5iO5PQV5Pc35mdIpbt3jXlkhUgj2FWDdLC8UTWzckERjrj/AGj60AdbqPiLWvE9ypt0CBTtjIH+rHsvr71R1XSLbSrZDqEzyzynIt0P7yY/7R7VasNamjxFaw+WWG1do+bHqTWVeR2ras0s8kl7fEYYDOFHsfWgDDuYpXuvMRU9I1T/AFcQ/uj1NMubRrVRJqMuxv4EbqPc+/pWtqGoR6cWCIkt/wDwooysQ+nTNc3qcz26vd3rCS6b7gJyq57getAFS8u1Wbaq4deQZOoPqfeo3xFCLiY7puSgP8J9RUVtbRxPHNqAeSVvmWDOWb/aY1NqW+Qj5PMum+6qD5VHtQBzEEkkMoeN9pzyf8a39MlaS6RoXWKVu+PlkP07Viqvky7LmM7epxyRWhbQxwqpEu+GQ/LIvDKfcelAHXzXaz2wg1G3FtcrzHJ1RvoRWZtMTG7t9+B8soA61LZ3q+WLa6AdF5Rh901FLaSWjtcabIAW5MbHKyD+6KANBrUzQi8ttjkclPUVpwaVY6vaJJZMIbxTyGONh9B6Vlaeolg8+xfyplOHt27nvW14dbyNQZTEFM/3o3G6NvoexoAiitbvTZxNGjxSg7WWVcxv9a7TTbVb+yMthZtHdqP31iG6+6ZrV0eweUyRadJ552YeyuzyP91u61kXa6pptwpNjcwwxtgblIeD6MOq+npQAnhfxRNDqo05oEngLY8qQGOVDnpk9fwrub5/sUqalp9rIW6upGc+zAdfrWHqNqdXtk+32lvcXDLxJjypfwI70zT7i70+H7FqM9wLEjYksnEkZ/3u9AHrGl6u9/pyyxb4Z2HzQv39vf8AGuM8Thbm1uYJLaJ5R95AvlMfwHBqTSJ3ht2tk1iO6kRcguBvI/2vWtKawsNa0veWaC+iH34wSD+XIHtQB4dq3h+2v7aVEt3Lp9wg/vF/xFeaPDHa3L20kzKQfuOAM/hivo5tGktpXe3mF5Io5iUhJB7iuH8VnTbxWTVNMe4UnaZI49kiH3oA8pi0e4NwGh3J3Dxtz+VaEF1MivBcXzvcp0Drg1sN4bewk8/S2ea2PKwXLbD9Fb1qhrd5pbwjzrC4gul7THco+jDrQBn3FwJ0wfKSTqyCRjmsWNA1yzPayyxd1VdpFdDBKsltvitsp/EGTOP901k6pMY5YvsbuBnkbs5JoAlgvbyxnWbT4JlgPVJ+VNeo+EPiTpem2u3V7AWjkfejxLG//Aa840ppxKpZ7YZ6owYH8j1q3qMdpDIJk2JKeSiYKH8DQB3Hi/UtF8WJDLoktmbkcmOJGjdv+A9q5a7je2t8zTiGYdBIjKycf3h1q14ZvIL9Sq6Rp0lyDtEj/I5/Fa1ruymUk6xbrbKPushZ+PrQBRtvE2paLpljdnWIZjctKGtomZ5rTY20eapUYDjlcE5HXnNa1r47vPElm2nG4aUsNpAHl1l2mkXS3HnQ36C2HzDzTwfzqGW/vn1BfKuNP/dn5ljYZP5UAdBb2kWl6fIDsLgZKSRBif8AgXSuS1m3/tFBNPbXkFup6xyLtHvtrsl03W9YsRInntB1PkoGGPxqjNoGYgss00ZA4Hk/zoA4/Tb7y5Cul6xfjHG2FBGf0HNehaNcMtuGvNX88sAPLuXIP4kVhaQ+raDen7HodhJG/BldeT7kVrf2RLrV0l1q9yNNh6lLNV5+o6igC1rGri3tGW2GlK/YLcu8h/DtXmV0l/fapiSWO0D8lpnPH55r1C58C2jwm5sGvplHV/K25/3jTdM8M2M8LT3s1nGw6AyOWY/SgDzLVvDUUQDW+pfanxlzGnyj8RWdHaLA6yfaskN82+Mj/wDXXo9z4U1vWGfy2lisgSsYjTbu+tUj8PLuCUtLrAt2XkIItzfrQBjw3huvLt4POAGC8kcO1P1r03w7Bb6jphtAdSkUDBcjy0H09aq+GdOj0/8AdQaffa1eMMBpuEWvSNIkNjbC41zS4/OH3LdDwtAHOwRHToRHbWCLAD/rrhsBj/MmkvvEaEpE88c110RIICVUehp2sz3+pagWeJYLbPyorDp6VmakIdKt2mubuG1hI5jib5n9i3egDG1qw1PVb1Wj8uG2Q7nedgXb2bsB9KyNeso7a1kb7fJd3DfKsdsmFQemfSkvpbrXIWZbiUQA9EUxRqv1PU1U+yRwwCS7upEtE6b2I3n6jqKANDwh4bsfKM95cLCPvPGp5P1x1pup6rpkV6ItOtpHCcAsAq/XFc/cam0ikaei29oD8zjLGqEU95eXGISViA5kkFAGzea3BauS6K95L12LuZR/IVTivnuImM0fl24PWR+D+PWqYS1idxHLJeXZ4cg7Y1HuaoXW2QklzcsOAo+WFfxoA0bebdIXjuo441OQI1zt+n+NaNldRwSFo1aWVjgFzyfeuSsJXa4woLy9ESJcgD19q3IXjhXykb96332Lc/hQB0+nXpEzpEDLOwwz5Cqo9M06+1Ow0eNooWSbUJfvbB9zNcXrV+9rbLBbnLt0VT0PqazdLmkwwUb5hzJI3RaANq7f7MDNLLhm+bGcsTVWE2ysbqRTc3JGVRuQnv8AWsq9meV2czkqPvSkfyqJ5WWJYYGKlh1P3j70Aa0CmW53TM09xIwAROn4+1bjPaaQm47LjUm4wuNsf0rmrSQWsXl277nbrKf1qVY49wRMyyN6UAc/KZpoAxwwT7yjqtFtIIg24nD8bv8AGnLL5j+YmFmA5HZvrUlsJAxkjiR0b78Tf0oAsWhuD/x7uJov7vQr9KuWt/MsjW06OqfTkVTt4pIJ82+UL9Ipeh9ga1FZJji6WW2lTjzMcp7+4oAn0idba5Kyu3ltyHHP+RXWaLcWEVwEu5PLD8wv/D+B6ZrlJIGgP79PMTGfOjGQ3v7fSrNncWfKyF/s0vDbeVVvb0oA9b0rXlsbuJbu3S8gz8s8JyV+p7V3eq6xby6Ys1pK0gYbTHKP3ifieor552z6UwnsJzLB3UfdZf8AaHrXZeH/ABRaXFt5TzG1YjBSX54z7AjkUAeh2Hh7XdRsPP0v7PMinJjlG049u1Tx3EukkJrNoY4T1ZvmQexpPB3iyPT41t0vjAByPKfcB74NbHiYy65pxWWS2cuMrPENqP7Mp6GgCtcaX4cu5IbqyIimXDKsT/IT9Oo/CsnVZptN1NLjSUkSbPzBBtE3sV/r9K5eTwXqkky/ZbhoJ1OTEWO0j/ZP9K6ZINcNh9g1GKK4IXAdzgj6EUAaJ1+x1SNYNXsorC+HCSuBG4b/AGc8EVi+IfDo1uENM1pFdLwJFbbvA6ZI4P4Vman/AGnYQKmu6JJNbIflkJLgL9asaH4g0eCRGtgLZs58oybkb6g8igDzbV9I1Gwla0updiHgFJdyn6Z6VjzXl1pw+yz21rdRdMyphvzr6F1qJdc01pY4bJWAydyBhj2xXnV5oto0Ukc88UjdgI8Mp/GgDzq4v1JSKEJayHlSiAj8R3q6dJ0fUrNRfMLO+HPmxREIx9SR0roF+HWq6nHHJY2KTkNhZbRlbA9160/WPBXijTUONO+zlB/rlRlz7FehoA4Rre90G5MnmW2oWROH+YE4rpLbT9A8TRqdKv7e1vMfNE77CfYZ4qCOy8QsfLvbKeSJhkuqK6Y+nWo7/wAB6rfxLNpWn204H3lKbGH5UAMPhV9MvvOGpPH5J+ZVQEH6NXSpfRX0It2jmljxjzWYgZrM0vQ9Q0+MJPa2yyjrHcSEc/iakvr17UhlsYlkHU2dyHH4igC1Z+HTqsrWkF1bAkcefdZUZ/2fwrr7X4d/2VYbrjTdOum2/NLHIAGrjV1/TzGqz6YFuHGN7phs+x7VYVHSLfNqV0YCfliuOUX24NABqeo3Wm3ps7G4OlwnhvKlH8q0dOswyqq69eyO/X5FH61man4g020jEI09fOPSZV4/WotPjvtVlSS1KSOveX5F/Tr+NAHQa54fu7K2E0OrCRiOjsN2K5dZrW3w2t3OorEvJWB1O707V6OmhyXFjGNSSSQ4H+qVdv4c1a0/QdKf/RWuLi33ceWY+PxJ/pQB5t/wlQhlRdG1m5S26C2uLgDd+GM1qW8HiK7LXU93pUKuMAPg16XdeF9C03Tw0GmaReMo/wBa8RZv0qTw/wCHIdVTGoabINOyWdjF5a/Rc0Acd4f0vxckga11G0eM5y6fMP8AAU7UdA1x78Sy3jXszdYraPzSfb2r0G2n8OaVcmy0TSXuH+7gyjCn3Gamu9R1a3KtPI9tCTxBZlVbHuaAK2g6HqFlY+bf6ZIu8cRRAhm/3vSnXOn30sblNDihi7tJJ0qbUtYb7IGgt9VeQjkSXAy361zN7q+rXVkRcwyQxdBEDgH6+p9qAOc8T3dpbOvm3kQlH/LKIb8H8Kw47K78QJkBZFU5Uun9OlXWsvskUtxevznIjSLB+nNWZdWvl0r9xpt0LYrwrsI935cmgDE1SUWUYtJrqWVwpAgtUBP49hXA6lcgX4MknnT/AMMLnzNnscdK6fX9QufscsVvbGJiuSFXaB9W71xVhLcRxy74wCTkuAMfnQA+8fULuVY1ZgMdCQqj8OtZ1zHIoYyTvKy/eIf5PpmnS3REhjWN5Sx5JPB/DqajvLV3RWdJAq9FA7/0/GgCG2ae7CR7AlsDwOxq/f20s6LH548iP7xPyp+VUI4/3waZZDJ2DNwPwFMvLtN3lxxvz1dzwKAHvqCWsTRwlmJOOOKSOdY909w7b8f6lOfzNPsfLwRDAryt0dzn9KkktWwyKYsL8zljgD6n+lAGWWlmlMz5jjPRV6mnrPPK4BUrbr0jHA/GmSo7yqkRdwONx+UH8KsXSfIkMXMjcMTwBQA24PnJ03FfuqvCioI5VV2BUuzHJCjvU01sYo1jWYs3cjv7CnohtYSRGEB6sfvUAV5C3meZPjB4CCr8MkxtikAECNwW7t9aisbF7k/arp/KhX7oxkt+FLfXOFZLcKiL0UckfWgCirGVfMZNoT7zD/CppN0AS5hbP94juKY8MloVuIG3xg4LjnHsRT1lXerqmY2++AOP/rUAaSXjXECFEAP+1yD/AIVftdYSGQRX0OUzj94MlfcN3HtWK0Elk4ubTbJbuclM8Yre06S0ugRMnmRD/WQSjLL7qfSgDQ0+7gtr8RKuIZeUOMj3yKtS6XGbp2twLcyEbuNyN9R2rNezgtWD2F06xHlVbkD2reikS4sxJv23CdcHIIoAguNLnhT5lkhAHDR/On5/41QSO8siXWGKeI/e2jGfwroLR7/7Os2mTxTRMcNGTx+IqaIoZC8ttJbPn95ERlH91PagDI0rUNPuQVtpPstyDzHLnBPtXceG/GWs6e50+WC2mt36K7cEex7ViJp+g3Nxtus24f8A5abchfqa2734Z6muni5sLtby225VlPIHtQB0lt4hWLbGPOtiTnZIN6ZrettXTVLcQyTRJcgH5Q5BPoRnrXjeNasIzG8sksS8DzULEfU1JbahcvGfOTbjpIhOBQB7rovivXNJT7PdQQaraAcxsNsmPQZ4NS6pb+G9ZtftMGjPp9ww+dZLbKfoMfjXiCeKZogFUyMy8bomK/n61ci+JF1YDybr+0FRuFeLqfqp60AdtN4cubLF9o8avGmSYY2IBH1GR+lc9falBdS+VLataXnpIuRn2YVTt/F9zBL9ptr+8t2c9JbfAP4dK2Y/EN7qKFbi4tbkSDO2SEAfmKAHWUMdpqENyouLWVf+Xq1Zs5/2l6NXp+keONtt5N/dQ6lF0zJHtYD3riPD17pRdI9Rkmt3Q8EHK13NpaeGNWgxY3djPMOGjmITJ+tADLuy0DxNZu+kwSJPuBZYsHHqMZzUkXhvS7LSHmjCx3SqTtcsj/kajTwtZWt0Xt7uPRrpjwRJkOPY5ro7PR9Vt1Mv9rnVISAGjZVYH6UAec2cGkX9wD4gniVGOFDhZF/E4yKyfFulaHbS29vo62N1dXEogtbaCILLNIQSFVshR0JyxA4616tdWmkANJNotmzn72E2En3rzTxT4c0fUZJVtNMMaMMFQyur+oKGgDidX+H2ujTrW4tNGvjqam6fUbd2hcWyB1+zHaXCjMRctsLEkc1e034UXsOlW2p6f4gsbu3uo0mRGRmDqyhgwzyOCCOBx71MPCafZ9N07ULSH+z9Ke7ezP2XcWNxKkhyhG1NmzaCC2QxOBjBpReIdO03Wxbm/ju75n8tQtwNwb+7s3E5zxwBk9qAKOueFdSmWQTafp/mAYNwjlPxwazvD/hi8spixuDKG4+9uA+mK7u51yPUbwWaX+hTXZIUWjygS7uuMZzn2xT5tZg0YBNSFpCT/BbS7v8A69AFvRlu9PVD9kW64+88owPwNZeq63u1MLcFLaXPEcUW7P4irE+o+FLuLdGlzLet3ETYH1Y8Vz0unzLKZLMQgE/ed1UgfXNAHSXeueImtAmm2FrbRkZWaeXaxHqBjiqtodQ1KBrfUdcvLiV+PIt2IAPuapWekSyy+ZJqZVfvMkEgZj7A9qtX3ivQtBjML6WwnxkXMqlm/SgDWh0O38N27XWolY4wOAJhvb8RUFm11q8nmafIIrQc75nxj3z3rzDV/GL38wS1QSRgk75U4A9Oans/iJb6PGsd0beQKMLbxQbs+5btQB7PpCvbBt9xY3BJ5c56fhya19W8b6VpdsEikW6u8fLbQQhcH3715ponj+91xVtNNsbazhccys2MfpXQaB4e0/7RJeXWu2E87nLRwRmQ5Hq1AHPa94k1C4nkvrjS7aFj0M8owo9a8+1TWriaaS5tLwST9DO5+RB6KM16f43utONoILiOOYqCdm0Kv4+teP6xard3HntcNbWq/dhWMKp9gO9AGNdX7lTJdXv2gseSVbBPoKqy2tzfIJMRwwgcAnGfwrpksNRvoQwtYbO1A+WW4wCw/wBlfWpbnT4NKszc3kE0vHymUYz9BQBwXlsJWRZndx0IqtcTtbtsM80kp/iHIWutR7GSM3V4GjT+GNF2/pVSW4iuZT9ngSCBRzLt5NAGNY2aO3mSvId/3mkOWP0ArRXQ729mjj0rT55+ylwFT8RXXeGpbGHc8Nm1xIf+W0gCj8M1q33ip7SJ4o9kIxk+Sg/nQByc/hO70woNQnV7lv8AlhAM4/KqWs2KwRLAqAOqlhD1AP8AeY+vtW5Z3d9qF0RbQSkN97ywSzf8C7VavdNFugl1BoFOcrGWyP8AgXcmgDitA0a9vJJJ8KkOcfaJ+Av4d60b2007TiViY31433pX4VPoKtanqEC2q3EzSTqp2x5+SJD/ALI7muUvJJZZN8iSZPIH3VH1oAeXQTMEHmSk87eBTlgZ2D3BCRg/c/iJptu8cKklgZT/AAoOvvVOS8neY7RwPUZNAGnduJFw2QuMY6ACqE1vH5GG/dW6jOM8n6+tMSaRTvmIBHVj2+lQbZtRkPlLhF6s3T8fSgC1BcKzkBhHcDrx8rCqatH5pVEKZOOD0qG1BdvlYF1/hbv+NLOjbvNVGXHX2oA2oYLq2QKAHik7EfK30qexkntJ/LeBri3BzhB+8jHp7ip/DN5LBGwlCz2zjvzj61pXltbzyRtbTeXL/AucE/Q/40ARPHFNEZLScSJnlW4dT9KIL6e3UMYd8YOBJGOn+960+WFZeLuMx3KcidRg/Q1Xk3xvvtp1SXoyZ4YetAGzY3Yhna4togrN97B4P4VsSa7LFDvlt2ePuo5A965S1nmPyybDGerqMFfrVsXNxbhknffB/Cy0ATjUHkujLAVMTHJRuQPwrstF8cXWjqqWU6hWGDC7fKfp6V55C1tNdNGZ9kx+66jA/GpXufsk/lahBFJEeBKRjNAH0F4d+IHhK9fy9ct20y7ZQPMIzEfqelXdZ0/w3fqTZxQgyf6q4gOUf39K+eUvFgCoY1AByjK+Qw9wf5VrW+o/Y0L2YktHPJQn5G/D/CgDsR4SkivZUa18tTyJfvRt+INU7/wbct8typjTtJESQP8ACq+h+NLi1BEl4ynPIY7lqe78TtdBjcB9jf8ALW2k7fSgCgPD2o2ZSNNS86zYkb/NBx9QRV628KapNaF7Oe4kVeMxEOo+g61jPf2drL5sEs8u7jcy4I+orqPC3icWLhrOF0DHP7luv4UAcrNp2pRXRkmgnkki65DIfzrcsNUMqYgtg08Y+aOdcH6g17NoXifSdTYDULmSxnHQzwDafxrV1bw5oOqw+bNY2l8D/wAt7Ftkg+oFAHjVv4lvrWNIrnRpDETwHHmJ+ecitePx/e6MqSWENnbgnoSSP1robnwLod4skGl6vLazE48m66j2ya868S/DfUNMnYNOsiscgr8ymgD0ix+JgvrXztUR4T3MJyv5ZNZOp+JfC2tEwwXMkc3dkhKkH1zmvMLW11O2V4IrSFgvG4k4P4VXjt50uWebyomJ58qUqR+FAHung6wsJLeKMeLrXdvGI5Ww/wBOWHNcfpVvHLd+DtFvWjl8N3NtqLaoJIQIpYUuJybl5QP3bIyRMJNykFhg8mudsbmVQDdaVBcDP+sz82PX61T1Oay+xNprWl6lkzbjaNf3D2+c7gfKL7CA3O0jGaAE0aS4XwjYafr81vbLrFhBDo1jd+TAITvDtqTuqjYCwZUJLSSkk9CK9c1jTdNs5WQ2EfmFjw0ZLH8T0ryD7fpsekpYG+1tbcKI1t2vbhoAq/dXyy+0gYHBGOMYqzcXt7qe2W48QysQd3zYwP6mgDV1S4ns790/sWf7Mx2opkx+lV9RvNMgtw0mhNHcEZyw6n8M1rWmsWsdmFu9WtpnA6lOR+dcf4s1W1kXK3jSLnpEuaAMqbU7+W5YWczW0ef9We4/IVga7qOsICqJC6kYaRD8w/EmqN0Ybu4IWRol7M7dKp3MG18G8tZEHRRIc/jQA+S+cwgu0rSAfcyOT78U7TpZGm+0XtjG7LzGGbH51myXsEHyIU3nq3NOlu7UwgoHmPfJ2igDt7LWbeUA3lzJb+kNumRn61dHjGSzm+zaOhaV+pkByPx6V53BrDxxmKOdLZDwRGNxP41a021H2lZmm2Z7tnn3oA9DikR387WdQmknk58mNsgfXFWJJ7NGVorWZpB0cRjge2TVHSb2xsoB5StdSjq0aYH51Ld3M06tJIrRnqAT0oAunWk0qHzY7CEXDjIluW85x+fAPvXI6xrc+o3W+eSWWQ9BncR9KoanFc3bsqebK5OBjgD8ahi0+8s9seVDP97DZI/GgB1wHEiPdMu4dFLZY1JcXSKipMGOeiIOW+tZ93ElpKAQVlzjzG5IrV022021j+0TzT3MjDO9+APpQBDapdzThkSVU6CNW4/E1vWEdpE/mX5ywPQHkD3NYN3rSMfKsIZXHochSKzy97PP5jZA7Bf4foOlAHa6n4njtLYrbxtbwk4CqQhf69z+lYD6kJhl4y0snTJxj8+tZcUEgdrq4mQNnhnO4gUyW4Qhls1djj555Dlj7D0HvQAt5KqziWeVpyp+VeiJ+FUbjUPtLZHzkcAKvH/ARUvkI48y4GYxyFzgE+/rUc1z18oBAONyj7v0oAhkEpAWVxET/wAs0649SajMx/497FRuPDSAc/nUUsSxgyXTtvblY+rn3PpUsF1DbW5AXY7dVByT9aAIpbeJH2PKxI+8T1+lTPcL5QQAxWyjhO7H/aNVYiJt0juQoOdij+tRSKzOWkG0dg1AAkXGVYEdsHmrMM0sR3RHzAeGRuaqlE3EBvLcdj3pUVvNVnzgnGV9aANPzCmZ7JXt5x95AOG/Cte01dru2DXlmk0Y/jiwGWsy080Ptifzc/ejY4P/AAFq1Yre6tgZbcCaJvvLxxQBt6dqFhKFiuWZojwsg4dP97/GrN9oYdPNj2XdseQ6/eWuZDSO24qMnofun8G7/Stiw1OW34RXUjqBxn8KAK7Wd9ZqWgkM0bdPNHI9s1VOrJHmG9gEXGD/AAkf0NdBDrkVzlXGHPDZHX/gNW4baG/HlmK2vIz1hf5W/D0oA557dUiE/wBma4tz8waMb8flWhDdi5tdiBbqHH+rkUb1/wAK07PQ7XTnY6bNc2zZ3G3lbhT7djQwimm/0m2tZWPB3Dyn/wC+l4oA5meyg2stu3kH/nnMcDPsajg1W5sgIkCSgHBilG4fgea6m6geG3b7M83l94riMTR49mHIridQV4pxJBsUA5KrJ8o/Pn8KANmOawvo2aXT5bW4xxsbj61mSxlXBtHyQeSHwfxFRSPNNGCqodvP7qTDCsm6luEfzJCAB0dTlqAOnZ5DEX3OfXY+cVWtNRSCUk3FxGP7yD+dc/BeFnz57xtnqFwPxrTh1OZWDFg/q8aD9RQB3mkeLb6FAtlfmbH8Eq7wfzrQsviJq6XISTTVhkzxNbSFAR9K4mGd2QPsR89WQbG/GpZ7jz08p7l44z03YzQB7HpXj8tj+17e7kXsflbH4jmt1PHGi3CbbW7ljk7xzA8V4Xp0cloN8VyZvTBHH4Grn9oTFi8kEDkfxGPmgD2ga/bTRtHFNEWPPMTHNZF7pFhqEm6aSRZm/uJgfrXndhrMNxJskNorL1Q5U/nXXabqkKwBEtbojPLQv5mPw60Ab/8Awi8lnCGtCXXHQuD+lY9/4ae/O6WEtInIWJSGzWxp32icZiniYnpHINjj65qDUINXinV0kvUA7I6lT+NAHAapBqVlO1u0Mxjzgbkzj61QeC4tUM6yoG6lVXJ/KvSJPNmDectxGf4sru3VJBpuhiPdIYhL/thhQB5kNZe5UoLSR5PU2+M/pVK5S6kjb7XYkRgcDcFr2e10C2uYiyNYPBnkrIw4+maoXPhzSBKUtRbxyd2fcRmgD5/uvsrXBDRyIw6IhHzfhmnm4tbWMeZa2659yz19AWnw6t9TlAz5n+1Bbjj8TV/VfhvDpVsvkIRKRj95EKAPlp4BdzGSCDag/vI36UklqFPlx25kY/8APNScfj2r3q+8BvcoRd3Lo39yOLbVey+Cmvalxp0zRwk9GbZkfU0AeJQ2wgx56vF3CrgH8TUokWWRFSCSZAevmZH0r3uX9nTUY4C1xqNrHMe5bJp9v8GP7Gti1/rdu6DqsWFz+NAHnWjanJHCkX2OOPH3VHzfyraI81d91vLEcIeB+VO1vT7fT5zDZyHb0zGeT9TWDdWJ2uXkl245HmHNAEN9BEt6wmuooo/9/wCYD0AFaC/2XZ2f+jsu9h/rZ2/kKyrbTLSJvOWziJP8UrEkn2HerP8AZeoyvvtbC2hU/wDLa5OAP+AnpQBn3DWkT+fHbrczDpLMDtX6VnPeJKS0mZ5iM4ReB+Hap9ZkiiLJdaj58q8FIFwv4VifbIymyKUwAnnPLn2wKAGS3F6Z3KIVQHtwAPeoZLq5nYhT5gHUrwB+NWLiymnjVg8iQ45M527vwqszxWyBY5S56YQcGgCaz027uctcSEIfVuKnltlQeXCHcj1OF/P0qs1/PLEA8nlRn7qjrU9s8oQzbvn/AIS/T60AaFrYRwRebeHzJSPlXPT6VnapdD5lDLDH0+QZJqpJPeuzlHLM3Bk7fhUcVnx5r5lbr7UARorSqfs8bFehbqWPvTLhAmFl2r6heWP1qxPeBYykbhAfvbBzVaMJGPNkQ47buS1ABHIz4SGPgdV/+vUUrFnO88Dt1qRrqUqVjURqf7o61X4ByTk0ATSRMvyyJtk9W6GkVzGy53Y7g8CpobpzCUuI/Oi7eq/SowSCdh82PuCMkCgDWgEF2i/P5Uq/cYj/ADmrNvqmo6dc8eW59AeGrIiVWT5ZHVexXn86ntmYPh2SSM9HU8igDrYphqaGSySITgZkt5fl3n2qGO5EFx9nvLOe1k9HHyn/AHTVM3G2MefGSFA2yAYI/GtS21Of7OPOH2y2H98bmT8aAJgruhkt0iuov4kcbXT8e9LHK4lU/Z5VjPRh1WtPTb61lKywgM69CCAw9sd6nvr61mUtJHhs8yRrhh9VoAgaXVsAq6XUPUEj5gPxqSO7hZCmr2CPHj78RKkVVFymMxkTw4+9C+HX6iop7yeBMoj3EB7EfOPw70AM1PZZMsuhanMU7wTHdj2rm7/VzOS17aJIRwSBgj3+lWr2FZJmkgcK/Upko35dKyLmYx5AuWA7pIm4/nQBXkNpOvmWiTROOmw4qr9plRhkOT3Ei9fxppWKGYSKwkB52jjFWHuYJkCmN+nVTyKAGIPO5ZZIf93kVKixRqfMZx/tJwTWeQTIfKkZh6McGnyxMibmMgX/AHqANNL5IWHlz59i1TPm5T5mgcehbmsa3Ab5Y3Qn0kH9acUVZQJGUEd1b/61AHXaVboYiPtBgPYEFh+dXbq4ubeLY19akdjzn8q5eG6ltgPKE7RkcbCD/SpodRJlJWZkc9pI6ALvmSSvuZUuD2KLg5rX068nhUb0ubcA9Ub+dYp1F+FuyFPZ0GM1FtlZ/NjkaaMnkM/b6UAegaVqcpcM1606A9JDkj9c1vv4nVExDPCXH8O7p+deWre2luQYbdY5D15PWpxqhlK+ZYRv/wBNAcY+tAHoaazqN9IRHqWznGwRirMX9pxvmeV3j7iQhQa4O21AIQ0d0kR9C3AqzealNdoEa7tZF/2jQB3r+IbS0YJ9pt4mH8Kjcc1OfGPlxH/SPNPYMmK8yiKQRljcWi/7u0n86x7vVojcMFMs7L02t8v6UAenyeLNRacvFfPboeyPtFWz401OQqv2szJ3LykmvIo7prqQiZGCn7qqCc/jmtGASwqGgmW3U9Q0gzQB6Td+I5QnyXE6yn0cHmpNC8XajA7Kupyg56SSZrzUXT5IDmVx/GGHH6U63nuFY7pJix/hVxj88UAe0S+Pd0e27uzcSeikisG+8XrcsUSRI1+hz+tedzaqbTDCNi57kAmse51u9uJjlwiDoAoJ/EdqAPQr3U7Xdm2tzPIerHgZrn7+/tYJibrDyH/llHzj6mubOryqB5tyB/sheaYl99obHlSMP73TNAHRJ4hs4QFs4iJDwWVc4P1NY+ragZdxlaW4fspYnFUbqZ1AjtbVQx7gZIq3Z2QgQPqV/DCWH3UGWNAGZIWVfMaFnOOnQCqUf2q6lzBCSq9MgKF9/et7UJ7EQFbY+YfUnJNc45YyATbljzkIhyW/woAfdROz7JrnfI3OC278x2qIRW6kRxs0s3fbwBU3nw4KrGsK9wfvH6+tNjvVhJ8nAJ/uKDQBD5RilxKFjHpjLH6CryWvmsolYxr2VnyzfgOlT2doW/e3UiwhvTkt/hWnHd2emjNpZtPcEdSvT3yaACPSYlj8y5V1i6JGvV6yNbdYmET7Y0P3beM5I+pqzq2r3ksZa4YW+4cKG3N+A7VzwMjD5Iss3/LQgkn3oAcEVBuk2p/sY5qGWQMc/Mx7Z7CgqhbG5mk9+lThVhjOzEr9z2X6UAUyT3JpdwA4Xn3pSpYFzSZJXgACgBVJXs2ParFrciJydoJPHIqOWOWJ/nUjHcdKkjkimxHMFA7SDgj8KAJv3MjkxkxyHrt6UnloOJSoJ6Mn9ajkt3t2VtxeM9celHkNsZ7SUSIOq9/yoA2dNvhFHskkWVO+avwCJ5A1jO0Ex58sN8j1y8ZRnCzRBXHQjj9KnELRsrQM45zgHOfwoA6pHtvOCzo8Nx3x8hb/AHe1W3uLQqc3EruowFkG1x+Peudi1y5jgCTwxXka9VlU7l+lXRq2n3saKIhDJjAVzkA+x6igCp9ot/tpMMrRSk8hl+U/jV+W8ng+dEk9R824H6Gox5SSZx5LgcGZRJG349aZ5sKDBH2X/bhO6Jvw7UAR3Wof2lFsktpFlXujYI+lYl00sbBZ98kXYSL8wrTuY5QfOguYn77kH8xWfLqMmD5iRP2JBoAgnEGzKKxPXNVEJVgUBzUjMjkkMyZ7dRSLKyHGFYe4oAdI6nDhGWQdx0qY3TzqI8IPdulQgrIcjCH2NSeYCNrlQfUoCD+VADHWWE52hR/snNWLe8nLf62IezCq8czI2QnHoMipGlhc/PCFb2NAG5bXLvHta4gGex6VFcLdRndHskB9HDA/hWMsdvnJlZc9sEY/Gmq4gcmB3b6UAXpL6927URoyPbimrf3cLAllB9RgVCl5Jg75n+hWhZJM7n259GTKkUAW5ru4l+Yhm+gWpbbU5EG13WPP99QRUEV/Ftw9qhPrEcfpQby1Y4e349GIzQBrxrbSKHaRXc87VGAacLhC21LOFG/vSjj86xVu7dT+4hYMOnz4psl+0pCXGQvoJKAN6SKdkybjT4V/2FBqsZUhB8yeGT3VlGaoRmLbmKFGHq4aT9DxTNhlkAbZGvqluBQBNJd2MjcW5U+odqLUWok3RWsjMO53EfrUd3CYI/M892I6A/LVI3M8w2vcYHpQBuuWkjINy0ZI4UHpVGOO5iky1y7J/wBdMVRwIAWJZiR1NJGwl+UzhD6MuaANK61GLaIj5rEddj8mqLFy3yy/Z093yaeLSTBKysy9yBtqSF44vlCW49TncaAGp9mxkPdzyf3hwtatrDlQ7ytGD0JPSsmeWNnA8wLj0NWLKyilw7XDEZ7jpQBpXN6tpGwtDJJL3d+n4VgTObqXzJpMydyAc1q3dxp9ujJEJbiT1bgA1jyXc8/yghV77RjFAEgaRzsjMgU9yuKebPyk3tMQO5HU1WiYoTiQA/3sjJqOWQu+S+4erHNAEzSRRkiBWd/770kEohO5UQSernNEKNLwIy4HU5wKikIDkAg/TgUAaNtftA5PmCRz1cjIFOS9M7HzboqtZseHzwD6knArTjs4YIhcSyKo6qTzn8KAHRW8Mjbo4ZAD/wAtHPX6UyeVgfJtWWJejvnrUE968i7FkYJ2C9TVPl8oBt7nufxoAuI9pBwMSMOpx1NU5pTNJwuFzwoprKuPkzgdW9aFkKfd6+tABIrIArYHqophPoMUuCeTx/WkAZumOKAJUnkC4DnHoelKysRvCqQOoqIkZ6EZ7CnRkxuCOQev0oAu2bSGIhUE0f8AFHn5hVqFbUlpCJEb34K1FZwxtKJLWby3B5Rhwa22tkuo/uBJx0z/ABUAZzNBKGU+XdoOuPlkX6eoqsIEAZoC1wi+jbZE/wCA96feWirkTRGKQHG4Vn3EUsZBbc2Ojr6UAatlqGW8meHzMdHIw1O1G2ZF81bOR0PXKYH5iscTysCjMH9m6itbRdavNOuQhmZYu6SHigCXT9YggQRSxOyDsDhh+fWr0l7psiEsUdT2ddjj/GtC4m0jVIR9ut0jkYZEseBXO39otmxNjfxyxnkK3agCtqK26p5tlLJjsrVksSxz371fEczkmIxqf9k4zVRgxkKyEK1ADERnOFGTSsjL94FaGCqcE5PqKdHK0Z4br1zQBHx3qVCgHysQTxtK5p8jiQcGPPpjB/OoCvOCDn36UAPAKvhsKPrUrSKgAVUc98HNQImWxwR9cVKYSDlYmP4g0AOjt55wXjj+UdRmnebPB8qoVP0zUDK6/eLR+xyKNzD+NDQBZa5eUhSAGPY8ZpVEUQ/epMhPdW4qLzpiu35dvtTJRKVXecr26UATvCjcqV2H+IjFRriP5QtvJ755qJWkAwmQPakO/qwf64oAvqbYANJbAH2bj8qUXEDfKq7D7JUcEsCqQJX3Ed0FWLdpd+RIr+23FAC7poFLJcAKezcGoftLOx8yaZ/ZGwKXUZWIAaOMHuc5qgJnD8Ntzx8oxQBJKySsoVWDE/xNup8ljMib8BvamvCSu7zst7mmxgsf3s+B7NQBGYz3BHtihW2N3zUjRRFvkkZx/u0EQAfKsjt6E4FADnJkVcsqj0Zs1GYto3fMfoOKTKnnaq47ZNTxxELvklVVPr1/KgCFTGh+ZST1p/m5OSGUduajmZCTsd29zUYLHjJoAuJdgJgxBz6momZn7FV/uoKktojGNzhCewJpkqs7Enj+VADDIFACRoD78mpIg5y7MqY6sy/ypu9IRhEy/qTUbSM53Ngnt2xQBYaXcmAsjKepBxmoiiM3zgRL+Zphmkb+Mj6U3g9dxb3oAmDRxtmKMsf4Weo3aSeTLHJ/IUrYxy35HOaQ7QvDEnuKAJYoVX78igHsDSOw5jRyUHQJ3+tNQRKN0pyf7gH9alYzFMqgROwoArbiM4yB0qWPYq7n/IdajIAOXOWPYUmc+gHoKAEY5Y4zj0NJml79aQ0AB61ZCg2O8/f37c+1FFAEO4iXgkY9K2YpZGABdsD3oooA1beV7iHy5z5iZxhgDVIgJM6KPl9OtFFAFGeKM3jxlBtAJxVGRQs5Qfc9DzRRQBJbsyPtUkLnpTr+NVIYDDHrRRQAySNVSNlGCRzg1WeiigAB+SmgcGiigBKMmiigB0X38dqvGGPGdoB9uKKKAK6TyB9m8lc9DzVnyY2wxUZNFFAFOcBX44pg5PNFFAASVIKkg0quzH5mJ/GiigC08SeVu28+tVfMccBiB9aKKAJ4HYrks3500zSJIQrHn15oooAikJaU5qfA2dB+VFFAFfcV+6SKd0APOfrRRQALNIv3WxUsJ3q7P8zepoooAbCPMch+QKmuD5aDZgfQUUUAVY+Tk81bjRWB3DNFFAEcihRwAKrnnOaKKABScGlaiigCS2RXJ3DPBpj8PxxRRQBH3pxdmxlicUUUALENz880sww/FFFACY4pveiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image revealing a microcystic lesion with a honeycomb appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42371=[""].join("\n");
var outline_f41_24_42371=null;
var title_f41_24_42372="Contents: Adult medical emergencies";
var content_f41_24_42372=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult medical emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult medical emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acid peptic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/18/42281\">",
"           Overview of the natural history and treatment of peptic ulcer disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Adrenal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33800\">",
"           Clinical manifestations of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/48/22282\">",
"           Epidemiology and clinical manifestations of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/63/1016\">",
"           Overview of the treatment of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/47/42745\">",
"           Treatment of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Airline",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/15/7417\">",
"           Management of inflight medical emergencies on commercial airlines",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37834\">",
"           Pharmacotherapy of allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/56/5002\">",
"           Treatment of acute exacerbations of asthma in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bacterial infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/48/39688\">",
"           Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/15/2297\">",
"           Acute sinusitis and rhinosinusitis in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/33/12825\">",
"           Cellulitis and erysipelas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/62/12264\">",
"           Clostridial myonecrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6616\">",
"           Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/38/5738\">",
"           Evaluation of acute pharyngitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/62/32743\">",
"           External otitis: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/22/362\">",
"           Necrotizing soft tissue infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/52/8010\">",
"           Staphylococcal toxic shock syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/38/2666\">",
"           Treatment and prevention of streptococcal tonsillopharyngitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary tract disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/33/29208\">",
"           Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/9/15511\">",
"           Treatment of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21992\">",
"           Ultrasonography of the hepatobiliary tract",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Brain tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/3/25657\">",
"           Clinical presentation and diagnosis of brain tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac arrhythmias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/19/31034\">",
"           Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/37/28250\">",
"           Brugada syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39481\">",
"           Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/54/28522\">",
"           Epidemiology of and risk factors for atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/15/18682\">",
"           Evaluation of syncope in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4490\">",
"           Evaluation of the survivor of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/6/39016\">",
"           Management of new onset atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/26/22952\">",
"           Management of nonsustained ventricular tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/21/30041\">",
"           Outcome of sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/22/361\">",
"           Overview of atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/20/6473\">",
"           Overview of the acute management of tachyarrhythmias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/60/13256\">",
"           Overview of the evaluation and management of atrial flutter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/42/18087\">",
"           Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/62/998\">",
"           Second degree atrioventricular block: Mobitz type II",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/50/3878\">",
"           Sinus bradycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/25/14742\">",
"           Sinus tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/24/8585\">",
"           Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/32/29193\">",
"           Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15285\">",
"           Third degree (complete) atrioventricular block",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cerebrovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/60/31688\">",
"           Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/17/40216\">",
"           Clinical diagnosis of stroke subtypes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/21/18773\">",
"           Definition of transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/39/38522\">",
"           Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/11/32953\">",
"           Headache, migraine, and stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/29/33242\">",
"           Initial assessment and management of acute stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/56/17290\">",
"           Neuroimaging of acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/47/28410\">",
"           Overview of the evaluation of stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/8/41098\">",
"           Reperfusion therapy for acute ischemic stroke",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/33/32281\">",
"           Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/54/37738\">",
"           Treatment of aneurysmal subarachnoid hemorrhage",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cirrhosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/22/34153\">",
"           Clinical manifestations and diagnosis of hepatic encephalopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/0/7172\">",
"           Clinical manifestations of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/0/12296\">",
"           Diagnosis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/15/4346\">",
"           Hepatic encephalopathy in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/1/4121\">",
"           Treatment and prophylaxis of spontaneous bacterial peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/61/23514\">",
"           Treatment of active variceal hemorrhage",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         CNS infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/3/15417\">",
"           Aseptic meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/37/23129\">",
"           Clinical features and diagnosis of acute bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/40/17033\">",
"           Epidural abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/32/44552\">",
"           Infections of central nervous system shunts and other devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/17/22810\">",
"           Initial therapy and prognosis of bacterial meningitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/13/38104\">",
"           Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/43/32438\">",
"           Treatment and prognosis of brain abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/3/38968\">",
"           Viral encephalitis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coagulation disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/57/8089\">",
"           Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/3/5178\">",
"           Approach to the adult patient with a bleeding diathesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/30/35305\">",
"           Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/20/25929\">",
"           Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/13/24794\">",
"           Clinical presentation and diagnosis of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/1/29721\">",
"           Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/31/42490\">",
"           Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/34/38442\">",
"           Treatment of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/22/21866\">",
"           Treatment of von Willebrand disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         COPD",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/5/23641\">",
"           Management of acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coronary heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/10/30890\">",
"           Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4282\">",
"           Conduction abnormalities after myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/39/25209\">",
"           Criteria for the diagnosis of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/43/15034\">",
"           Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/27/8634\">",
"           Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/41/44697\">",
"           Overview of the acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/20/37193\">",
"           Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/59/7098\">",
"           Overview of the non-acute management of ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/33/44569\">",
"           Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/14/25830\">",
"           Prehospital fibrinolysis (thrombolysis) for suspected acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/37/35418\">",
"           Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/31/37369\">",
"           Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/27/11701\">",
"           Serum cardiac enzymes in patients with renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16615\">",
"           Supraventricular arrhythmias after myocardial infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Critical care medicine",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/15/29945\">",
"           Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/48/4871\">",
"           Acute respiratory distress syndrome: Prognosis and outcomes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/20/5448\">",
"           Hyperbaric oxygen therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Crystal diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/24/17800\">",
"           Treatment of acute gout",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28057\">",
"           Evaluation of cognitive impairment and dementia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes mellitus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/39/26233\">",
"           Management of diabetes mellitus in hospitalized patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Electrocardiography",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/10/22689\">",
"           Differential diagnosis of basic electrocardiographic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/24/11658\">",
"           Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Epilepsy and EEG",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25753\">",
"           Evaluation of the first seizure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/11/19642\">",
"           Status epilepticus in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Esophageal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/58/29606\">",
"           Boerhaave's syndrome: Effort rupture of the esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/17/12569\">",
"           Evaluation of dysphagia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/54/21353\">",
"           Ingested foreign bodies and food impactions in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/19/43317\">",
"           Mallory-Weiss syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fluid and electrolytes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/29/6613\">",
"           Alcoholic and fasting ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/44/31432\">",
"           Approach to the adult with metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/5/33882\">",
"           Causes and evaluation of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/17/5402\">",
"           Causes of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/30/3562\">",
"           Causes of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/44/3781\">",
"           Causes of lactic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/22/8551\">",
"           Causes of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/2/9258\">",
"           Clinical manifestations and treatment of hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/2/44069\">",
"           Clinical manifestations of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/63/36857\">",
"           Etiology and evaluation of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/42/1706\">",
"           Exercise-associated hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/53/10074\">",
"           Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/34/18986\">",
"           Overview of the treatment of hyponatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/24/41353\">",
"           Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/41/27288\">",
"           Simple and mixed acid-base disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/54/17258\">",
"           Treatment and prevention of hyperkalemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/52/24393\">",
"           Treatment of hypernatremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/14/14568\">",
"           Treatment of metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/20/13639\">",
"           Treatment of severe hypovolemia or hypovolemic shock in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/7/5242\">",
"           Acute appendicitis in adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/21/44377\">",
"           Acute mesenteric ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/24/34181\">",
"           Anal fissure: Clinical manifestations, diagnosis, prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/6/34919\">",
"           Clinical manifestations and diagnosis of colonic diverticular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/20/42313\">",
"           Colonic ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/54/20324\">",
"           Diverticular colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/6/7272\">",
"           Etiology of lower gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/15/3319\">",
"           Management of severe ulcerative colitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/54/19305\">",
"           Overview of the medical management of mild to moderate Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/11/6329\">",
"           Overview of the medical management of severe or refractory Crohn's disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/15/24826\">",
"           Overview of the treatment of bleeding peptic ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/40/26246\">",
"           Perianal abscess: Clinical manifestations, diagnosis, treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/53/26453\">",
"           Sigmoid volvulus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/46/14058\">",
"           Small bowel obstruction: Causes and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/38/8807\">",
"           Small bowel obstruction: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/8/13450\">",
"           Treatment of acute diverticulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/61/6105\">",
"           Treatment of hemorrhoids",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/29/20954\">",
"           Clostridium difficile in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/27/18868\">",
"           Prevention and treatment of viral gastroenteritis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/29/29145\">",
"           Travelers' diarrhea",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General oncologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/58/7077\">",
"           Assessment of cancer pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/9/39066\">",
"           Cancer pain management: Adjuvant analgesics (coanalgesics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4488\">",
"           Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/56/19338\">",
"           Malignancy-related superior vena cava syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/21/26970\">",
"           Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Headache",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21194\">",
"           Acute treatment of migraine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/11/32953\">",
"           Headache, migraine, and stroke",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7544\">",
"           Evaluation of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/55/35701\">",
"           Nesiritide in the treatment of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/53/28503\">",
"           Pathophysiology of cardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/40/38538\">",
"           Acute liver failure in adults: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/18/34090\">",
"           Approach to the patient with abnormal liver biochemical and function tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/30/17897\">",
"           HELLP syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Interventional pulmonology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/36/35399\">",
"           Airway foreign bodies in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/13/26838\">",
"           Massive hemoptysis: Causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/47/30454\">",
"           Massive hemoptysis: Initial management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Labor and delivery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/7/26742\">",
"           Mechanism of normal labor and delivery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mineral and bone metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/43/28346\">",
"           Osteonecrosis (avascular necrosis of bone)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/1/19481\">",
"           Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/20/3402\">",
"           Tumor lysis syndrome: Prevention and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myopericardial disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/52/19273\">",
"           Cardiac tamponade",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/47/37625\">",
"           Clinical presentation and diagnostic evaluation of acute pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/12/12490\">",
"           Constrictive pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/44/713\">",
"           Treatment of acute pericarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic examination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/30/38377\">",
"           The detailed neurologic examination in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/33/10777\">",
"           Causes of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/55/32632\">",
"           Clinical manifestations and diagnosis of rhabdomyolysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/23/36216\">",
"           Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/27/9655\">",
"           Bell's palsy: Prognosis and treatment in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/32/8712\">",
"           Differential diagnosis of peripheral nerve and muscle disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/15/42233\">",
"           Overview of lower extremity peripheral nerve syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/44/8906\">",
"           Overview of upper extremity peripheral nerve syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Office gynecology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/49/36633\">",
"           Approach to women with symptoms of vaginitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/41/20122\">",
"           Chronic menorrhagia or anovulatory uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/9/1178\">",
"           Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/5/31833\">",
"           Emergency contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/23/19834\">",
"           Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/35/7738\">",
"           Treatment of acute pancreatitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Peripheral arterial disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/3/13368\">",
"           Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14486\">",
"           Clinical manifestations and evaluation of chronic critical limb ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/16/10506\">",
"           Noninvasive diagnosis of arterial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/58/19370\">",
"           Treatment of chronic lower extremity critical limb ischemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Platelet disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/19/15674\">",
"           Approach to the adult patient with thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/6/24681\">",
"           Approach to the patient with thrombocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pleural disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/3/10297\">",
"           Primary spontaneous pneumothorax in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/35/24121\">",
"           Secondary spontaneous pneumothorax in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/15/41207\">",
"           Clinical features and evaluation of nausea and vomiting of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/13/35032\">",
"           Clinical features, diagnosis, and course of placenta previa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39801\">",
"           Eclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/13/32982\">",
"           Overview of Rhesus (Rh) alloimmunization in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/46/29417\">",
"           Placental abruption: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/20/27978\">",
"           Preeclampsia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/44/40648\">",
"           Prevention of Rh(D) alloimmunization",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary care ophthalmology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34600\">",
"           Corneal abrasions and corneal foreign bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/12/17607\">",
"           Evaluation of the red eye",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/41/36504\">",
"           Retinal detachment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Red cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/46/29418\">",
"           Approach to the adult patient with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/11/42170\">",
"           Overview of the clinical manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/38/25190\">",
"           Diagnosis of urinary tract obstruction and hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/60/35785\">",
"           Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/54/12138\">",
"           Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/61/36823\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/34/43560\">",
"           Management and complications of tuboovarian abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin soft tissue bone infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/50/12071\">",
"           Approach to imaging modalities in the setting of suspected osteomyelitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/33/538\">",
"           Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/51/43831\">",
"           Skin abscesses, furuncles, and carbuncles",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14503\">",
"           Clinical manifestations of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33655\">",
"           Thyroid storm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/53/43865\">",
"           Treatment of hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tick flea mite louse borne",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/51/14135\">",
"           Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/48/28425\">",
"           Diagnosis of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/54/27498\">",
"           Treatment of Lyme disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/24/14725\">",
"           Treatment of Rocky Mountain spotted fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/20/44360\">",
"           Evaluation of the acute scrotum in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/48/33543\">",
"           Paraphimosis reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/39/29302\">",
"           Paraphimosis: Definition, pathophysiology, and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Valvular and aortic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/35/20022\">",
"           Acute aortic regurgitation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22712\">",
"           Clinical features and diagnosis of thoracic aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/8/31881\">",
"           Indications for valve replacement in aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/7/10361\">",
"           Management and outcome of thoracic aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/43/41654\">",
"           Medical management of symptomatic aortic stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/53/30551\">",
"           Natural history of aortic stenosis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/31/6649\">",
"           Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/33/18969\">",
"           Clinical manifestations of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Venous and pulmonary vascular",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/32/42503\">",
"           Treatment of acute pulmonary embolism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vertigo",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/15/13559\">",
"           Treatment of vertigo",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections (except HIV)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/7/15479\">",
"           Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/18/31018\">",
"           Infectious mononucleosis in adults and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/55/24440\">",
"           The common cold in adults: Diagnosis and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         White cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4ABD18B6F3-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_24_42372=[""].join("\n");
var outline_f41_24_42372=null;
var title_f41_24_42373="Benzoyl peroxide: Drug information";
var content_f41_24_42373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzoyl peroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/55/15221?source=see_link\">",
"    see \"Benzoyl peroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/60/18372?source=see_link\">",
"    see \"Benzoyl peroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Clear Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      BenzEFoam Ultra&trade;;",
"     </li>",
"     <li>",
"      BenzEFoam&trade;;",
"     </li>",
"     <li>",
"      Benziq&trade;;",
"     </li>",
"     <li>",
"      BP Cleanser [OTC];",
"     </li>",
"     <li>",
"      BP Cleansing Lotion [OTC];",
"     </li>",
"     <li>",
"      BP Wash [OTC];",
"     </li>",
"     <li>",
"      BPO;",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; advantage&reg; 3-in-1 [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; continuous control&reg; [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; persa-gel&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Clearskin [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 5 [OTC];",
"     </li>",
"     <li>",
"      Inova&reg;;",
"     </li>",
"     <li>",
"      Neutrogena&reg; On The Spot&reg; Acne Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Clinical Clearing Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Face Wash [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Spot Treatment [OTC];",
"     </li>",
"     <li>",
"      Pacnex&reg;;",
"     </li>",
"     <li>",
"      Pacnex&reg; HP;",
"     </li>",
"     <li>",
"      Pacnex&reg; LP;",
"     </li>",
"     <li>",
"      PanOxyl&reg; Bar [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg; [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-4 [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-8 [OTC];",
"     </li>",
"     <li>",
"      PR&trade; Wash;",
"     </li>",
"     <li>",
"      SE BPO;",
"     </li>",
"     <li>",
"      TL BPO MX;",
"     </li>",
"     <li>",
"      Zapzyt&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetoxyl&reg;;",
"     </li>",
"     <li>",
"      Benoxyl&reg;;",
"     </li>",
"     <li>",
"      Benzac AC&reg;;",
"     </li>",
"     <li>",
"      Benzac W&reg; Gel;",
"     </li>",
"     <li>",
"      Benzac W&reg; Wash;",
"     </li>",
"     <li>",
"      Desquam-X&reg;;",
"     </li>",
"     <li>",
"      Oxyderm&trade;;",
"     </li>",
"     <li>",
"      PanOxyl&reg;;",
"     </li>",
"     <li>",
"      Solugel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acne:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Topical formulations:",
"     </i>",
"     Apply sparingly once daily; gradually increase to 2-3 times/day if needed. If excessive dryness or peeling occurs, reduce dose frequency or concentration. If excessive stinging or burning occurs, remove with mild soap and water; resume use the next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Topical cleansers:",
"     </i>",
"     Wash once or twice daily; control amount of drying or peeling by modifying dose frequency or concentration.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/60/18372?source=see_link\">",
"      see \"Benzoyl peroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2566147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical [emollient-based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzEFoam Ultra&trade;: 9.8% (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BenzEFoam&trade;: 5.3% (60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bar, topical [wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg; Bar: 10% (113 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cloth, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BPO: 3% (60s); 6% (60s); 9% (60s) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearskin: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; On The Spot&reg; Acne Treatment: 2.5% (21 g) [vanishing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum Spot Treatment: 10% (18.4 g) [vanishing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [cleanser]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; continuous control&reg;: 10% (141 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 2.5% (60 g); 5% (42.5 g, 60 g, 90 g); 10% (42.5 g, 60 g, 90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acne Clear Maximum Strength: 10% (42.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benziq&trade;: 5.25% (50 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BPO: 4% (42.5 g); 8% (42.5 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; persa-gel&reg; 10: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zapzyt&reg;: 10% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [cleanser]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleanser: 4.25% (480 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TL BPO MX: 4.25% (480 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [emulsion-based/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg;: 7% (480 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [wash]: 5% (148 g, 237 g); 10% (148 g, 237 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Wash: 5.25% (175 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Maximum Face Wash: 10% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;-4: 4% (170 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;-8: 8% (170 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PanOxyl&reg;: 10% (156 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SE BPO: 7% (180 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical [wash/water based]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benziq&trade;: 5.25% (175 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desquam-X&reg; 5: 5% (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desquam-X&reg; 10: 10% (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 5% (30 mL); 10% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OXY&reg; Clinical Clearing Treatment: 5% (35.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [cleanser]: 6% (170 g, 355 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clean &amp; Clear&reg; advantage&reg; 3-in-1: 5% (141 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [emulsion-based/wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PR&trade; Wash: 7% (473 mL) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical [wash]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BP Cleansing Lotion: 4% (297 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inova&reg;: 4% (30s); 8% (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg; HP: 7% (60s) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacnex&reg; LP: 4.25% (60s) [contains aloe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Gel, lotion",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of mild-to-moderate acne vulgaris and acne rosacea",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benzoyl peroxide may be confused with benzyl alcohol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benoxyl&reg; may be confused with Brevoxyl&reg;, Peroxyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benzac&reg; may be confused with Benza&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brevoxyl&reg; may be confused with Benoxyl&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fostex&reg; may be confused with pHisoHex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%: Dermatologic: Irritation, contact dermatitis, dryness, erythema, peeling, stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9610539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzoyl peroxide or any other component of the formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9610540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleaching effects: May bleach hair, colored fabric, or carpet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin irritation: Discontinue use if severe skin irritation or redness occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eye, eyelids, lips, and mucous membranes. Inform patients to use skin protection and minimize prolonged exposure to sun or tanning beds.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; ~2% of the applied dose is expected to be absorbed systemically (Akhavan, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9610538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if benzoyl peroxide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering benzoyl peroxide to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bar",
"     </b>",
"     (PanOxyl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (1): $5.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Clearskin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (30 g): $3.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (BenzEFoam External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.3% (60 g): $243.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (BenzEFoamUltra External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9.8% (100 g): $268.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (BenzePrO External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.3% (60 g): $208.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (BenzePrO Short Contact External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9.8% (100 g): $230.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Benzoyl Peroxide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.3% (60 g): $213.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benziq External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.25% (50 g): $88.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benziq LS External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.75% (50 g): $84.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benzoyl Peroxide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (60 g): $19.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (60 g): $20.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (90 g): $25.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Clearplex V External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (45 g): $3.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Clearplex X External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (45 g): $3.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (OC8 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (45 g): $24.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Inova External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 &amp; 5% (58): $225.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 &amp; 5% (58): $225.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lavoclen-4 Acne Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (1): $62.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Lavoclen-8 Acne Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (1): $64.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benzac AC Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (226 g): $166.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benzac W Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (226 g): $166.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benziq Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.25% (175 g): $80.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Desquam-X Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (140 g): $26.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (140 g): $28.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Lavoclen-4 Creamy Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (170.1 g): $55.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Lavoclen-8 Creamy Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (170.1 g): $57.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (PanOxyl Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (156 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (PanOxyl-4 Creamy Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (170.1 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (PanOxyl-8 Creamy Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (170.1 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (PR Benzoyl Peroxide Wash External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7% (473 mL): $136.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Benzoyl Peroxide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 mL): $3.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (30 mL): $3.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Oscion Cleanser External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6% (170.3 g): $47.39",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Derm (IL);",
"     </li>",
"     <li>",
"      Acnecide (IE);",
"     </li>",
"     <li>",
"      Acnetick-10 (CO);",
"     </li>",
"     <li>",
"      Acnexyl (TH);",
"     </li>",
"     <li>",
"      Acnie (TW);",
"     </li>",
"     <li>",
"      Aknefug (EE);",
"     </li>",
"     <li>",
"      Aknefug-oxid (PL);",
"     </li>",
"     <li>",
"      Akneroxid (AT, BE, CH, CZ, DE, HK, HN, HU, LU, MY, NL, PL, SG);",
"     </li>",
"     <li>",
"      Ambix (PL);",
"     </li>",
"     <li>",
"      Antopar (HR, PL);",
"     </li>",
"     <li>",
"      Basiron (CZ, DK, FI, NO);",
"     </li>",
"     <li>",
"      Basiron AC (SE);",
"     </li>",
"     <li>",
"      Benoxid (IT);",
"     </li>",
"     <li>",
"      Benoxyl (AE, BB, BF, BH, BJ, BM, BR, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Benoxyl AQ AL (MX);",
"     </li>",
"     <li>",
"      Benzac (AU, IL, IT, LU, PT);",
"     </li>",
"     <li>",
"      Benzac AC (AU, CO, HK, MX, MY, NZ, PE, PH, SG, TH, TW, VE);",
"     </li>",
"     <li>",
"      Benzac MR AC (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Benzac W (BB, BM, BS, BZ, CN, GR, GY, JM, MX, PR, SR, TT);",
"     </li>",
"     <li>",
"      Benzacne (PL);",
"     </li>",
"     <li>",
"      Benzapur (PL);",
"     </li>",
"     <li>",
"      Benzihex (AR, CL);",
"     </li>",
"     <li>",
"      Benzihex AC (PY, UY);",
"     </li>",
"     <li>",
"      Benzoile Perossido (IT);",
"     </li>",
"     <li>",
"      Benzolac (ID);",
"     </li>",
"     <li>",
"      Benzomix (IT);",
"     </li>",
"     <li>",
"      Benzoylperoxide-Galderma (LU);",
"     </li>",
"     <li>",
"      Benzperox (BG);",
"     </li>",
"     <li>",
"      Bexid (SE);",
"     </li>",
"     <li>",
"      Brevoxyl (AU, CH, DE, FI, FR, HK, NZ, PK, PL, SE, SG, TW);",
"     </li>",
"     <li>",
"      Clearasil Ultra (IT, PL);",
"     </li>",
"     <li>",
"      Eclaran (FR, LU);",
"     </li>",
"     <li>",
"      Ecuaderm (VE);",
"     </li>",
"     <li>",
"      Effacne (FR, LU);",
"     </li>",
"     <li>",
"      Enzoxid (TH);",
"     </li>",
"     <li>",
"      Lubexyl (PL);",
"     </li>",
"     <li>",
"      Medigel (PL);",
"     </li>",
"     <li>",
"      Oxiderma (ES);",
"     </li>",
"     <li>",
"      Oxy (BR, HU, PE, PL, SE);",
"     </li>",
"     <li>",
"      Oxy Preps. (AU);",
"     </li>",
"     <li>",
"      Pangel (BE);",
"     </li>",
"     <li>",
"      Panoxyl (AE, AT, BB, BH, BM, BR, BS, BZ, CY, DE, EG, FR, GB, GY, HK, IE, IL, IQ, IR, IT, JM, JO, KW, LB, LU, LY, NO, OM, PH, QA, SA, SR, SY, TH, TT, TW, YE, ZA);",
"     </li>",
"     <li>",
"      PanOxyl (AU, SG);",
"     </li>",
"     <li>",
"      Pansulfox (CN);",
"     </li>",
"     <li>",
"      Pernox Gel (IN);",
"     </li>",
"     <li>",
"      Peroxiben (PT);",
"     </li>",
"     <li>",
"      Persol Gel (IN);",
"     </li>",
"     <li>",
"      Pretty (TW);",
"     </li>",
"     <li>",
"      Reloxyl (IT);",
"     </li>",
"     <li>",
"      Scherogel (AT, IT, LU);",
"     </li>",
"     <li>",
"      Solugel (CO);",
"     </li>",
"     <li>",
"      Stioxyl (SE);",
"     </li>",
"     <li>",
"      Tinagel (LU);",
"     </li>",
"     <li>",
"      Vixiderm (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Releases free-radical oxygen which oxidizes bacterial proteins in the sebaceous follicles decreasing the number of anaerobic bacteria and decreasing irritating-type free fatty acids",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~5% via skin; gel more penetrating than cream",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to benzoic acid in skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Akhavan A and Bershad S, \"Topical Acne Drugs: Review of Clinical Properties, Systemic Exposure, and Safety,\"",
"      <i>",
"       Am J Clin Dermatol",
"      </i>",
"      , 2003, 4(7):473-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42373/abstract-text/12814337/pubmed\" id=\"12814337\" target=\"_blank\">",
"        12814337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8811 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42373=[""].join("\n");
var outline_f41_24_42373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140054\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140055\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140087\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140057\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140070\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2566147\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140045\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140046\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140091\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140085\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9610539\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9610540\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298844\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140040\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140041\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293362\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9610538\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257740\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140049\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140050\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140036\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140048\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/55/15221?source=related_link\">",
"      Benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/60/18372?source=related_link\">",
"      Benzoyl peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42374="Tremor artifact tutorial";
var content_f41_24_42374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Tremor artifact",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This dramatic example of tremor artifact demonstrates complexes which simulate a run of ventricular tachycardia. However, QRS complexes (arrows) can clearly be seen marching through the rhythm strip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42374=[""].join("\n");
var outline_f41_24_42374=null;
var title_f41_24_42375="Quinapril: Pediatric drug information";
var content_f41_24_42375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinapril: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=see_link\">",
"    see \"Quinapril: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/24/15749?source=see_link\">",
"    see \"Quinapril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Accupril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accupril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1033968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1034004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=see_link\">",
"      see \"Quinapril: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Limited data available: Oral: Initial: 5-10 mg once daily; may titrate every 2 weeks; maximum daily dose: 80 mg/day; for younger patients or those who are small for age, begin at lower end of range. A pharmacokinetic analyses of a 0.2 mg/kg single-dose in 24 pediatric patients &lt;7 years of age, reported similar serum concentrations to those in adults who received a single 10 mg dose (Blumer, 2003; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 5 mg once or twice daily, titrated at weekly intervals to 20-40 mg daily in 2 divided doses; target dose (heart failure): 20 mg twice daily (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 10-20 mg once daily, adjust according to blood pressure response at peak and trough blood levels; initial dose may be reduced to 5 mg in patients receiving diuretic therapy if the diuretic is continued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Usual dose range (JNC 7): 10-40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Lower initial doses should be used; after initial dose (if tolerated), administer initial dose twice daily; may be increased at weekly intervals to optimal response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: Administer 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer 2.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: No recommendations; insufficient data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Administer 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer 2.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: No recommendations; insufficient data available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults: In patients with alcoholic cirrhosis, hydrolysis of quinapril to quinaprilat is impaired; however, the subsequent elimination of quinaprilat is unaltered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accupril&reg;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accupril&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14723630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1033990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1033969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with thiazide diuretics (FDA approved in adults); management of heart failure as adjunctive therapy in combination with conventional therapy (eg, diuretics, digitalis) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accupril&reg; may be confused with Accolate&reg;, Accutane&reg;, AcipHex&reg;, Monopril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accupril [U.S., Canada] may be confused with Acepril which is a brand name for captopril [Great Britain]; enalapril [Hungary, Switzerland]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, first-dose hypotension, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN/serum creatinine increased, worsening of renal function (in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, upper respiratory symptoms,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, agranulocytosis, alopecia, amblyopia, anaphylactoid reaction, angina, angioedema, arrhythmia, cerebrovascular accident, depression, dermatopolymyositis, eosinophilic pneumonitis, exfoliative dermatitis, gastrointestinal hemorrhage, heart failure, hemolytic anemia, hepatitis, hyperkalemia, hypertensive crisis, impotence, insomnia, MI, orthostatic hypotension, pancreatitis, pemphigus, photosensitivity, shock, stroke, syncope, thrombocytopenia, viral infection, visual hallucinations (Doane, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     A syndrome which may include arthralgia, elevated ESR, eosinophilia and positive ANA, fever, interstitial nephritis, myalgia, rash, and vasculitis has been reported with ACE inhibitors. In addition, hepatic necrosis, neutropenia, pancreatitis, and/or agranulocytosis (particularly in patients with collagen-vascular disease or renal impairment) have been associated with many ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1033975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to quinapril, any component, or other ACE inhibitors; patients with idiopathic or hereditary angioedema or a history of angioedema with ACE inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14723593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Use caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents, and monitor potassium closely. Concurrent use of angiotensin receptor blockers (ARBs) may increase the risk of clinically significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor.  In pediatric patients, an isolated dry hacking cough  lasting &gt;3 weeks was reported in 7 of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of  3.2% (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1033976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery. Prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor therapy has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus); incidence with quinapril is less than other ACE inhibitors. Onset of neutropenia is usually within 3 months of ACEI inhibitor initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Quinapril may decrease the serum concentration of Quinolone Antibiotics.  Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Quinapril may decrease the serum concentration of Tetracycline Derivatives.  Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1033989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with a high-fat meal moderately decreases the rate and extent of absorption by 25% to 30%. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Quinapril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14723631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, renal function, urine dipstick for protein, serum potassium, WBC with differential, especially during first 3 months of therapy for patients with renal impairment and/or collagen vascular disease; monitor for angioedema and anaphylactoid reactions; hypovolemia and postural hypotension when beginning therapy, adjusting dosage, and on a regular basis throughout",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1033993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14723594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Antihypertensive: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Antihypertensive: 2-4 hours postdose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours (chronic dosing)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1033995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Quinapril: &ge;60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;6 years: 0.7 L/kg (range: 0.27-1.48 L/kg) (Blumer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.5 L/kg (Aronoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Quinapril: 97%; Quinaprilat: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed to quinaprilat, the active metabolite (~38% of an oral dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;7 years: Quinaprilat: 2.3 hours (Blumer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Quinaprilat: 3 hours; increases as Cl",
"     <sub>",
"      cr",
"     </sub>",
"     decreases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;7 years: 1.7 hours (range: 1-4 hours) (Blumer, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Quinaprilat: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (50% to 60% primarily as quinaprilat)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1034012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/24/15749?source=see_link\">",
"      see \"Quinapril: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol. Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not use a salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy; sit and stand up slowly. May cause rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F14470446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL quinapril oral suspension may be made with tablets, K-Phos&reg; Neutral (equivalent to 250 mg elemental phosphorus, 13 mEq sodium, and 1.1 mEq potassium per tablet), Bicitra&reg;, and Ora-Sweet SF&trade;. Place ten quinapril 20 mg tablets in an amber plastic prescription bottle (eg, 240 mL). In a separate container, prepare a buffer solution by crushing one K-Phos&reg; Neutral tablet and dissolving it in 100 mL sterile water for irrigation. Add 30 mL of the prepared K-Phos&reg; buffer solution to the quinapril tablets. Shake for at least 2 minutes, then remove cap and allow the concentrate to stand for 15 minutes, then shake the concentrate again for an additional minute. Add 30 mL of Bicitra&reg; and shake for 2 minutes. Add quantity sufficient of Ora-Sweet SF&reg; (~140 mL) to make 200 mL and shake the suspension. Store in amber plastic prescription bottles; label &ldquo;shake well&rdquo; and &ldquo;refrigerate.&rdquo; Stable for 28 days refrigerated (Freed, 2005).",
"    </p>",
"    <div class=\"reference\">",
"     Freed A, Silbering SB, Kolodsick KJ, et al, &ldquo;The Development and Stability Assessment of Extemporaneous Pediatric Formulations of Accupril,&rdquo;",
"     <i>",
"      Int J Pharm",
"     </i>",
"     , 2005, 304(1-2):135-44.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Daniels SR, Dreyer WJ, et al, \"Pharmacokinetics of Quinapril in Children: Assessment During Substitution for Chronic Angiotensin-Converting Enzyme Inhibitor Treatment,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2003, 43(2):128-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/12616664/pubmed\" id=\"12616664\" target=\"_blank\">",
"        12616664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, \"Black Americans Have an Increased Rate of Angiotensin Converting Enzyme Inhibitor-Associated Angioedema,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/8689816/pubmed\" id=\"8689816\" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, \"Management of Hypertension in the Young: Role of Antihypertensive Medications,\"",
"      <i>",
"       J Cardiovasc Pharmacol",
"      </i>",
"      , 2011, 58(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/21242810/pubmed\" id=\"21242810\" target=\"_blank\">",
"        21242810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, \"Cough Is Common in Children Prescribed Converting Enzyme Inhibitors,\"",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/24/42375/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86286 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42375=[""].join("\n");
var outline_f41_24_42375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709380\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216351\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216352\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033968\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1034004\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216312\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14723630\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033990\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033969\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216400\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216398\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033975\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14723593\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033976\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299972\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216321\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033989\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216323\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14723631\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14723594\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033995\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1034012\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14470446\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=related_link\">",
"      Quinapril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/24/15749?source=related_link\">",
"      Quinapril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42376="Pathogenesis and clinical features of pulmonary histoplasmosis";
var content_f41_24_42376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and clinical features of pulmonary histoplasmosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Joseph Wheat, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42376/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/24/42376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis was first described by a United States Army physician in Panama in 1906 and subsequently has become recognized as a common and usually asymptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Histoplasmosis is the most prevalent endemic mycosis in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/3\">",
"     3",
"    </a>",
"    ]. While most infections are asymptomatic or self-limited, some individuals develop acute pulmonary infections or severe and progressive disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis and clinical features of the various pulmonary syndromes that may result from H. capsulatum infection will be reviewed here. The diagnosis and treatment of pulmonary histoplasmosis, as well as the pathogenesis, clinical manifestations, diagnosis, and treatment of disseminated histoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESERVOIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. capsulatum proliferates best in soil contaminated with bird or bat droppings, which are believed to alter the soil characteristics favoring sporulation of the organism. Sites commonly associated with exposure to H. capsulatum include chicken coops or farm buildings with large accumulations of chicken droppings, abandoned buildings, bird roost sites, caves, and wood lots. Activities that have been associated with exposure include excavation, construction, demolition, remodeling, wood cutting and gathering, exploring caves, and visiting campsites that are visibly contaminated with bat guano [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heavy exposure usually occurs with activities disturbing a large accumulation of droppings in an enclosed area, such as a cave or an attic. However, in most cases, patients recall no such exposure or exposure would not be recalled without specific questioning by a physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis and its causative agent, Histoplasma capsulatum, are found worldwide, particularly in North and Central America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/4\">",
"     4",
"    </a>",
"    ]. In the United States, H. capsulatum is most prevalent in the midwestern and central states along the Ohio and Mississippi River valleys, but also occurs in microfoci in several states along the East Coast. It is also found throughout Mexico, Central and South America, as well as in parts of eastern and southern Europe, Africa, eastern Asia, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is estimated that up to 500,000 new infections occur each year in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/13\">",
"     13",
"    </a>",
"    ]. Among the endemic mycoses, histoplasmosis is the most common cause for hospitalization, with a mortality of 7.5 percent and cost of $20,300 per hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although histoplasmosis occurs most commonly in individuals who live in endemic regions, outbreaks have also been reported in travelers with exposures to H. capsulatum. Clusters of histoplasmosis have occurred in travelers to Mexico who stayed in a hotel that was undergoing construction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/14\">",
"     14",
"    </a>",
"    ], and among members of mission groups that renovated a church in El Salvador [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs provide the portal of entry for H. capsulatum in the vast majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ], the rare exceptions being transmission from an infected organ in patients who have undergone transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/17\">",
"     17",
"    </a>",
"    ] and sharp injury in persons working with the organism in the laboratory. Conidia or mycelial fragments are inhaled and, if they evade nonspecific lung defenses, cause a localized or patchy bronchopneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/18\">",
"     18",
"    </a>",
"    ]. The clinical spectrum of acute histoplasmosis varies according to the extent of exposure, presence of underlying lung disease, general immune status, and specific immunity to H. capsulatum. With low-inoculum exposure, most otherwise healthy individuals remain asymptomatic (",
"    <a class=\"graphic graphic_figure graphicRef75641 \" href=\"mobipreview.htm?18/62/19430\">",
"     figure 1",
"    </a>",
"    ). However, patients who inhale a large inoculum can develop a severe and potentially fatal, acute diffuse pulmonary infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages initially are able to ingest but not kill the fungi (",
"    <a class=\"graphic graphic_picture graphicRef86524 \" href=\"mobipreview.htm?36/63/37873\">",
"     picture 1",
"    </a>",
"    ). Infected macrophages serve to disseminate the infection hematogenously during the first two weeks of infection, before specific immunity has developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/21,22\">",
"     21,22",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    ). Dissemination is usually clinically silent and may result in the development of H. capsulatum-containing granulomata in the liver and spleen, which may later be discovered incidentally at biopsy or autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/23\">",
"     23",
"    </a>",
"    ]. Progressive, clinically evident dissemination occurs primarily in patients with underlying immunosuppressive disorders, those at the extremes of age,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patients who have experienced an unusually heavy exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cellular immunity to H. capsulatum develops approximately 10 to 14 days after exposure; it is demonstrable first in the lungs and mediastinal lymph nodes and then throughout the reticuloendothelial system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/21\">",
"     21",
"    </a>",
"    ]. Sensitized T lymphocytes activate macrophages to develop fungicidal properties, and the infection is brought under control in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Tumor necrosis factor and interferon-gamma play critical roles in defense against H. capsulatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/27\">",
"     27",
"    </a>",
"    ]. Progressive illness with both pulmonary and extrapulmonary infection occurs in the absence of intact cellular immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/24\">",
"     24",
"    </a>",
"    ]. Increasingly, cases are recognized in patients receiving treatment with tumor necrosis factor inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A heightened immune response is believed to occur following reinfection in persons with preexisting cellular immunity to H. capsulatum, accounting for a shortened clinical course despite the diffuse, intense inflammation of the pulmonary parenchyma, which is often observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,29\">",
"     16,29",
"    </a>",
"    ]. The augmentation of the inflammatory response that is suspected clinically has been difficult to study in experimental models, but may play a role in the pathogenesis of caseating tissue necrosis seen in some patients with histoplasmosis, including those with chronic pulmonary manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Fibrosing mediastinitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/32\">",
"     32",
"    </a>",
"    ] and a sarcoidosis-like syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/33\">",
"     33",
"    </a>",
"    ] may occur in individuals who exhibit an atypical immunologic or inflammatory response to H. capsulatum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than five percent of exposed individuals develop symptomatic disease after a low level exposure to H. capsulatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/34\">",
"     34",
"    </a>",
"    ]. Asymptomatic pulmonary histoplasmosis is the most common syndrome following infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptomatic pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the illness presents as a subacute pulmonary infection weeks to months following exposure. Symptoms are usually mild, and the events causing the exposure are difficult to identify. Radiographs typically show focal infiltrates and mediastinal or hilar lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever, chills, headache, myalgia, anorexia, cough, and chest pain generally develop between two and four weeks after exposure but may be seen within one week in more heavily exposed cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,35\">",
"     16,35",
"    </a>",
"    ]. Coryza and sore throat are not typical of histoplasmosis and should suggest alternative diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/35\">",
"     35",
"    </a>",
"    ]. Chest pain usually is described as substernal and often is aggravated by deep inspiration; patients may experience pleuritic pain if lesions abut the pleura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination usually is unremarkable except for fever but may reveal rales and evidence of consolidation. Symptoms typically resolve within several weeks, but fatigue and asthenia may persist for months, particularly in patients with more severe initial manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,36\">",
"     16,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologically, the pulmonary lesion is characterized by a lobular or acinar bronchopneumonia, initially with neutrophilic infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/18\">",
"     18",
"    </a>",
"    ]. Recruitment of macrophages, lymphocytes, and plasma cells, and the formation of granulomas with conspicuous giant cells occurs at the second week and beyond; central caseous necrosis occurs later during the second month (",
"    <a class=\"graphic graphic_picture graphicRef74406 \" href=\"mobipreview.htm?5/36/5699\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest radiographs usually show enlarged hilar or mediastinal lymph nodes with focal infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69279 \" href=\"mobipreview.htm?12/8/12418\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79648 \" href=\"mobipreview.htm?29/52/30543\">",
"     image 2",
"    </a>",
"    ), but may be normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/36\">",
"     36",
"    </a>",
"    ]. The pulmonary infiltrates usually are patchy or nodular; cavitation is rarely noted in the pulmonary infiltrates except in persons with underlying obstructive lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/31,37\">",
"     31,37",
"    </a>",
"    ]. Infiltrates may be diffuse or miliary following heavy exposure. Nodules measure between 1 and 4 cm in diameter and often are multiple. Of note, diffuse pulmonary infiltrates in an immunosuppressed patient usually represent progressive disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/38\">",
"     38",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    ). Pleural effusions are seen in a minority of patients with acute pulmonary histoplasmosis, and organisms are rarely isolated from pleural fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,39,40\">",
"     16,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither the time course for resolution of radiographic abnormalities nor the effect of antifungal therapy on the rate of clinical or radiographic improvement has been adequately studied. Anecdotal experience suggests that infiltrates clear within two to four months in most persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ], while adenopathy may persist for years. Calcification of mediastinal nodes or parenchymal lesions may be seen by chest radiography within a few months in children but usually takes several years to develop in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute diffuse pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following extensive exposure, such as occurs with activities that disturb heavily contaminated soil or areas with large amounts of bird or bat droppings, the majority of patients develop acute symptomatic infection within a week or two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Diffuse reticulonodular or miliary pulmonary infiltrates are noted (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73494 \" href=\"mobipreview.htm?36/38/37487\">",
"     image 3",
"    </a>",
"    ) and the disease can progress to respiratory failure or progressive extrapulmonary dissemination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/19,22,41\">",
"     19,22,41",
"    </a>",
"    ]. Most patients recover from heavy exposure without treatment, but may be severely ill and frequently remain dyspneic and fatigued for months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/41\">",
"     41",
"    </a>",
"    ]. For this reason, antifungal therapy is generally offered to these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of radiographic improvement with and without antifungal therapy has not been reported. Diffuse fibrosis and chronic restrictive lung disease occasionally result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying lung disease are at risk for the development of chronic pulmonary infection following exposure to H. capsulatum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Affected patients develop a productive cough, dyspnea, chest pain, fatigue, fevers, and sweats and have fibrotic apical infiltrates with cavitation on chest radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86523 \" href=\"mobipreview.htm?9/56/10114\">",
"     image 4",
"    </a>",
"    ) or computed tomography (CT) scans. The clinical and radiographic findings resemble those seen in reactivation tuberculosis; the two syndromes are often confused, and incorrect diagnoses have resulted in inappropriate treatment.",
"   </p>",
"   <p>",
"    These cavities tend to enlarge, involve new areas of the lung, and may result in the formation of bronchopleural fistulae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30,31,41\">",
"     30,31,41",
"    </a>",
"    ]. Pathologic examination reveals the presence of underlying emphysema, vascular compromise caused by intimal proliferation in small and medium-sized arteries, tissue necrosis, and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30\">",
"     30",
"    </a>",
"    ]. Inflammation is disproportionate to the fungal burden, suggesting that hypersensitivity to fungal antigens may play a role in the pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care must be taken to evaluate for both tuberculosis and histoplasmosis in patients with these findings who have lived in or been exposed to areas where histoplasmosis is endemic. Tuberculin skin testing, interferon-gamma release assay for M. tuberculosis, sputum cultures, and lung biopsy may be required to make this distinction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Aspergilloma (ie, fungus ball), atypical mycobacterial infections, and chronic or recurrent pneumonia caused by a variety of bacterial pathogens may develop in areas of lung damaged by chronic pulmonary histoplasmosis and must also be excluded.",
"   </p>",
"   <p>",
"    Most patients with chronic pulmonary histoplasmosis have smoked tobacco for long periods and are therefore at high risk for the development of lung cancer. Lung cancer should be suspected in patients who have nodular lesions that do not respond to treatment or that develop during the course of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Broncholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph nodes and pulmonary granulomas calcify within several years of initial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,42\">",
"     16,42",
"    </a>",
"    ]. In rare cases, calcified lymph nodes erode into adjacent bronchi, causing symptoms such as chronic cough, wheezing, hemoptysis, fever, chills, and purulent sputum production. Patients may report expectoration of small stones, gravel, or gritty material, and massive hemoptysis may result if the bronchial arteries are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organisms may be demonstrated in the calcified nodes, but cultures usually are negative. Broncholiths may be removed bronchoscopically or surgically; the latter approach often is required in patients with significant hemoptysis, recurrent pneumonia, or a bronchoesophageal fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mediastinal granuloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary histoplasmosis is rarely complicated by enlarging, encapsulated, caseous mediastinal lymph nodes, a syndrome known as mediastinal granuloma. Overall, mediastinal granuloma causes less morbidity and is more amenable to treatment than fibrosing mediastinitis, but compression of compliant structures such as the esophagus, pulmonary vessels, and occasionally the airways may result in a variety of symptoms including chest pain, cough, hemoptysis, and dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,44-47\">",
"     16,44-47",
"    </a>",
"    ]. Involvement of the trachea can cause respiratory distress, especially in young children, and prolonged obstruction can cause bronchiectasis or bronchial stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ]. Involvement of the esophagus may result in dysphagia, odynophagia, or chest pain, and rarely in the development of a bronchoesophageal or tracheoesophageal fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16,45,48,49\">",
"     16,45,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enlarged and occasionally cystic mediastinal lymph nodes are seen by radiographs or CT scans of the chest (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78054 \" href=\"mobipreview.htm?11/33/11794\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/44,50,51\">",
"     44,50,51",
"    </a>",
"    ]. Yellow or white cystic masses of lymph nodes measuring up to 10 cm in diameter are comprised of a necrotic central core surrounded by granulomatous tissue and encased in a fibrous capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/50\">",
"     50",
"    </a>",
"    ]. Older lesions demonstrate calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ]. Liquefied mediastinal lesions may rupture into the tracheobronchial tree, producing air-filled cystic masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fibrosing mediastinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosing mediastinitis represents an excessive fibrotic response to a prior episode of histoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/32,52\">",
"     32,52",
"    </a>",
"    ]. In most cases, however, the acute episode of histoplasmosis was not identified. Approximately 80 percent of cases occur in persons between the ages of 20 and 40, with only 7 percent noted in persons over 45 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms are cough, dyspnea, hemoptysis, pleurisy, and sweats, occurring in 20 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/52\">",
"     52",
"    </a>",
"    ]. This rare manifestation of histoplasmosis is characterized by extensive fibrosis that may result in entrapment, distortion, and invasion of structures adjacent to mediastinal lymph nodes, including the heart and great vessels, airways, and the esophagus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50957 \" href=\"mobipreview.htm?7/24/7567\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other manifestatations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis occurs in 5 to 10 percent of symptomatic cases of pulmonary histoplasmosis; it is caused by an immunologic reaction to histoplasmosis in the adjacent mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Pericarditis rarely results from dissemination of organisms into the pericardial space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings of pulmonary histoplasmosis may be unrecognized or may precede the development of pericarditis by several weeks or months. Patients present with chest pain, pericardial friction rub, and fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Signs of hemodynamic compromise occur in 40 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53749 \" href=\"mobipreview.htm?18/31/18933\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rheumatologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis or arthralgia occurs in about 5 to 10 percent of symptomatic patients with pulmonary histoplasmosis and appears to be more common in women. These manifestations almost always represent a systemic inflammatory reaction to acute pulmonary infection rather than dissemination of fungi to the joints or soft tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arthritis is polyarticular and symmetric in approximately one-half of cases and involves the large or small joints of the upper and lower extremities with similar frequency. Joint radiographs are normal and symptoms usually resolve spontaneously or in response to treatment with non-steroidal anti-inflammatory drugs. However, treatment with corticosteroids is sometimes required; careful follow-up is essential in such patients, with monitoring for signs of progressive infection caused by the immunosuppressive effects of the steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dermatologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly one-half of patients with joint pain exhibit erythema nodosum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythema multiforme, and about one-half complain of fever and respiratory symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Antifungal therapy is not indicated unless there is evidence that the bone or joint involvement is a manifestation of disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/55,59\">",
"     55,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH SARCOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a syndrome of unknown cause which may produce clinical findings similar to those seen with histoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/33\">",
"     33",
"    </a>",
"    ]. Shared findings include diffuse pulmonary infiltrates, mediastinal lymphadenopathy, erythema nodosum, hepatic enzyme elevation, and splenomegaly. Serum angiotensin converting enzyme concentrations are elevated in both conditions, and noncaseating granulomas are a shared pathologic finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/33,60\">",
"     33,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated titers of antibodies to H. capsulatum are found in some patients with sarcoidosis, but it is unclear if this relationship is causal. It has been hypothesized that histoplasmosis may cause a chronic inflammatory condition typical of sarcoidosis, but definitive evidence for this theory is lacking.",
"   </p>",
"   <p>",
"    The diagnosis of sarcoidosis is often based upon a triad of a compatible chest radiograph, noncaseating granulomas in tissues, and a negative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interferon-gamma release assay result, without specific testing to exclude histoplasmosis. Care must be taken to exclude active histoplasmosis in patients with such findings in order to prevent corticosteroid treatment from depressing the immune response to H. capsulatum and promoting dissemination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/33\">",
"     33",
"    </a>",
"    ]. Positive fungal stains or cultures and detection of antigen in urine or serum support a diagnosis of active histoplasmosis rather than sarcoidosis. Elevated titers of antibodies to H. capsulatum do not exclude a diagnosis of sarcoidosis but necessitate careful follow-up for evidence of disseminated histoplasmosis in patients who are treated with immunosuppressive medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT PULMONARY HISTOPLASMOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings of histoplasmosis are varied, and the disease should be considered in the following clinical presentations, particularly in the appropriate epidemiologic setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumonia with mediastinal or hilar lymphadenopathy",
"     </li>",
"     <li>",
"      Mediastinal or hilar masses suggestive of malignancy or tuberculosis",
"     </li>",
"     <li>",
"      Pulmonary nodule suggestive of malignancy",
"     </li>",
"     <li>",
"      Cavitary lung disease suggestive of tuberculosis",
"     </li>",
"     <li>",
"      Pericarditis with mediastinal lymphadenopathy",
"     </li>",
"     <li>",
"      Pulmonary manifestations with arthritis or arthralgia plus erythema nodosum",
"     </li>",
"     <li>",
"      Suspected sarcoidosis",
"     </li>",
"     <li>",
"      Dysphagia caused by esophageal narrowing",
"     </li>",
"     <li>",
"      Superior vena cava syndrome or obstruction of other mediastinal structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manifestations place pulmonary histoplasmosis in the differential diagnosis of sarcoidosis, tuberculosis, and malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/5,61\">",
"     5,61",
"    </a>",
"    ]. Thus, testing for histoplasmosis should be included in patients who are under evaluation for these conditions in the appropriate epidemiologic setting.",
"   </p>",
"   <p>",
"    Failure to exclude histoplasmosis in the evaluation of sarcoidosis may lead to marked disease exacerbation if immunosuppressive therapy is initiated in a patient who actually has acute histoplasmosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42376/abstract/62\">",
"     62",
"    </a>",
"    ]. Similarly, failure to consider histoplasmosis in patients under evaluation for malignancy may lead to unnecessary surgical evaluation or antimycobacterial treatment in patients with suspected tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13393?source=see_link\">",
"       \"Patient information: Histoplasmosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histoplasmosis is the most prevalent endemic mycosis in the United States. While most infections are asymptomatic or self-limited, some individuals develop acute pulmonary infections or severe and progressive disseminated infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      H. capsulatum proliferates best in soil contaminated with bird or bat droppings, which are believed to alter the soil characteristics favoring sporulation of the organism. Sites commonly associated with exposure to H. capsulatum include chicken coops or farm buildings with large accumulations of chicken droppings, abandoned buildings, bird roost sites, caves, and wood lots. Activities associated with exposure include excavation, construction, demolition, remodeling, wood cutting and gathering, and exploring caves. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Reservoir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histoplasmosis and its causative agent, Histoplasma capsulatum, are found worldwide, particularly in North and Central America. In the United States, H. capsulatum is most prevalent in the midwestern and central states along the Ohio and Mississippi River valleys, but also occurs in microfoci in several states along the East Coast. It is also found throughout Mexico, Central and South America, as well as in parts of eastern and southern Europe, Africa, eastern Asia, and Australia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lungs provide the portal of entry for H. capsulatum in the vast majority of cases. Conidia or mycelial fragments are inhaled and, if they evade nonspecific lung defenses, cause a localized or patchy bronchopneumonia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic pulmonary histoplasmosis is the most common syndrome following infection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic pulmonary histoplasmosis typically presents as a subacute pulmonary infection weeks to months following exposure. Symptoms are usually mild, and the events causing the exposure are difficult to identify. Radiographs typically show focal infiltrates and mediastinal or hilar lymphadenopathy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69279 \" href=\"mobipreview.htm?12/8/12418\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79648 \" href=\"mobipreview.htm?29/52/30543\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptomatic pulmonary histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following extensive exposure, such as occurs with activities that disturb heavily contaminated soil or areas with large amounts of bird or bat droppings, the majority of patients develop acute diffuse pulmonary histoplasmosis within a week or two. Diffuse reticulonodular or miliary pulmonary infiltrates are noted and the disease can progress to respiratory failure or progressive extrapulmonary dissemination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acute diffuse pulmonary histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with underlying lung disease are at risk for the development of chronic pulmonary infection following exposure to H. capsulatum. Affected patients develop a productive cough, dyspnea, chest pain, fatigue, fevers, and sweats and have fibrotic apical infiltrates with cavitation on chest radiographs or computed tomography (CT) scans (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86523 \" href=\"mobipreview.htm?9/56/10114\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic pulmonary histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less common pulmonary manifestations include broncholithiasis, mediastinal granuloma, and fibrosing mediastinitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Broncholithiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Mediastinal granuloma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Fibrosing mediastinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings of histoplasmosis are varied, and the disease should be considered in the following clinical presentations, particularly in the appropriate epidemiologic setting:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pneumonia with mediastinal or hilar lymphadenopathy",
"     </li>",
"     <li>",
"      Mediastinal or hilar masses suggestive of malignancy or tuberculosis",
"     </li>",
"     <li>",
"      Pulmonary nodule suggestive of malignancy",
"     </li>",
"     <li>",
"      Cavitary lung disease suggestive of tuberculosis",
"     </li>",
"     <li>",
"      Pericarditis with mediastinal lymphadenopathy",
"     </li>",
"     <li>",
"      Pulmonary manifestations with arthritis or arthralgia plus erythema nodosum",
"     </li>",
"     <li>",
"      Suspected sarcoidosis",
"     </li>",
"     <li>",
"      Dysphagia caused by esophageal narrowing",
"     </li>",
"     <li>",
"      Superior vena cava syndrome or obstruction of other mediastinal structures (see",
"      <a class=\"local\" href=\"#H17\">",
"       'When to suspect pulmonary histoplasmosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/1\">",
"      Darling ST. A protozoan general infection producing pseudotubercles in the lungs and focal necrosis in the liver, spleen and lymph nodes. JAMA 1906; 46:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/2\">",
"      Riley WA, Watson CJ. Histoplasmosis of Darling with report of a case originating in Minnesota. Am J Trop Med 1926; 6:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/3\">",
"      Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/4\">",
"      Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/5\">",
"      Wheat LJ, Conces D, Allen SD, et al. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med 2004; 25:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/6\">",
"      Gustafson TL, Kaufman L, Weeks R, et al. Outbreak of acute pulmonary histoplasmosis in members of a wagon train. Am J Med 1981; 71:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/7\">",
"      Ward JI, Weeks M, Allen D, et al. Acute histoplasmosis: clinical, epidemiologic and serologic findings of an outbreak associated with exposure to a fallen tree. Am J Med 1979; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of histoplasmosis among industrial plant workers--Nebraska, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/9\">",
"      Luby JP, Southern PM Jr, Haley CE, et al. Recurrent exposure to Histoplasma capsulatum in modern air-conditioned buildings. Clin Infect Dis 2005; 41:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Histoplasmosis outbreak among day camp attendees--Nebraska, June 2012. MMWR Morb Mortal Wkly Rep 2012; 61:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/11\">",
"      Panackal AA, Hajjeh RA, Cetron MS, Warnock DW. Fungal infections among returning travelers. Clin Infect Dis 2002; 35:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/12\">",
"      Cano MV, Hajjeh RA. The epidemiology of histoplasmosis: a review. Semin Respir Infect 2001; 16:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/13\">",
"      Hammerman KJ, Powell KE, Tosh FE. The incidence of hospitalized cases of systemic mycotic infections. Sabouraudia 1974; 12:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/14\">",
"      Morgan J, Cano MV, Feikin DR, et al. A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg 2003; 69:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of histoplasmosis among travelers returning from El Salvador--Pennsylvania and Virginia, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/16\">",
"      Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. Medicine (Baltimore) 1981; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/17\">",
"      Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 2000; 343:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/18\">",
"      PROCKNOW JJ, PAGE MI, LOOSLI CG. Early pathogenesis of experimental histoplasmosis. Arch Pathol 1960; 69:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/19\">",
"      Kataria YP, Campbell PB, Burlingham BT. Acute pulmonary histoplasmosis presenting as adult respiratory distress syndrome: effect of therapy on clinical and laboratory features. South Med J 1981; 74:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/20\">",
"      Wynne JW, Olsen GN. Acute histoplasmosis presenting as the adult respiratory distress syndrome. Chest 1974; 66:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/21\">",
"      Fojtasek MF, Sherman MR, Garringer T, et al. Local immunity in lung-associated lymph nodes in a murine model of pulmonary histoplasmosis. Infect Immun 1993; 61:4607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/22\">",
"      Paya CV, Roberts GD, Cockerill FR 3rd. Transient fungemia in acute pulmonary histoplasmosis: detection by new blood-culturing techniques. J Infect Dis 1987; 156:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/23\">",
"      SCHWARZ J, SILVERMAN FN, ADRIANO SM, et al. The relation of splenic calcification to histoplasmosis. N Engl J Med 1955; 252:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/24\">",
"      Wheat LJ, Slama TG, Norton JA, et al. Risk factors for disseminated or fatal histoplasmosis. Analysis of a large urban outbreak. Ann Intern Med 1982; 96:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/25\">",
"      Allendoerfer R, Biovin GP, Deepe GS Jr. Modulation of immune responses in murine pulmonary histoplasmosis. J Infect Dis 1997; 175:905.",
"     </a>",
"    </li>",
"    <li>",
"     Wu-Hsieh B, Howard DH. Histoplasmosis. In: Fungal Infections and Immune Responses, Murphy JW, Friedman H, Bendinelli M (Eds), Plenum Publishing, New York 1993. p.213.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/27\">",
"      Deepe GS Jr. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 2005; 41 Suppl 3:S204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/28\">",
"      Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41 Suppl 3:S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/29\">",
"      Goodwin RA Jr, Des Prez RM. State of the art: histoplasmosis. Am Rev Respir Dis 1978; 117:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/30\">",
"      Goodwin RA Jr, Owens FT, Snell JD, et al. Chronic pulmonary histoplasmosis. Medicine (Baltimore) 1976; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/31\">",
"      Wheat LJ, Wass J, Norton J, et al. Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine (Baltimore) 1984; 63:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/32\">",
"      Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 1972; 51:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/33\">",
"      Wheat LJ, French ML, Wass JL. Sarcoidlike manifestations of histoplasmosis. Arch Intern Med 1989; 149:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/34\">",
"      Wheat LJ. Diagnosis and management of histoplasmosis. Eur J Clin Microbiol Infect Dis 1989; 8:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/35\">",
"      Brodsky AL, Gregg MB, Loewenstein MS, et al. Outbreak of histoplasmosis associated with the 1970 Earth Day activities. Am J Med 1973; 54:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/36\">",
"      Wheat LJ, Slama TG, Eitzen HE, et al. A large urban outbreak of histoplasmosis: clinical features. Ann Intern Med 1981; 94:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/37\">",
"      Chick EW, Bauman DS. Editorial: Acute cavitary histoplasmosis--fact or fiction? Chest 1974; 65:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/38\">",
"      Sathapatayavongs B, Batteiger BE, Wheat J, et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/39\">",
"      Connell JV, Muhm JR. Radiographic manifestations of pulmonary histoplasmosis: a 10-year review. Radiology 1976; 121:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/40\">",
"      Quasney MW, Leggiadro RJ. Pleural effusion associated with histoplasmosis. Pediatr Infect Dis J 1993; 12:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/41\">",
"      RUBIN H, FURCOLOW ML, YATES JL, BRASHER CA. The course and prognosis of histoplasmosis. Am J Med 1959; 27:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/42\">",
"      Conces DJ Jr, Tarver RD, Vix VA. Broncholithiasis: CT features in 15 patients. AJR Am J Roentgenol 1991; 157:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/43\">",
"      Arrigoni MG, Bernatz PE, Donoghue FE. Broncholithiasis. J Thorac Cardiovasc Surg 1971; 62:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/44\">",
"      Garrett HE Jr, Roper CL. Surgical intervention in histoplasmosis. Ann Thorac Surg 1986; 42:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/45\">",
"      Coss KC, Wheat LJ, Conces DJ Jr, et al. Esophageal fistula complicating mediastinal histoplasmosis. Response to amphotericin B. Am J Med 1987; 83:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/46\">",
"      Rabinowitz JG, Prater W, Silver J, et al. Mediastinal histoplasmosis. Mt Sinai J Med 1980; 47:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/47\">",
"      Schowengerdt CG, Suyemoto R, Main FB. Granulomatous and fibrous mediastinitis. A review and analysis of 180 cases. J Thorac Cardiovasc Surg 1969; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/48\">",
"      Savides TJ, Gress FG, Wheat LJ, et al. Dysphagia due to mediastinal granulomas: diagnosis with endoscopic ultrasonography. Gastroenterology 1995; 109:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/49\">",
"      Sakulsky SB, Harrison EG, Dines DE, et al. Mediastinal granuloma. J Thorac Cardiovasc Surg 1967; 54:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/50\">",
"      KUNKEL WM Jr, CLAGETT OT, McDONALD JR. Mediastinal granulomas. J Thorac Surg 1954; 27:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/51\">",
"      Landay MJ, Rollins NK. Mediastinal histoplasmosis granuloma: evaluation with CT. Radiology 1989; 172:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/52\">",
"      Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988; 67:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/53\">",
"      Picardi JL, Kauffman CA, Schwarz J, et al. Pericarditis caused by Histoplasma capsulatum. Am J Cardiol 1976; 37:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/54\">",
"      Wheat LJ, Stein L, Corya BC, et al. Pericarditis as a manifestation of histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/55\">",
"      Rosenthal J, Brandt KD, Wheat LJ, Slama TG. Rheumatologic manifestations of histoplasmosis in the recent Indianapolis epidemic. Arthritis Rheum 1983; 26:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/56\">",
"      Medeiros AA, Marty SD, Tosh FE, Chin TD. Erythema nodosum and erythema multiforme as clinical manifestations of histoplasmosis in a community outbreak. N Engl J Med 1966; 274:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/57\">",
"      Ozols II, Wheat LJ. Erythema nodosum in an epidemic of histoplasmosis in Indianapolis. Arch Dermatol 1981; 117:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/58\">",
"      SELLERS TF Jr, PRICE WN Jr, NEWBERRY WM Jr. AN EPIDEMIC OF ERYTHEMA MULTIFORME AND ERYTHEMA NODOSUM CAUSED BY HISTOPLASMOSIS. Ann Intern Med 1965; 62:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/59\">",
"      Jones PG, Rolston K, Hopfer RL. Septic arthritis due to Histoplasma capsulatum in a leukaemic patient. Ann Rheum Dis 1985; 44:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/60\">",
"      Ryder KW, Jay SJ, Kiblawi SO, Hull MT. Serum angiotensin converting enzyme activity in patients with histoplasmosis. JAMA 1983; 249:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/61\">",
"      Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am 2003; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42376/abstract/62\">",
"      Gulati M, Saint S, Tierney LM Jr. Clinical problem-solving. Impatient inpatient care. N Engl J Med 2000; 342:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2450 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42376=[""].join("\n");
var outline_f41_24_42376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESERVOIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptomatic pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute diffuse pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Broncholithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mediastinal granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other manifestatations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rheumatologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dermatologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ASSOCIATION WITH SARCOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      WHEN TO SUSPECT PULMONARY HISTOPLASMOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2450\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2450|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/8/12418\" title=\"diagnostic image 1\">",
"      Acute histoplasmosis chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/52/30543\" title=\"diagnostic image 2\">",
"      Acute pulmonary histoplasmosis chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/38/37487\" title=\"diagnostic image 3\">",
"      Diffuse histoplasmosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/56/10114\" title=\"diagnostic image 4\">",
"      Chronic pulmonary histoplasmosis chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/33/11794\" title=\"diagnostic image 5\">",
"      Acute histoplasmosis chest CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/24/7567\" title=\"diagnostic image 6\">",
"      Fibrosing mediastinitis PAgram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/31/18933\" title=\"picture 3\">",
"      Histoplasmosis pericarditis chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2450|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/62/19430\" title=\"figure 1\">",
"      Histoplasma clinical syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2450|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/63/37873\" title=\"picture 1\">",
"      Histoplasma in macrophage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/36/5699\" title=\"picture 2\">",
"      Histoplasmosis lung granuloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15526?source=related_link\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13393?source=related_link\">",
"      Patient information: Histoplasmosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42377="Focal nodular hyperplasia Light";
var content_f41_24_42377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66952%7EGAST%2F52949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66952%7EGAST%2F52949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimen showing fibrosis closely mimicking cirrhosis. Note the large feeder artery typical of FNH (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank A Mitros, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Focal nodular hyperplasia of the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimen showing the fibrous septae and a large, thick-walled artery at the edge of the stellate scare (arrow). (Klatskin trichrome stain X 10).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frank A Mitros, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42377=[""].join("\n");
var outline_f41_24_42377=null;
var title_f41_24_42378="Cancer prevention";
var content_f41_24_42378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Kathleen Y Wolin, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Graham A Colditz, MD, DrPh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/24/42378/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/24/42378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, there were an estimated 12.7 million cancer cases and 7.6 million cancer deaths worldwide, despite overwhelming evidence that many malignancies are preventable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Survival rates are improving, but over half a million people die from cancer each year in the United States (US) alone. Cancer outranks cardiovascular disease as the number one cause of death in the US for those under the age of 85 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both screening and prevention can reduce mortality from cancer. Screening detects abnormalities before they are clinically apparent, allowing for intervention either before cancer develops or at an early stage, when treatment is most often effective. Prevention strategies focus on modifying environmental and lifestyle risk factors that promote cancer. It is estimated that 50 percent of cancer is preventable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple cancer risk factors have been identified; tobacco use, excess weight, poor diet, and inactivity account for two-thirds of all cancers in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study, nine modifiable risks were identified as the cause of 35 percent of cancer deaths worldwide: smoking, alcohol use, diet low in fruit and vegetables, excess weight, inactivity, unsafe sex, urban air pollution, use of solid fuels, and contaminated injections in healthcare settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/6\">",
"     6",
"    </a>",
"    ]. The International Agency for Research on Cancer (IARC) has identified and tabulated over 100 human carcinogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifestyle factors have been linked to a variety of malignancies, including the most common in the developed world: lung, colorectal, prostate, and breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/8\">",
"     8",
"    </a>",
"    ]. In a longitudinal study, participants who had all four lifestyle factors (never smoking, BMI &lt;30, physical activity &gt;3.5 hours weekly, prudent diet) had approximately one-third the risk of cancer compared to those who had none of these factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/9\">",
"     9",
"    </a>",
"    ]. A comprehensive systematic review with a global focus conducted by the World Cancer Research Fund came to similar conclusions regarding dietary, weight, and activity factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/10\">",
"     10",
"    </a>",
"    ]. A study of an index, based on recommendations from the World Cancer Research Fund and the American Institute of Cancer Research related to weight management, physical activity, plant and animal food consumption, breastfeeding in women, and alcohol intake, found a significant association of higher scores (better compliance) with risk reduction for total cancer and multiple specific cancers (colorectal, stomach, breast, endometrium, lung, kidney, liver, esophagus) but not for prostate, ovarian, pancreatic, or bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/11\">",
"     11",
"    </a>",
"    ]. Despite a robust knowledge of what factors decrease cancer risk, implementation of cancer prevention lags [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the major modifiable cancer risk factors and briefly addresses chemoprevention. Lifestyle issues which are associated with an increased risk of cancer are also risk factors for other diseases, such as stroke, heart disease, and diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The roles of physical activity, dietary patterns, and weight in cancer survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TOBACCO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tobacco use is the most preventable cause of cancer, and accounts for 21 percent of worldwide total cancer deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately one-half of all smokers die of a tobacco-related disease, and adult smokers lose an average of 13 years of life due to this addiction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking is responsible for approximately 30 percent of all cancer-related deaths in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/15\">",
"     15",
"    </a>",
"    ]. It is the strongest risk factor for lung cancer, increasing risk 10 to 20-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Smoking is also implicated as a causative factor for leukemia as well as cancers of the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, larynx, esophagus, pancreas, liver, stomach, cervix, kidney, large bowel, and bladder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Some evidence also ties smoking to more aggressive prostate cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], while the relationship of smoking and breast cancer risk is controversial. (See relevant topic reviews on the risk factors for all of these cancers).",
"   </p>",
"   <p>",
"    Tobacco acts on multiple stages of carcinogenesis: it delivers carcinogens directly to tissues, causes irritation and inflammation, and interferes with the body's natural protective barriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/22\">",
"     22",
"    </a>",
"    ]. The dangers of tobacco are most commonly associated with cigarette smoking, but also occur with cigar, pipe, smokeless tobacco, and exposure to environmental (second-hand) tobacco smoke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant health benefits accompany quitting, even for longtime tobacco users. Smoking cessation leads to reduced risk of most tobacco-related diseases and a decrease in all cause mortality. The health benefits of quitting can be seen at all ages and can be measured almost immediately after cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tobacco prevention and cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is crucial to both prevent initiation and promote cessation of tobacco use, given the tremendous harm of tobacco dependency. Programs and policies that reduce youth initiation and facilitate smoking cessation must be implemented in both clinical and community settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/24\">",
"     24",
"    </a>",
"    ]. Responsibilities for health care providers include advice and counseling, referrals to behavioral therapy and support groups, and prescriptions for nicotine replacement and other medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXCESS SUN EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 1 million cases of skin cancer, including basal cell and squamous cell carcinoma, are diagnosed each year. The American Cancer Society estimates over 68,000 cases of malignant melanoma in the US in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/27\">",
"     27",
"    </a>",
"    ], and the incidence continues to rise. Although most skin cancers are curable, in 2011 there are projected to be 8790 deaths related to melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/28\">",
"     28",
"    </a>",
"    ]. Radiation from the sun is the primary cause of both melanomatous and non-melanomatous skin cancer. Ultraviolet radiation causes genetic mutations and interferes with the cutaneous immune system, limiting the body's ability to reject abnormal cells. Risk of squamous cell and basal cell cancer appear to correlate with total lifetime sun exposure. Cumulative sun exposure may also increase melanoma risk, but repeated intense exposures leading to blistering burns may be even more dangerous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultraviolet exposure from tanning beds has been classified as a human carcinogen, with a 75 percent increase in risk for melanoma in patients who utilized tanning booths before age 35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendations for sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted interventions for high-risk characteristics such as fair skin, large number of nevi, or positive family history, fails to identify an adequate proportion of people who develop disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/31\">",
"     31",
"    </a>",
"    ]. All individuals should limit the time spent in the sun, especially between the hours of 10 am and 3 pm, wear hats, sunglasses, and other protective clothing, and use sunscreen. Because the majority of lifetime sun exposure usually occurs during childhood and adolescence, protective behaviors early in life will provide the greatest benefit. In addition, the World Health Organization has recommended against tanning bed use by anyone under the age of 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349227082\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased physical activity appears to increase the risk for cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/8\">",
"     8",
"    </a>",
"    ]. Over 60 percent of US adults are not regularly active, including 25 percent who are almost entirely sedentary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/33\">",
"     33",
"    </a>",
"    ]. It is estimated that sedentary lifestyle is associated with 5 percent of cancer deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/34\">",
"     34",
"    </a>",
"    ]. For people who do not smoke, exercise is one of the most important modifiable risk factors (along with weight control and dietary choices) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a Japanese cohort, physical activity was associated with a decreased risk for colon, liver, pancreatic, and stomach cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/36\">",
"     36",
"    </a>",
"    ]. The most compelling data are in colon and breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study demonstrated a negative correlation between moderate to strenuous exercise and ER-negative, but not ER-positive, breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 52 studies, there was a significant 24 percent reduced risk of colon cancer when comparing the most versus the least active individuals across all studies (RR 0.76, 95% CI 0.72 to 0.81) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/37\">",
"       37",
"      </a>",
"      ]. A subsequent meta-analysis of 21 studies found that the risk of colorectal cancer was reduced by 27 percent, comparing the most and least physically active participants, and the risk reduction was the same for both proximal and distal cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/41\">",
"       41",
"      </a>",
"      ]. Physical activity also decreases risk of colon polyps by 15 percent as reported in a meta-analysis of 20 studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The association between physical activity and decreased risk for breast and colon cancer has been demonstrated across levels of obesity, suggesting that the protective effect of activity goes beyond its impact on body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/36,43-45\">",
"       36,43-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited evidence suggests that activity offers some protection against endometrial and prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/37,46,47\">",
"       37,46,47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several mechanisms have been proposed to explain the possible protective effect of physical activity including: reduction in circulating levels of insulin, hormones, and other growth factors; impact on prostaglandin levels; improved immune function, and altered bile acid metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Physical activity during certain periods of life, such as adolescence, may offer additional protection against disease, particularly for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The optimal duration, intensity, and frequency of physical activity that may afford cancer protection is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349227125\">",
"    <span class=\"h1\">",
"     EXCESS WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 65 percent of US adults are overweight; over 30 percent are considered obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/53\">",
"     53",
"    </a>",
"    ]. The obesity epidemic affects people of all ages, socioeconomic levels, geographic regions, and ethnicities, and causes significant medical consequences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for obesity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excess weight and obesity are associated with an increase in the risk of multiple cancers including colorectal, postmenopausal breast, endometrial, renal, and esophageal cancer, with a population attributable risk from 9 percent (postmenopausal breast cancer) to 39 percent (endometrial cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/37\">",
"     37",
"    </a>",
"    ]. A meta-analysis of prospective epidemiologic studies reported significant direct associations with additional cancers including pancreas, thyroid, non-Hodgkin lymphoma, leukemia, and myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/54\">",
"     54",
"    </a>",
"    ]. Emerging evidence suggests a role for obesity in aggressive prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity has been estimated to cause 20 percent of all cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/4\">",
"     4",
"    </a>",
"    ]. Bariatric surgery has been associated with a 60 percent reduction in cancer mortality (5.5 versus 13.3 per 10,000 person-years) over seven year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/56\">",
"     56",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Weight gain is also associated with cancer risk. Men who gained &ge;21 kg after age 20 had a 60 percent higher risk of colorectal cancer than men who gained only 1 to 5 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, women who lost &ge;10 kg after menopause and kept it off saw a 50 percent reduction in breast cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms underlying the effect of obesity and weight change likely vary by tumor site with the current focus on endogenous estrogens in breast and endometrial cancer and on insulin and inflammation in colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dietary factors have been studied in relation to cancer. Overall, dietary fat, fruits, vegetables, and fiber have not consistently been shown to affect cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/59\">",
"     59",
"    </a>",
"    ] . Intake of other nutrients, particularly certain micronutrients, may offer a degree of protection against certain malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=see_link\">",
"     \"Healthy diet in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inconsistencies in results of nutritional (diet or supplement) studies can be attributed to multiple factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/60\">",
"     60",
"    </a>",
"    ]. Observational studies are subject to imprecision in diet recall, and confounding factors that influence the risk of cancer and occur disproportionately among individuals exposed and not exposed to the nutrient of interest. Randomized controlled trials may yield inaccurate results because of poor adherence to the dietary intervention, insufficient follow-up time, wrong dose or form of the nutrient, or a study population that is replete in the nutrient studied. Additionally, studies tend to focus on one nutrient in isolation, when whole foods or the full composition of a diet may correlate better with cancer risk than any single component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dietary fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary fat has been extensively studied as a possible factor explaining the variation in international cancer rates. No clear link has been found between total fat intake and colon or breast cancer; the data are somewhat more convincing for prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While some reports suggest that a diet low in animal fat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cholesterol may be protective against colorectal cancer, epidemiologic studies of colon cancer, controlled for caloric intake, have shown no consistent association between total fat intake and cancer risk. In the largest trial to examine this issue, the prospective Women's Health Initiative Dietary Modification Trial, 48,835 women were randomly assigned to a behavioral modification program to decrease dietary fat or a usual diet control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/62\">",
"       62",
"      </a>",
"      ]. The intervention group, compared to controls, reduced the percentage of calories consumed as fat (by 10.7 percent in year one, 8 percent at year six). There was no difference in incidence of colorectal cancer during 8.1 years of follow-up. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H16#H16\">",
"       \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Diet'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Animal and ecologic (international) studies show a positive correlation between fat consumption and increased breast cancer risk. Results of case-control and cohort studies have been mixed, however. As an example, in the same cohort from the Women's Health Initiative cited above, the incidence of breast cancer in 8.1 years of follow-up was not statistically different between low dietary fat and control groups; there was a trend to breast cancer reduction in the low fat intervention group, especially for women with high baseline fat intake who were adherent to the diet modification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diet high in animal fat may be an important factor in the development of prostate cancer. In particular, intake of large amounts of alpha-linoleic acid and low amounts of linoleic acid appear to increase risk; this combination is common in red meat and some dairy products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/64\">",
"       64",
"      </a>",
"      ]. The mechanism of this association may be that serum levels of testosterone are lower in men who decrease their fat intake. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H10#H10\">",
"       \"Risk factors for prostate cancer\", section on 'Animal fat'",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While total fat does not appear to impact cancer risk, questions remain as to whether particular types of fat (saturated, unsaturated, or trans fats) affect risk differently, and whether fat intake in childhood or adolescence carries a greater risk than intake during adulthood. One consistent finding is that excess calories from any source leads to weight gain and an increase in the risk of multiple cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H349227125\">",
"     'Excess weight'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Red meat",
"    </span>",
"    &nbsp;&mdash;&nbsp;High intake of red meat including beef, pork, veal, and lamb, is associated with an elevated risk of colorectal cancer in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. One large study (n = 148,610) concluded that the risk of colon cancer was increased in those with a long-term high intake of processed meat (relative risk [RR] 1.5, 95% CI 1.04-2.17) and with a high ratio of red meat to poultry and fish (RR 1.53, 95% CI 1.08-2.18) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red meat consumption has also been associated with an increase in cancer-specific mortality. In one large population study (n = 617,119), an association between cancer-specific mortality and red meat intake, comparing highest and lowest quintiles of consumption (HR 1.2, 95% CI 1.1-1.3), was found in individuals aged 50 to 71 years; specific types of cancer were not reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/71\">",
"     71",
"    </a>",
"    ]. Findings were similar in another study of over 121,000 men and women where red meat consumption was also associated with an increased risk of cancer mortality (HR 1.16, 95% CI 1.09-1.23) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms for this increased risk have not been determined but several factors have been suggested including heme content in the meat, animal fat, and carcinogens produced when the meat is cooked at high temperatures. It isn&rsquo;t known if risk varies with different animal raising strategies (eg, grass-fed beef).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fruits and vegetables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite suggestions from case control studies that high intake of fruit and vegetables is associated with a significant reduction in cancer, prospective studies have found less consistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. Data from the EPIC study, a cohort study of nearly 500,000 European men and women followed for nine years, found only a weak association between increased intake of fruits and vegetables with overall risk of cancer (HR 0.97, 95% CI 0.96-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], though not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/80\">",
"     80",
"    </a>",
"    ], suggest a weak association between the intake of a diet high in fruits and vegetables and protection from colorectal cancer. A pooled analysis of fourteen cohort studies (n &gt;750,000), including the previous study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/80\">",
"     80",
"    </a>",
"    ], concluded that eating more than 800 g fruit and vegetables daily, compared to less than 200 g, decreased risk for distal colon cancer (RR 0.74) but not for proximal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/81\">",
"     81",
"    </a>",
"    ]. A subsequent meta-analysis of 19 cohort studies concluded a weaker protective effect, with most of the risk reduction attributable identified at a far lower threshold (100",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    of fruit and vegetable intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/82\">",
"     82",
"    </a>",
"    ]. A meta-analysis of the relationship between fiber and colorectal cancer found no significant association between fruit, vegetable, or legume fiber and the incidence of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence is slightly stronger for a link between prostate cancer and tomato products. Several cohort studies have demonstrated a significant reduction of prostate cancer risk in men with the highest intake of tomatoes and tomato products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. However, a systematic review performed by the FDA found \"very limited evidence\" to support an association between tomato consumption and reduced risk of prostate or other (ovarian, gastric, and pancreatic) cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/86\">",
"     86",
"    </a>",
"    ]. Lycopene, a carotenoid found in tomatoes, has been postulated to be responsible for this benefit. A systematic review identified three trials of lycopene and prostate cancer, but only one with incident disease as an endpoint, and found a decrease in risk but no difference in serum lycopene levels between groups, concluding that there was insufficient evidence to determine whether lycopene is related to prostate cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/87\">",
"     87",
"    </a>",
"    ]. Other studies have failed to support the hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/86,88\">",
"     86,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis found that intake of high amounts of soy (20 mg per day of isoflavone) in Asian women was associated with a decreased risk for breast cancer, compared to Asian women consuming lower amounts (5 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/89\">",
"     89",
"    </a>",
"    ]. However, even the lowest intake of soy isoflavones in the Asian population was more than fivefold the \"high\" intake (0.8 mg per day) of women in Western countries, where studies have not shown a protective effect for soy. In another meta-analysis, Chinese women who were in the highest quintile of soy intake had a decreased risk of lung cancer compared to those in the lowest quintile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/90\">",
"     90",
"    </a>",
"    ]. Increased flavonoids found in tomatoes, green peppers, berries, and citrus fruits have been associated with a modest decrease in breast cancer risk in Western populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dairy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 21 studies evaluating the relationship of dairy food intake and ovarian cancer found no evidence of association in case control studies (RR 0.96) but three prospective cohort studies did demonstrate increased risk of ovarian cancer with high intake of dairy foods (RR 1.13, 95% CI 1.05-1.22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/92\">",
"     92",
"    </a>",
"    ]. Inaccuracy of retrospective diet reports in the case control studies may affect their reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/93\">",
"     93",
"    </a>",
"    ]. However, a subsequent cohort study found no increase in risk of ovarian cancer with dietary dairy or lactose intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/94\">",
"     94",
"    </a>",
"    ]. Thus, the relationship of dairy intake to ovarian cancer is uncertain.",
"   </p>",
"   <p>",
"    Several studies suggest that intake of low-fat dairy products may protect against breast cancer, mainly in premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. In the largest prospective cohort study of over 88,000 women in the Nurses' Health Study, there was an inverse association between breast cancer risk and the intake of low-fat dairy products, calcium (mainly dairy intake), and vitamin D (mainly non-dairy intake) in premenopausal but not postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/95\">",
"     95",
"    </a>",
"    ]. In contrast, a large pooled analysis of eight prospective studies mainly comprising postmenopausal women did not find a strong association between dairy intake and breast cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium intake, as determined by a food frequency questionnaire, was associated with decreased total cancer risk over seven years in women, but not in men, in a large US cohort of 567,000 participants aged 50 to 71 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/100\">",
"     100",
"    </a>",
"    ]. A decrease in cancers of the digestive tract (particularly colon cancer) with higher dairy food and calcium intake was noted in both men and women, however (for highest versus lowest quintile, RR 0.84 in men and 0.77 in women).",
"   </p>",
"   <p>",
"    The association between calcium intake and colorectal cancer risk is discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Calcium'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiber intake is associated with a reduction in the risk of heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/101,102\">",
"     101,102",
"    </a>",
"    ] and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/103,104\">",
"     103,104",
"    </a>",
"    ], but its effect on cancer risk reduction is less certain. Results have been variable among large epidemiologic studies and meta-analyses, and the degree of protection from dietary fiber, if any, will remain unsettled until prospective intervention studies are done. In the absence of randomized trials, observational data may be confounded by the relationship of fiber intake with other micronutrients and with other choices related to lifestyle and diet. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H17#H17\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Fiber'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several large epidemiologic studies have reported a significant inverse associated between fiber intake and colorectal cancer risk. As an example, a large European study involving 519,978 patients found that intake of dietary fiber was inversely related to colon cancer incidence (adjusted RR 0.58, 95% CI 0.41-0.85), comparing the highest to lowest quintiles of fiber intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/105\">",
"     105",
"    </a>",
"    ]. However, the results may have been confounded by lack of control for folate intake, and fiber may have served as a proxy for this micronutrient. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Folate and other B vitamins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several large cohort studies from the US have not shown an association between the development of colorectal adenomas or cancer risk and either fiber intake in general or cereal fiber in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/67,106-108\">",
"     67,106-108",
"    </a>",
"    ]. A pooled analysis of 13 prospective cohort studies (725,628 men and women followed up to 20 years) found the inverse association of fiber with the risk of colorectal cancer was no longer apparent after accounting for other dietary risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/107\">",
"     107",
"    </a>",
"    ]. Likewise, a meta-analysis of five studies concluded that fiber did not affect the incidence or recurrence of adenomatous polyps (the precursor to colorectal adenocarcinomas) within a two to four year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/108\">",
"     108",
"    </a>",
"    ]. However, a meta-analysis of 16 studies from multiple countries did find a relationship between decreased risk of colorectal cancer and total dietary fiber intake (relative risk [RR] of colon cancer for each 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    intake was 0.90, 95% CI 0.86-0.84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/83\">",
"     83",
"    </a>",
"    ]. This study also found that the decreased risk was associated with cereal fiber but was not significant with fruit, vegetable, or legume fiber.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Glycemic load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin and insulin-like growth factors promote cell proliferation, and it is hypothesized that hyperinsulinemia may promote certain cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/109\">",
"     109",
"    </a>",
"    ]. An increased risk for certain cancers has been associated with diabetes (primarily type 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/110\">",
"     110",
"    </a>",
"    ]. Patients with diabetes have a two-fold or greater risk of cancers of the liver, pancreas, and endometrium and a slightly lower but increased risk for cancers of the colon, breast and bladder; the risk of prostate cancer is decreased in patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glycemic load is a function of a food's glycemic index (a measure of how rapidly and to what extent the blood glucose level rises), carbohydrate content per serving, and frequency of intake. Intake of foods with a high glycemic index has been evaluated for association with risk of cancer. These studies have yielded equivocal results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=see_link\">",
"     \"Dietary carbohydrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large study involving participants in the National Institutes of Health-AARP Diet and Health Study found no significant association between glycemic index or glycemic load (calculated from food questionnaires) with 15,000 cases of cancer in women or 33,000 cases of cancer in men identified over nine years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One case control study of breast cancer reported an association with high glycemic load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/113\">",
"       113",
"      </a>",
"      ], but large cohort studies have not confirmed this finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/114-118\">",
"       114-118",
"      </a>",
"      ]. A meta-analysis of prospective cohort studies found no significant association between glycemic load and breast cancer risk, but noted that a diet with a high glycemic index was positively associated with increased breast cancer risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glycemic load was not associated with prostate cancer risk in a large cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of colorectal cancer and glycemic load have also shown inconsistent results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/64,121-124\">",
"       64,121-124",
"      </a>",
"      ]. Data from the Women's Health Study, evaluating dietary habits of 174 incident colon cancer patients in a cohort of 38,451 women, showed that dietary glycemic load was significantly associated with an increased risk of colorectal cancer (adjusted RR 2.85, 95% CI 1.4 to 5.8), comparing highest to lowest quintiles of glycemic load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/121\">",
"       121",
"      </a>",
"      ]. On the other hand, a large study of Canadian women found no increase in risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/123\">",
"       123",
"      </a>",
"      ]. Evaluation of data from the Nurse's Health Study and from the Health Professionals Follow Up Study found a small increase in risk among men with high dietary glycemic load (RR 1.32, 95% CI 0.98-1.79) but no association among women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/124\">",
"       124",
"      </a>",
"      ]. A meta-analysis found no association of glycemic load or glycemic index with colorectal cancer risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Omega-3 fatty acids and dietary fish",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of prospective studies evaluating the effect of omega-3 fatty acid consumption on tumor incidence concluded that there is no association between omega-3 fatty acids and cancer risk for 11 different types of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/126\">",
"     126",
"    </a>",
"    ]. Ten studies evaluated in this review reported significant findings, but individual studies indicated both increased and decreased risk with no consistent pattern. A subsequent randomized trial found an increase in cancer risk for women treated with omega-3 fatty acids, but not for men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While an association has not been found for dietary supplementation with omega-3 fatty acids and cancer incidence, an association was found in a systematic review of 41 observational studies for fish consumption and a decreased incidence of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/128\">",
"     128",
"    </a>",
"    ]. In that analysis, including case control and cohort studies, an inverse relationship between fish intake and rectal cancer was demonstrated (OR 0.79, 95% CI 0.65-0.97), while an inverse trend was suggested for colon cancer (OR 0.96, 95% CI 0.81-1.14).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VITAMINS AND MICRONUTRIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational and prospective studies of the use of supplemental vitamins and minerals to prevent cancer have been disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/129\">",
"     129",
"    </a>",
"    ]. A systematic review of 38 studies found that neither vitamin C nor vitamin E supplementation was beneficial for prevention of the cancers evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/130\">",
"     130",
"    </a>",
"    ]. A 2006 National Institutes of Health (NIH) consensus conference panel concluded that \"present evidence is insufficient to recommend either for or against the use of multivitamin supplements by the American public to prevent chronic disease\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/131\">",
"     131",
"    </a>",
"    ]. A subsequent long-term randomized trial (mean 9.4 years treatment) in 8000 women found no evidence that supplementation with vitamin C, E, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    (singly or in combination) decreased cancer incidence or cancer mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/132\">",
"     132",
"    </a>",
"    ]. Additionally, two long term observational studies, one including over 160,000 women with follow-up of approximately eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/133\">",
"     133",
"    </a>",
"    ] and another including over 180,000 multiethnic participants with eleven year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/134\">",
"     134",
"    </a>",
"    ], found no association between multivitamin use and risk of cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the large (n = 14,641) randomized Physicians&rsquo; Health Study II found that supplementation with a multivitamin resulted in a small reduction in total cancer that narrowly reached statistical significance (HR 0.92, 95% CI 0.86-0.998) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/135\">",
"     135",
"    </a>",
"    ]. The study population was male physicians 50 years and older at recruitment, and thus generally well nourished and highly educated. With a mean follow-up of 11.2 years, there was a reduction in total cancer from 18.3 to 17.0 events per 1000 person-years, comparing groups assigned to multivitamins and placebo, respectively. No difference was found in the secondary outcome of decreased incidence of specific cancers, and there was no impact on cancer mortality. For men with a baseline history of cancer, multivitamin use was associated with a reduction in total cancer (HR 0.73, 95% CI 0.56-0.96).",
"   </p>",
"   <p>",
"    Given the variability of study findings, with only marginal benefit in some and no benefit in others, meta-analysis incorporating the prior studies would be helpful. Pending such analysis, it has not been established that multivitamin and mineral supplements provide added benefit to a balanced, healthful diet for most individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/136\">",
"     136",
"    </a>",
"    ]. The only prospective trial of vitamin supplementation (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    plus vitamin E and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    ) to show a durable finding of fewer deaths in the treated group was conducted in remote Linxian Province, China, a region where the population consumes a poor diet, and enrollees likely suffered deficiencies of the nutrients tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the relationship between vitamin D intake or serum levels of 25(OH)D and cancer risk have been inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/138\">",
"     138",
"    </a>",
"    ]. Studies vary in regard to participants (sex, baseline serum levels), types of cancer evaluated and dose of vitamin D. Overall, it does not appear that vitamin D supplements should be prescribed to decrease cancer risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/139\">",
"     139",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D may reduce the risk of colon cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/139-143\">",
"     139-143",
"    </a>",
"    ] but the data do not show a consistent relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. A pooled analysis of 10 cohort studies found a trend towards reduction of colorectal cancer with increasing vitamin D intake, but the protective effect was only statistically significant among those individuals with the highest vitamin D intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/146\">",
"     146",
"    </a>",
"    ]. Vitamin D may decrease cancer risk through improved calcium absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prostate and breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a theoretical basis to predict an effect of vitamin D on prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/147\">",
"     147",
"    </a>",
"    ], at least two studies did not demonstrate such a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H20#H20\">",
"     \"Risk factors for prostate cancer\", section on 'Calcium and vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin D plus calcium supplementation does not appear to affect risk for breast cancer. In the Women's Health Initiative trial, 36,000 postmenopausal women were randomly assigned to take 1000 mg elemental calcium with 400 IU vitamin D daily, or placebo, for a mean of seven years (with hip fracture rate as the primary outcome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/150\">",
"     150",
"    </a>",
"    ]. There was no difference between the two groups in the incidence of invasive breast cancer, a secondary outcome of the trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Total cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increment of 25",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    in the serum 25(OH)D level was projected to result in a 17 percent reduction in total cancer risk in men, extrapolated from data from the US Health Professionals Follow-Up Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/151\">",
"     151",
"    </a>",
"    ]. This incremental level of serum 25(OH)D is not readily achieved with diet (one glass of milk is predicted to increase the plasma level only by 2 to 3",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    and would require supplementation with at least 1500 IU vitamin D daily.",
"   </p>",
"   <p>",
"    A randomized trial comparing four-year supplementation with calcium (1400 to 1500 mg daily), calcium plus vitamin D (1100 IU daily) or placebo in 1179 women &ge;55 years found a decreased risk of cancer for both calcium alone and calcium combined with vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/152\">",
"     152",
"    </a>",
"    ]. After the first year, there was a large risk reduction in women who received vitamin D (RR 0.23, 95% CI 0.1-0.6). This large magnitude of effect seems difficult to explain in light of inconsistent results from other studies.",
"   </p>",
"   <p>",
"    Data from nearly 17,000 participants in NHANES III, a large national nutritional survey, found that overall cancer mortality risk was not related to baseline 25(OH)D levels, with a mean study follow-up of 13.4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/139\">",
"     139",
"    </a>",
"    ]. Interestingly, cancer mortality risks were increased for some men with higher baseline 25(OH)D levels (&gt;100",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    compared with &lt;37.5",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    although there was a suggestion of an inverse relationship for colorectal cancer. For women, however, higher serum levels were associated with a decreased cancer mortality risk for those living in the north and sampled in warmer months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased calcium intake has been linked to reduced risk of colorectal cancer but may be associated with an increased risk of prostate cancer. There may be a minimum level of calcium intake, around 700",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    that confers protection against colorectal cancer without significantly increasing prostate cancer risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have demonstrated that higher calcium intake (either dietary or supplemental) is associated with a reduced risk of colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/153,154\">",
"     153,154",
"    </a>",
"    ]. As an example, in a combined cohort from the Health Professionals Follow-up Study and Nurse's Health Study, the risk of distal, but not proximal, colon cancer was reduced in subjects who took up to 1250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    elemental calcium versus &lt;500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (RR 0.58, 95% CI 0.32-1.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium supplementation appears to prevent the recurrence of colorectal adenomas. A meta-analysis of three randomized, placebo-controlled trials of subjects with colorectal adenomas (total n = 1485) concluded that the risk of recurrence was significantly lower in patients randomized to calcium supplementation (RR 0.80, 95% CI 0.68-0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/156\">",
"     156",
"    </a>",
"    ]. As a result of these data, calcium supplementation has been recommended for the primary or secondary prevention of colonic adenomas by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/157\">",
"     157",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these benefits in adenoma prevention trials, whether calcium supplementation reduces the risk of colorectal cancer is unproven.",
"   </p>",
"   <p>",
"    A protective effect of calcium supplementation could not be shown by the Women's Health Initiative (n = 36,282), which found no significant decrease in incidence or stage of colorectal cancer in the group who had been randomly assigned to receive calcium 500 mg and vitamin D 200 IU twice daily, compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/158\">",
"     158",
"    </a>",
"    ]. The average age of women at the start of randomization was 62 years, and follow-up was seven years. Given the known slow progression rate for colorectal cancer, seven years may be too short an interval to find an effect on cancer incidence, and longer-term follow-up for this study population is planned. However, it has been noted that the baseline mean calcium intake in the Women&rsquo;s Health Initiative participants (1151",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was above the threshold for effect indicated by previous studies and thus increasing intake would be expected to show no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-control and prospective studies of calcium and prostate cancer have reported inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/160\">",
"     160",
"    </a>",
"    ]. Three large cohort studies found an increased risk of prostate cancer with different measures of calcium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/161-163\">",
"     161-163",
"    </a>",
"    ]. Two other prospective studies found no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/164,165\">",
"     164,165",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H20#H20\">",
"     \"Risk factors for prostate cancer\", section on 'Calcium and vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of prostate cancer may be increased with high, but not moderate, calcium intake. One study of 3811 incident cases of prostate cancer found that total calcium over 2000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    from both diet and supplementation was linked to a 20 percent increase in prostate cancer risk (RR 1.2, 95% CI 1.0-1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/163\">",
"     163",
"    </a>",
"    ]. High dietary calcium (&ge;2000",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    was associated with an even greater increased risk of prostate cancer (RR 1.6, 95% CI 1.1-2.3), but moderate dietary calcium was not. Data from another study showed stronger associations between high calcium intake (&ge;2000",
"    <span class=\"nowrap\">",
"     mg/d)",
"    </span>",
"    and total, advanced, and metastatic disease (RR 1.71, 2.97, and 4.57, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that high calcium levels may increase prostate cancer risk by down-regulating the active form of vitamin D, thus interfering with vitamin D's proposed inhibition of tumor growth and metastasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Selenium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    decreases the risk of a variety of tumors, and some epidemiologic studies have shown an inverse relationship between selenium and cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/166-168\">",
"     166-168",
"    </a>",
"    ]. One study using NHANES III data from 14,000 adults found an inverse association between selenium levels and cancer mortality at levels of selenium up to 130",
"    <span class=\"nowrap\">",
"     ng/ml,",
"    </span>",
"    but an increase in mortality at levels &gt;150",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A placebo-controlled randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    for prevention of nonmelanoma skin cancer showed a significant mortality reduction in cancers of the lung, colon, and prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/170\">",
"     170",
"    </a>",
"    ]. A systematic review of the effects of antioxidant supplements on cancer included four randomized trials of selenium alone or in combination with other supplements and found that selenium reduced the overall risk of cancer in men (RR 0.77, 95% CI 0.64-0.92) but not in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/171\">",
"     171",
"    </a>",
"    ]. However, a later meta-analysis of randomized trials of antioxidant therapy included five trials of selenium and found no significant cancer risk reduction (RR 0.62, 0.36-1.08) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/172\">",
"     172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on preliminary evidence from earlier smaller trials, the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    in decreasing the incidence of prostate cancer was evaluated in the much larger Selenium and Vitamin E Cancer Prevention Trial (SELECT), which included over 35,000 men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/173\">",
"     173",
"    </a>",
"    ]. The trial was stopped prematurely for futility as neither vitamin E nor selenium protected participants from prostate cancer and there was a nonsignificant trend toward increased risk for diabetes in the selenium group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/174\">",
"     174",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H15#H15\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Selenium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=see_link&amp;anchor=H17#H17\">",
"     \"Risk factors for type 2 diabetes mellitus\", section on 'Selenium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34459741\">",
"    <span class=\"h2\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence does not support a role for vitamin E supplementation in the prevention of cancer, and some evidence suggests that vitamin E may be harmful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In long term follow-up (7 up to 12 years) of the SELECT trial, the risk of prostate cancer was higher in the men who were assigned to take vitamin E alone, compared to placebo (HR 1.17, 99%CI 1.004-1.36) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/175\">",
"       175",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin E (600 IU alpha-tocopherol every other day) did not prevent invasive cancer in a 10-year follow-up to the Women's Health Study, evaluating healthy women age 45 years and older (mean age 55 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/176\">",
"       176",
"      </a>",
"      ]. Neither vitamin E nor vitamin C decreased risk for prostate or total cancer in a Physicians Health Study randomized trial of 14,641 men aged 50 and older followed for eight years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/177\">",
"       177",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of six randomized trials, vitamin E supplementation had no effect on cancer incidence or cancer mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/171\">",
"       171",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Folate and other B vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate is present in green, leafy vegetables, fruits, cereals and grains, nuts, and meats.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    , a synthetic form included in supplements, has many of the same biologic effects as folate, but is more bioavailable. Folate is important in DNA synthesis, methylation, and repair, as well as in the regulation of gene expression.",
"   </p>",
"   <p>",
"    The role of folate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    in cancer prevention is uncertain. Folate has been associated with a decreased risk for colon and other cancers, especially in individuals who consume alcohol, in observational studies. However, some randomized trials have suggested the possibility that folic acid may increase risk for cancer.",
"   </p>",
"   <p>",
"    Support from observational studies for folate as a factor in cancer protection is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects with lower levels of methylenetetrahydrofolate reductase, an enzyme involved in folate metabolism, have a reduced risk of colon cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/178\">",
"       178",
"      </a>",
"      ], as well as cancers of the esophagus, stomach and pancreas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An inverse relationship was found between folate intake and the risk of developing adenomatous polyps in the combined analysis of data from the Nurses&rsquo; Health Study and Health Professionals Follow-Up Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/180\">",
"       180",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Nurses&rsquo; Health Study demonstrated a decreased risk of colon cancer (RR 0.25, CI 0.13-0.51) in women who took",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      -containing multivitamins for at least 15 years, suggesting that folate levels may be particularly important in the early stages of colorectal cancer development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/181\">",
"       181",
"      </a>",
"      ]. Findings from the Women's Health Initiative data, however, showed that increased dietary folate and vitamin B6 intake lowered colorectal cancer risk, while vitamin supplementation with folic acid and B6 did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dietary folate, but not vitamin supplementation, was associated with a reduced risk for pancreatic cancer in a Swedish cohort of 82,000 men and women prospectively followed for seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/183\">",
"       183",
"      </a>",
"      ]. A meta-analysis found that dietary folate was associated with reduced risk for esophageal squamous cell cancer (RR 0.66, 95% CI 0.53-0.83), and pancreatic cancer (RR 0.49, 95% CI 0.35-0.67), comparing highest versus lowest intake categories [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a meta-analysis of case-control studies and observational studies did not demonstrate an association between low dietary folate intake and breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/184\">",
"     184",
"    </a>",
"    ]. The study found evidence of publication bias in previous studies that had suggested an association.",
"   </p>",
"   <p>",
"    In contrast to biologic and observational evidence supporting a role for folate in cancer prevention, randomized trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation have not shown benefit and some trials have raised the possibility of harm. Concern for a possible increase in cancer risk had been initially raised by findings from several individual trials, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest controlled trial to evaluate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation in patients with colorectal adenomas found no decrease in new adenomas at three and six-year follow-up, but an increase in risk of advanced colon lesions and in noncolorectal cancer in patients who received folic acid, compared to controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/185\">",
"       185",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combined analysis of two trials evaluating vitamin supplementation in patients with ischemic heart disease found an increased risk for cancer incidence (primarily lung cancer) (HR 1.21, 95% CI 1.03-1.41) and cancer mortality (HR 1.38, CI 1.07-1.79) at three year follow-up in participants who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      plus vitamin B12 supplementation for three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/186\">",
"       186",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of prostate cancer was increased in the group of men randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in a placebo-controlled trial of chemoprevention for colorectal polyps [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/187\">",
"       187",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two meta-analyses, however, have not found an increase in the risk of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/188,189\">",
"     188,189",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest meta-analysis of individual patient data from randomized trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      for the prevention of cardiovascular disease (10 trials, n = 49,969) and colorectal adenoma (3 trials, n = 2652), during an average of 5.2 years of treatment, there was no significant difference in overall cancer incidence for patients assigned to folic acid or placebo (RR 1.06, 95% CI 0.99-1.13) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/189\">",
"       189",
"      </a>",
"      ]. There was also no significant effect on the incidence of specific cancers, including cancers of the large intestine, prostate, lung, or breast.",
"     </li>",
"     <li>",
"      Similarly, a meta-analysis based on individual patient data from eight randomized trials of patients with increased cardiovascular risk (n = 37,485) found no significant effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation in varying doses (0.8 to 40 mg per day) on cancer incidence (RR 1.05, 95% CI 0.98-1.13) or cancer mortality (1.00, 0.85-1.18) with a median follow-up of five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/188\">",
"       188",
"      </a>",
"      ]; findings were similar in a subsequent trial in patients with cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/127\">",
"       127",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum levels of other B vitamins have been associated with reduced cancer risk in observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of prospective studies found an inverse association for risk of colorectal cancer with vitamin B6 intake and blood levels of pyridoxal 5'-phosphate, the active form of vitamin B6 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/190\">",
"       190",
"      </a>",
"      ]. However, it is not known whether supplementation with vitamin B6 will decrease cancer risk.",
"     </li>",
"     <li>",
"      In a prospective study over eight years, involving more than 500,000 participants, having a serum level above median for B6 and methionine was associated with a lower risk of lung cancer, in both never and current smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/191\">",
"       191",
"      </a>",
"      ]. In this cohort, a lower risk of lung cancer was also seen in smokers (past or current) with higher levels of folate, but not in those who never smoked.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Folate in alcohol users",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction between folate and alcohol may be important in cancer prevention (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Alcohol'",
"    </a>",
"    below). Alcohol consumption is known to both interfere with folate availability and increase the risk of colon and breast cancer. In one study, the increase in colon cancer risk associated with alcohol use was not seen in men with the highest folate intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/192\">",
"     192",
"    </a>",
"    ]. Similarly, the increased risk of breast cancer associated with alcohol use was most pronounced in women with the lowest folate intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/193,194\">",
"     193,194",
"    </a>",
"    ]. An inverse relationship between folate intake and breast cancer was most evident among women whose alcohol consumption was greater than 15 g (about one drink) per day (",
"    <a class=\"graphic graphic_figure graphicRef74192 \" href=\"mobipreview.htm?16/34/16942\">",
"     figure 1",
"    </a>",
"    ). Increasing levels of plasma folate correlated with decreased risk of breast cancer particularly among women who consumed alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest that increased iron stores or dietary iron may be associated with increased risk for cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/196,197\">",
"     196,197",
"    </a>",
"    ]. A randomized trial conducted to evaluate the benefits of phlebotomy in patients with peripheral artery disease found a significant reduction in cancer incidence at six months (HR 0.65, 95% CI 0.43-0.97) in patients assigned to the phlebotomy group, compared to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/198\">",
"     198",
"    </a>",
"    ]. This finding warrants confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other vitamin supplements have been evaluated, with variable findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      have been associated with an increased incidence of lung cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/171,199,200\">",
"       171,199,200",
"      </a>",
"      ]. Beta-carotene doses used in some of these trials may also be found in multivitamin formulations used to promote visual health. Beta-carotene did not decrease cancer incidence in studies of American women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/201\">",
"       201",
"      </a>",
"      ] and men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/202\">",
"       202",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=see_link&amp;anchor=H9#H9\">",
"       \"Cigarette smoking and other risk factors for lung cancer\", section on 'Beta-carotene supplementation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supplementation with a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      , and zinc decreased the incidence of noncardia stomach cancer, but not other intestinal malignancies, in a population in rural China with baseline deficiencies in micronutrients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/203\">",
"       203",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ALCOHOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess alcohol consumption increases the risk of multiple cancers (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Alcohol and specific illnesses'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of over one million women (average age 56 years) found that, at an average follow-up of 7.5 years, 10 g of alcohol (one drink) per day increased the risk for cancers of the oropharynx, esophagus, larynx, rectum, liver, and breast [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/204\">",
"       204",
"      </a>",
"      ]. The overall risk for cancer was increased 6 percent (95% CI 4 to 7 percent) per consumption of",
"      <span class=\"nowrap\">",
"       10/g",
"      </span>",
"      day alcohol of any type. The increased risk for cancers involving the upper respiratory and digestive tract was seen only in current smokers.",
"     </li>",
"     <li>",
"      Increased risk for breast cancer with moderate alcohol consumption was found in the Women's Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/205\">",
"       205",
"      </a>",
"      ] as well as in the Nurse&rsquo;s Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/206\">",
"       206",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Prospective Investigation into Cancer and Nutrition (EPIC) study in eight European countries found alcohol consumption could account for 10 percent of the attributable risk for any cancer in men, and three percent in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/207\">",
"       207",
"      </a>",
"      ]. The risk was greatest for consumption of more than recommended upper limits of alcohol, and was greatest for upper gastrointestinal and hepatocellular cancer.",
"     </li>",
"     <li>",
"      It has been estimated that worldwide 3.6 percent of cancers are associated with chronic alcohol drinking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/208\">",
"       208",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Moderate alcohol use has beneficial effects on cardiovascular health, but the increased cancer risk may offset such benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/209\">",
"     209",
"    </a>",
"    ]. Even light alcohol consumption (up to one drink per day) has been associated with a small increased risk for breast cancer in women, as well as increased risk for oropharyngeal and esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/210\">",
"     210",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several mechanisms have been postulated to account for the carcinogenicity of alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/208\">",
"     208",
"    </a>",
"    ]. Its solvent properties may allow carcinogens to penetrate cell membranes. Alcohol increases estrogen levels and impacts folate metabolism. Alcohol may also act as an irritant, causing increased cell production; as a transporter carrying carcinogens; as an inhibitor of DNA methylation; or as a prometabolite for identified carcinogens such as acetaldehyde [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/208,211,212\">",
"     208,211,212",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For unclear reasons, moderate consumption of alcohol has been associated with a decreased risk of renal cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link&amp;anchor=H1046155726#H1046155726\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Alcohol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that 17 percent of all new cancers worldwide are due to infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/15\">",
"     15",
"    </a>",
"    ]. Viruses may increase cancer risk through cellular transformation, disruption of cell cycle control, increased cell turnover rates, and immune suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple links between viral agents and cancer have been established:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human papillomavirus (HPV) with cervical and other anogenital cancers as well as squamous cell cancers of the head and neck [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/214\">",
"       214",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=see_link\">",
"       \"Virology of human papillomavirus infections and the link to cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis B (HBV) and C (HCV) with hepatocellular carcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/215\">",
"       215",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human T-cell lymphotropic virus (HTLV-I) with adult T cell leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/216\">",
"       216",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2793?source=see_link\">",
"       \"Treatment of large granular lymphocyte leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV-I) with Kaposi sarcoma, non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/15\">",
"       15",
"      </a>",
"      ], and multiple non-AIDS defining malignancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/217\">",
"       217",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=see_link\">",
"       \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human herpes virus 8 (HHV-8) with Kaposi sarcoma and primary effusion lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/218,219\">",
"       218,219",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30138?source=see_link\">",
"       \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epstein-Barr virus (EBV) with Burkitt lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/218\">",
"       218",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2791?source=see_link\">",
"       \"Pathobiology of Burkitt lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of these viruses are spread through contact with infected blood or body fluids, thus offering opportunities for prevention. Vaccinations for HBV and HPV are particularly promising. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9866?source=see_link&amp;anchor=H14#H14\">",
"     \"Adolescent sexuality\", section on 'STIs and HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strategies to prevent transmission through infected blood and blood products must also be implemented. Examples include use of sterile disposable needles for a single patient in healthcare settings, needle exchange programs, regulation of tattooing, continued screening of blood, organ, and semen donors, and the development of artificial blood products.",
"   </p>",
"   <p>",
"    For some viruses, interventions are available to prevent or delay progression to cancer after infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A quadrivalent HPV vaccine is recommended for girls and women aged 9 to 26 years of age. Additionally, cervical cancer screening has dramatically reduced the incidence of cervical cancer where screening is widely available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/220\">",
"       220",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"       \"Recommendations for the use of human papillomavirus vaccines\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"       \"Screening for cervical cancer: Rationale and recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retroviral therapy for HIV infection has greatly altered the course of disease and associated cancers. Highly active antiretroviral therapy (HAART) has been shown to reduce the incidence of AIDS-related lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/221\">",
"       221",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreasing the hepatitis B viral load by treatment with interferon or",
"      <span class=\"nowrap\">",
"       nucleoside/tide",
"      </span>",
"      analogues in patients with chronic hepatitis B infection was associated with a decreased risk for hepatoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/222,223\">",
"       222,223",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"       \"Overview of the management of hepatitis B and case examples\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excess alcohol use may play a role in cancer development in patients with chronic HBV and HCV infections and should be avoided. Preliminary data suggest that antiviral therapy may reduce the risk of cancer in patients with chronic HCV infections, with reduction of HCV RNA, but the long-term effect of antiviral therapy on cancer risk is not known [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/224\">",
"       224",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to viral agents, the bacterium Helicobacter pylori (H. pylori) has been associated with gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/225\">",
"     225",
"    </a>",
"    ] and with MALT lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For several cancers, prophylactic medication can reduce cancer risk for high risk individuals. The",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio for chemoprevention must be evaluated for individual cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is a selective estrogen receptor modulator (SERM) with both estrogen agonist and antagonist properties.",
"   </p>",
"   <p>",
"    Data from four randomized trials and a meta-analysis suggests a statistical decrease in the risk of hormone receptor-positive invasive breast cancer with five years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/226-232\">",
"     226-232",
"    </a>",
"    ]. Neither the individual studies nor the meta-analysis have shown whether a reduction in the incidence of breast cancer will lead to a reduction in overall mortality or breast cancer-related mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/232\">",
"     232",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H2105620482#H2105620482\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Premenopausal women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is approved in the United States for the prevention of breast cancer in high-risk women. High-risk women, as defined in the trials of tamoxifen for breast cancer prevention, include those with a history of lobular carcinoma in situ (LCIS), a five-year estimated risk for breast cancer of at least 1.66 percent as determined by the Gail model, or family history of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/233\">",
"     233",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk prediction models for breast cancer screening\", section on 'Breast Cancer Risk Assessment Tool (Gail model)'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The acceptance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    as a preventive agent has been limited by its association with serious adverse events, including endometrial cancer and thromboembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/234\">",
"     234",
"    </a>",
"    ]. The greatest clinical benefits with the least side effects appear to be derived in premenopausal women (who are less likely to have thromboembolic sequelae and uterine cancer), women without a uterus, and women at higher breast cancer risk. Models to assess benefit and risk of tamoxifen in individual women are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the potential for serious side effects, the US Preventive Services Task Force (USPSTF) recommended against routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for breast cancer prevention in women of average risk in a 2002 guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/235\">",
"     235",
"    </a>",
"    ]. They recommended that health care providers discuss the risks and benefits of tamoxifen for breast cancer prevention with women at high risk of breast cancer and low risk of adverse effects from the medication. The USPSTF clinical practice guideline for prevention of breast cancer, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is another SERM that is approved for the prevention of osteoporosis, and for breast cancer prevention in postmenopausal women at high risk for invasive breast cancer. In the STAR breast cancer prevention trial that directly compared both agents, raloxifene was slightly less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/236\">",
"     236",
"    </a>",
"    ]. However, raloxifene is associated with fewer of the most serious side effects associated with tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/234,236\">",
"     234,236",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H31421397#H31421397\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2002 USPSTF guidelines for breast cancer chemoprevention did not address the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    for breast cancer prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/235\">",
"     235",
"    </a>",
"    ]. However, raloxifene is a reasonable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for postmenopausal women with a high risk for breast cancer (a history of LCIS or a five-year estimated risk for breast cancer of at least 1.66 percent as determined by the Gail model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/233\">",
"     233",
"    </a>",
"    ]) and who still have an intact uterus or need treatment for osteoporosis.",
"   </p>",
"   <p>",
"    There are no data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    in premenopausal women, and it is potentially teratogenic. Thus, at present, use of raloxifene should be restricted to postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6644636\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (AIs) such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    suppress plasma estrogen levels in postmenopausal women by inhibiting or inactivating aromatase. AIs appear to be associated with a lower risk of life-threatening adverse events than are SERMs.",
"   </p>",
"   <p>",
"    In the placebo-controlled NCIC CTG MAP.3 trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    reduced the risk of breast cancer in women at high risk for the disease by approximately 65 percent, with minimal side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/237\">",
"     237",
"    </a>",
"    ]. In this trial, high-risk was defined as age &ge; 60 years, estimated risk of breast cancer &ge; 1.66 percent over five years from the Gail model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/233\">",
"     233",
"    </a>",
"    ], history of atypical ductal hyperplasia or atypical lobular hyperplasia, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS) treated with mastectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H31421434#H31421434\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Aromatase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data establish AIs as an option for breast cancer prevention in high-risk postmenopausal women. However, questions remain as to long-term effects of an AI on bone loss and cardiovascular risk, since follow-up data for the MAP.3 trial is limited. Furthermore, joint and muscle symptoms associated with AIs may limit patient acceptance of this medication for preventive purposes. Additionally,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/4/7238?source=see_link\">",
"     exemestane",
"    </a>",
"    is more costly than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , although an alternative AI is available as a less expensive generic and has similar activity to exemestane when used for adjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H2110938459#H2110938459\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H2110938219#H2110938219\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Aromatase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIs are generally avoided in premenopausal women because of concerns that reduced feedback of estrogen to the hypothalamus and pituitary will increase gonadotropin secretion and stimulate the ovary. Thus, use of an AI for breast cancer prevention should be restricted to postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Aspirin and other anti-inflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several theories have been proposed for why",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs are effective in reducing colorectal cancer risk, and possibly effective for other cancers. These medications may cause cell cycle arrest or apoptosis (programmed cell death) of abnormal cells. Reduced risk may also relate to irreversible inhibition of cyclooxygenase-2. Inhibition of this enzyme decreases the synthesis of prostaglandins, which may inhibit tumor growth. Finally, aspirin may influence intracellular signaling through inhibition of phospholipase activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to decrease the risk of adenomatous polyps and colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/238-241\">",
"     238-241",
"    </a>",
"    ]. In high-risk patients with Lynch Syndrome, a randomized controlled trial found",
"    <span class=\"nowrap\">",
"     600mg/day",
"    </span>",
"    of aspirin decreased the risk of colorectal cancer by 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/242\">",
"     242",
"    </a>",
"    ]. The optimal dose of aspirin for patients at lower risk, however, has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/243\">",
"     243",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accumulated evidence indicates that long-term usage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is necessary to reduce risk. In addition, it appears that daily dosing (at a minimum of 75 mg) is needed to reduce risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/240,241,244-247\">",
"     240,241,244-247",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations from the US Preventive Services Task Force (USPSTF) in 2007 (preceding publication of many of the studies discussed above) noted that chronic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , at doses suggested to decrease the incidence of colorectal cancer, increases the risk for gastrointestinal bleeding and hemorrhagic stroke, as well as renal failure and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/248\">",
"     248",
"    </a>",
"    ]. Existing recommendations from the USPSTF and the American Cancer Society do not recommend aspirin use because of complication concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/248,249\">",
"     248,249",
"    </a>",
"    ] but do not consider the recent findings for a strong benefit with long-term use and do not take into account the additional benefit of aspirin for the prevention of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=see_link\">",
"     \"Aspirin in the primary prevention of cardiovascular disease and cancer\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Other cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the prevention of cancers other than colorectal are less consistent, but seem to suggest that daily (but not alternate day) dosing of aspirin decreases the risk of cancer but with a long latency, requiring long-term follow-up of individual patient data to assess the impact of aspirin on cancer prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/240,244,247,250-253\">",
"     240,244,247,250-253",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     5-Alpha reductase inhibitors and prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized Prostate Cancer Prevention Trial (PCPT) evaluated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , a 5-alpha reductase inhibitor, as a chemopreventive agent in 19,000 men who were at increased risk for prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/254\">",
"     254",
"    </a>",
"    ]. The incidence of prostate cancer was decreased in the finasteride group, compared to men in the placebo group (18.4 versus 24.4 percent) but there was an apparent increase in the absolute number and proportion of high grade tumors with finasteride. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An international, double-blind, placebo-controlled chemoprevention trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    (REDUCE) in 8336 men found a statistically significant 23 percent decrease in the incidence of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/255\">",
"     255",
"    </a>",
"    ]. However, the reduction was significant only among lower grade tumors (Gleason scores of 5 or 6) with no significant difference for Gleason scores 7 to 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/255\">",
"     255",
"    </a>",
"    ]. As part of an analysis for the US Food and Drug Administration (FDA), regrading of the specimens using a modified Gleason score subsequently found that there was an absolute increase of 0.5 percent in the incidence of tumors with modified Gleason scores 8 to 10 (RR 2.06, 95% CI 1.13-3.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/256\">",
"     256",
"    </a>",
"    ]. Although detection bias based upon the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    on prostate size or PSA sensitivity had been suggested as an explanation for the increased incidence of high grade tumors in the PCPT trial, it would not account for a similar finding in biopsy samples from the REDUCE trial.",
"   </p>",
"   <p>",
"    The advisory committee to the FDA concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    do not have a favorable risk-benefit profile for the chemoprevention of prostate cancer in healthy men, with an estimation that one additional high grade cancer would occur for every three to four lower grade cancers that would be prevented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/256\">",
"     256",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28310607\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-diabetic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is associated with reduced cancer incidence in patients with type 2 diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 4085 type 2 diabetic patients in the United Kingdom who used",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      from 1994 to 2003, investigators found that the risk of cancer was reduced by 40 percent among those who took metformin compared with individually matched diabetic patients who did not take metformin (7.3 versus 11.6 percent, HR 0.46, 95% CI 0.40-0.53) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/257\">",
"       257",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 1353 patients with type 2 diabetes in the Netherlands, during 9.6 years of follow-up, cancer mortality was significantly reduced comparing those who used",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      with those who did not (HR 0.43, CI 0.23-0.80) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/258\">",
"       258",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review and meta-analysis included 11 independent studies contributing 4042 cases of cancer and 529 deaths in patients with diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/259\">",
"       259",
"      </a>",
"      ]. Both cancer incidence and cancer mortality were reduced by 30 percent among users of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      . Significant reduction in the incidence of pancreatic and liver cancer was noted; reductions for breast, colon and pancreas were observed, though were not statistically significant. There was a trend toward a dose-response relationship. Two subsequent meta-analyses in patients with diabetes found an association between metformin use and a significant decrease in colorectal cancer risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/260\">",
"       260",
"      </a>",
"      ] and a decrease in risk of colorectal, liver, and lung cancers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/261\">",
"       261",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A registry-based case control study in the UK reported",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      use decreased pancreatic cancer risk among women by 60 percent but had no significant effect among men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/262\">",
"       262",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among postulated mechanisms for such a benefit are the inhibition of cancer cell growth and suppression of HER2 overexpression and inhibition of mTOR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/263-265\">",
"     263-265",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results may reflect increased risk due to use of other regimens for diabetes rather than decreased risk due to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . Ongoing randomized trials in patients with early stage breast cancer may directly address the benefit in the setting of established cancer therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/24/42378/abstract/266\">",
"     266",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=see_link\">",
"       \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cancers are preventable. Basic lifestyle changes can have a tremendous impact on the rates of cancer. The fact that such changes also protect against other chronic diseases (cardiovascular disease, stroke, and diabetes) makes the case for prevention even more compelling.",
"   </p>",
"   <p>",
"    General lifestyle recommendations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid tobacco",
"     </li>",
"     <li>",
"      Be physically active",
"     </li>",
"     <li>",
"      Maintain a healthy weight",
"     </li>",
"     <li>",
"      Eat a diet rich in fruits, vegetables, and whole grains and low in",
"      <span class=\"nowrap\">",
"       saturated/trans",
"      </span>",
"      fat",
"     </li>",
"     <li>",
"      Limit alcohol",
"     </li>",
"     <li>",
"      Protect against sexually transmitted infections",
"     </li>",
"     <li>",
"      Avoid excess sun",
"     </li>",
"     <li>",
"      Get regular screening for breast, cervical, and colorectal cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific factors associated with cancer risk include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tobacco use is responsible for 90 percent of all lung cancer deaths and is tied to multiple other cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tobacco use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The association of dietary fat, fruits, vegetables, and fiber with cancer risk is largely unconfirmed. Red meat consumption may promote colorectal cancer and a high intake of tomatoes probably decreases prostate cancer risk. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vitamin D may reduce the risk of colorectal cancer. Calcium intake, at a minimum of 700",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      may protect against colorectal cancer but high calcium intake (&gt;2000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      increases risk for prostate cancer. Folate in diet has been associated with a decreased risk of colon and breast cancer, especially in women who drink alcohol; data on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      or multivitamin supplementation are inconsistent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vitamins and micronutrients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol intake, even in moderate quantities, increases the risk for colon, breast, esophageal, and oropharyngeal cancer. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical activity is inversely related to risk for colon and breast cancer. Excess weight increases the risk of multiple cancers. (See",
"      <a class=\"local\" href=\"#H349227082\">",
"       'Physical activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H349227125\">",
"       'Excess weight'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin cancer is directly related to sun exposure, and melanoma rates are increasing. A history of blistering sunburns is of particular risk for melanoma; cumulative sun exposure has more impact on non-melanoma cancers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Excess sun exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPV, HCV, HTLV1, HIV, EBV, and H pylori have been linked to human cancers. Exposure prevention, screening, vaccination for HPV, and early treatment for abnormal cervical findings and HIV infection can prevent cancer. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemoprevention may be helpful in high-risk patients, but risks and benefits should be weighed carefully.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and NSAIDs offer protection against adenomatous polyps and colorectal cancer, and long-term use in low doses likely decreases cancer-related mortality risk from other solid tumors. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Chemoprevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      decreases incidence of breast cancer in high-risk women but increases the risk for thromboembolic disease and early-stage endometrial cancer.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      is an alternative but has not been evaluated in premenopausal women. Aromatase inhibitors also decrease the risk of breast cancer but may cause muscle and joint pain and are not recommended for premenopausal women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/2\">",
"      Brawley OW. Avoidable cancer deaths globally. CA Cancer J Clin 2011; 61:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/4\">",
"      Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/5\">",
"      Harvard Report on Cancer Prevention Volume 2: Prevention of Human Cancer. Cancer Causes and Control 1997; 8:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/6\">",
"      Danaei G, Vander Hoorn S, Lopez AD, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/7\">",
"      Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/8\">",
"      Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/9\">",
"      Ford ES, Bergmann MM, Kr&ouml;ger J, et al. Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. Arch Intern Med 2009; 169:1355.",
"     </a>",
"    </li>",
"    <li>",
"     World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/11\">",
"      Romaguera D, Vergnaud AC, Peeters PH, et al. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. Am J Clin Nutr 2012; 96:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/12\">",
"      Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med 2012; 4:127rv4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/13\">",
"      Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs--United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002; 51:300.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer Facts and Figures 2005. American Cancer Society, Atlanta, GA 2005.",
"    </li>",
"    <li>",
"     Colditz G, Ryan CT, Dart CH. Lifestyle Behaviors Contributing to the Burden of Cancer. In: Fulfilling the Potential of Cancer Prevention and Early Detection, Curry S, Byers T, Hewitt M (Eds), The National Academies Press, Washington, DC 2003.",
"    </li>",
"    <li>",
"     Thun M, Day-Lally C, Myers E, et al.. Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). In: Changes in Cigarette-related Disease Risk and their Implications for Prevention and Control, Burns D, Garfinkel L, Samet J (Eds), National Institute of Health, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/18\">",
"      Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 45 Suppl 2:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/19\">",
"      Brownson RC, Novotny TE, Perry MC. Cigarette smoking and adult leukemia. A meta-analysis. Arch Intern Med 1993; 153:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/20\">",
"      Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003; 12:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/21\">",
"      Giovannucci E, Rimm EB, Ascherio A, et al. Smoking and risk of total and fatal prostate cancer in United States health professionals. Cancer Epidemiol Biomarkers Prev 1999; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Atlanta, GA 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/23\">",
"      Samet JM. The 1990 Report of the Surgeon General: The Health Benefits of Smoking Cessation. Am Rev Respir Dis 1990; 142:993.",
"     </a>",
"    </li>",
"    <li>",
"     Curry S, Byers T, Hewitt M. Fulfilling the potential of cancer prevention and early detection. National Academic Press; Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/25\">",
"      The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996; 275:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/26\">",
"      A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/27\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/28\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/29\">",
"      Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/30\">",
"      International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/31\">",
"      English DR, Armstrong BK. Identifying people at high risk of cutaneous malignant melanoma: results from a case-control study in Western Australia. Br Med J (Clin Res Ed) 1988; 296:1285.",
"     </a>",
"    </li>",
"    <li>",
"     www.who.int/mediacentre/factsheets/fs287/en/ (Accessed on August 13, 2009).",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Promoting Physical Activity: A Guide for Community Action. US Department of Health and Human Services, Champaign, IL 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/34\">",
"      Harvard Report on Cancer Prevention. Volume 1: Causes of human cancer. Cancer Causes Control 1996; 7 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/35\">",
"      Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/36\">",
"      Inoue M, Yamamoto S, Kurahashi N, et al. Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 2008; 168:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/37\">",
"      Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009; 100:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/38\">",
"      Colditz GA, Cannuscio CC, Frazier AL. Physical activity and reduced risk of colon cancer: implications for prevention. Cancer Causes Control 1997; 8:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/39\">",
"      Dallal CM, Sullivan-Halley J, Ross RK, et al. Long-term recreational physical activity and risk of invasive and in situ breast cancer: the California teachers study. Arch Intern Med 2007; 167:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/40\">",
"      Chao A, Connell CJ, Jacobs EJ, et al. Amount, type, and timing of recreational physical activity in relation to colon and rectal cancer in older adults: the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2004; 13:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/41\">",
"      Boyle T, Keegel T, Bull F, et al. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/42\">",
"      Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer 2011; 104:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/43\">",
"      Mart&iacute;nez ME, Giovannucci E, Spiegelman D, et al. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst 1997; 89:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/44\">",
"      Rockhill B, Willett WC, Hunter DJ, et al. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med 1999; 159:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/45\">",
"      Hu FB, Willett WC, Li T, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/46\">",
"      Antonelli JA, Jones LW, Ba&ntilde;ez LL, et al. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol 2009; 182:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/47\">",
"      Patel AV, Rodriguez C, Jacobs EJ, et al. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomarkers Prev 2005; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/48\">",
"      McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994; 3:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/49\">",
"      Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995; 122:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/50\">",
"      Mart&iacute;nez ME, Heddens D, Earnest DL, et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst 1999; 91:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/51\">",
"      Maruti SS, Willett WC, Feskanich D, et al. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst 2008; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/52\">",
"      Bernstein L. Exercise and breast cancer prevention. Curr Oncol Rep 2009; 11:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/53\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/54\">",
"      Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/55\">",
"      Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/56\">",
"      Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/57\">",
"      Campbell PT, Cotterchio M, Dicks E, et al. Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:1735-44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/58\">",
"      Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/59\">",
"      Key TJ. Fruit and vegetables and cancer risk. Br J Cancer 2011; 104:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/60\">",
"      Mart&iacute;nez ME, Marshall JR, Giovannucci E. Diet and cancer prevention: the roles of observation and experimentation. Nat Rev Cancer 2008; 8:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/61\">",
"      Kushi L, Giovannucci E. Dietary fat and cancer. Am J Med 2002; 113 Suppl 9B:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/62\">",
"      Beresford SA, Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/63\">",
"      Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/64\">",
"      Franceschi S, Dal Maso L, Augustin L, et al. Dietary glycemic load and colorectal cancer risk. Ann Oncol 2001; 12:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/65\">",
"      Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 2001; 10:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/66\">",
"      Giovannucci E, Goldin B. The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 1997; 66:1564S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/67\">",
"      Giovannucci E, Rimm EB, Stampfer MJ, et al. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 1994; 54:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/68\">",
"      Willett WC, Stampfer MJ, Colditz GA, et al. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990; 323:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/69\">",
"      Norat T, Bingham S, Ferrari P, et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005; 97:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/70\">",
"      Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. JAMA 2005; 293:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/71\">",
"      Sinha R, Cross AJ, Graubard BI, et al. Meat intake and mortality: a prospective study of over half a million people. Arch Intern Med 2009; 169:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/72\">",
"      Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012; 172:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/73\">",
"      Benetou V, Orfanos P, Lagiou P, et al. Vegetables and fruits in relation to cancer risk: evidence from the Greek EPIC cohort study. Cancer Epidemiol Biomarkers Prev 2008; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/74\">",
"      Takachi R, Inoue M, Ishihara J, et al. Fruit and vegetable intake and risk of total cancer and cardiovascular disease: Japan Public Health Center-Based Prospective Study. Am J Epidemiol 2008; 167:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/75\">",
"      Hung HC, Joshipura KJ, Jiang R, et al. Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 2004; 96:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/76\">",
"      George SM, Park Y, Leitzmann MF, et al. Fruit and vegetable intake and risk of cancer: a prospective cohort study. Am J Clin Nutr 2009; 89:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/77\">",
"      Boffetta P, Couto E, Wichmann J, et al. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2010; 102:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/78\">",
"      Feskanich D, Ziegler RG, Michaud DS, et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J Natl Cancer Inst 2000; 92:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/79\">",
"      Smith-Warner SA, Spiegelman D, Yaun SS, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA 2001; 285:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/80\">",
"      Michels KB, Joshipura KJ, Rosner BA, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000; 92:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/81\">",
"      Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 2007; 99:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/82\">",
"      Lee JE, Chan AT. Fruit, vegetables, and folate: cultivating the evidence for cancer prevention. Gastroenterology 2011; 141:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/83\">",
"      Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011; 343:d6617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/84\">",
"      Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999; 91:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/85\">",
"      Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA 2002; 287:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/86\">",
"      Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007; 99:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/87\">",
"      Ilic D, Forbes KM, Hassed C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev 2011; :CD008007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/88\">",
"      Kristal AR. Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. J Urol 2004; 171:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/89\">",
"      Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008; 98:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/90\">",
"      Yang G, Shu XO, Chow WH, et al. Soy food intake and risk of lung cancer: evidence from the Shanghai Women's Health Study and a meta-analysis. Am J Epidemiol 2012; 176:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/91\">",
"      Fink BN, Steck SE, Wolff MS, et al. Dietary flavonoid intake and breast cancer risk among women on Long Island. Am J Epidemiol 2007; 165:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/92\">",
"      Larsson SC, Orsini N, Wolk A. Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Int J Cancer 2006; 118:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/93\">",
"      Newcomb PA, Egan KM. Dairy food and ovarian cancer risk. Lancet 2006; 367:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/94\">",
"      Mommers M, Schouten LJ, Goldbohm RA, van den Brandt PA. Dairy consumption and ovarian cancer risk in the Netherlands Cohort Study on Diet and Cancer. Br J Cancer 2006; 94:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/95\">",
"      Shin MH, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 2002; 94:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/96\">",
"      Knekt P, J&auml;rvinen R, Sepp&auml;nen R, et al. Intake of dairy products and the risk of breast cancer. Br J Cancer 1996; 73:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/97\">",
"      Boyd NF, Martin LJ, Noffel M, et al. A meta-analysis of studies of dietary fat and breast cancer risk. Br J Cancer 1993; 68:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/98\">",
"      Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007; 167:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/99\">",
"      Missmer SA, Smith-Warner SA, Spiegelman D, et al. Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies. Int J Epidemiol 2002; 31:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/100\">",
"      Park Y, Leitzmann MF, Subar AF, et al. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern Med 2009; 169:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/101\">",
"      Rimm EB, Ascherio A, Giovannucci E, et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996; 275:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/102\">",
"      Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary heart disease among women. JAMA 1999; 281:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/103\">",
"      Salmer&oacute;n J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997; 20:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/104\">",
"      Salmer&oacute;n J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997; 277:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/105\">",
"      Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/106\">",
"      Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999; 340:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/107\">",
"      Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/108\">",
"      Asano T, McLeod RS. Dietary fibre for the prevention of colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2002; :CD003430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/109\">",
"      Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/110\">",
"      Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/111\">",
"      Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/112\">",
"      George SM, Mayne ST, Leitzmann MF, et al. Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. Am J Epidemiol 2009; 169:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/113\">",
"      Augustin LS, Dal Maso L, La Vecchia C, et al. Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study. Ann Oncol 2001; 12:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/114\">",
"      Jonas CR, McCullough ML, Teras LR, et al. Dietary glycemic index, glycemic load, and risk of incident breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2003; 12:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/115\">",
"      Holmes MD, Liu S, Hankinson SE, et al. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol 2004; 159:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/116\">",
"      Nielsen TG, Olsen A, Christensen J, et al. Dietary carbohydrate intake is not associated with the breast cancer incidence rate ratio in postmenopausal Danish women. J Nutr 2005; 135:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/117\">",
"      Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. Cancer Epidemiol Biomarkers Prev 2004; 13:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/118\">",
"      Romieu I, Ferrari P, Rinaldi S, et al. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2012; 96:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/119\">",
"      Dong JY, Qin LQ. Dietary glycemic index, glycemic load, and risk of breast cancer: meta-analysis of prospective cohort studies. Breast Cancer Res Treat 2011; 126:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/120\">",
"      Shikany JM, Flood AP, Kitahara CM, et al. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Cancer Causes Control 2011; 22:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/121\">",
"      Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. J Natl Cancer Inst 2004; 96:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/122\">",
"      Slattery ML, Curtin K, Ma K, et al. Diet activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomarkers Prev 2002; 11:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/123\">",
"      Terry PD, Jain M, Miller AB, et al. Glycemic load, carbohydrate intake, and risk of colorectal cancer in women: a prospective cohort study. J Natl Cancer Inst 2003; 95:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/124\">",
"      Michaud DS, Fuchs CS, Liu S, et al. Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2005; 14:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/125\">",
"      Aune D, Chan DS, Lau R, et al. Carbohydrates, glycemic index, glycemic load, and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Cancer Causes Control 2012; 23:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/126\">",
"      MacLean CH, Newberry SJ, Mojica WA, et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 2006; 295:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/127\">",
"      Andreeva VA, Touvier M, Kesse-Guyot E, et al. B vitamin and/or &omega;-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial. Arch Intern Med 2012; 172:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/128\">",
"      Wu S, Feng B, Li K, et al. Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med 2012; 125:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/129\">",
"      Vastag B. Nutrients for prevention: negative trials send researchers back to drawing board. J Natl Cancer Inst 2009; 101:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/130\">",
"      Coulter ID, Hardy ML, Morton SC, et al. Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med 2006; 21:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/131\">",
"      NIH State-of-the-Science Panel. National Institutes of Health State-of-the-science conference statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 2006; 145:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/132\">",
"      Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst 2009; 101:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/133\">",
"      Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med 2009; 169:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/134\">",
"      Park SY, Murphy SP, Wilkens LR, et al. Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. Am J Epidemiol 2011; 173:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/135\">",
"      Gaziano JM, Sesso HD, Christen WG, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2012; 308:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/136\">",
"      Huang HY, Caballero B, Chang S, et al. The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. Ann Intern Med 2006; 145:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/137\">",
"      Qiao YL, Dawsey SM, Kamangar F, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009; 101:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/138\">",
"      Chung M, Lee J, Terasawa T, et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/139\">",
"      Freedman DM, Looker AC, Abnet CC, et al. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010; 70:8587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/140\">",
"      Harris DM, Go VL. Vitamin D and colon carcinogenesis. J Nutr 2004; 134:3463S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/141\">",
"      Mart&iacute;nez ME. Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Cancer Res 2005; 166:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/142\">",
"      Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/143\">",
"      Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/144\">",
"      Kampman E, Slattery ML, Caan B, Potter JD. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). Cancer Causes Control 2000; 11:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/145\">",
"      Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/146\">",
"      Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004; 96:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/147\">",
"      Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998; 9:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/148\">",
"      Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/149\">",
"      Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008; 100:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/150\">",
"      Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/151\">",
"      Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/152\">",
"      Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/153\">",
"      Pietinen P, Malila N, Virtanen M, et al. Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 1999; 10:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/154\">",
"      Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/155\">",
"      Wu K, Willett WC, Fuchs CS, et al. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002; 94:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/156\">",
"      Shaukat A, Scouras N, Sch&uuml;nemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol 2005; 100:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/157\">",
"      Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/158\">",
"      Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/159\">",
"      Mart&iacute;nez ME, Jacobs ET. Calcium supplementation and prevention of colorectal neoplasia: lessons from clinical trials. J Natl Cancer Inst 2007; 99:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/160\">",
"      Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/161\">",
"      Giovannucci E, Rimm EB, Wolk A, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/162\">",
"      Chan JM, Stampfer MJ, Ma J, et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001; 74:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/163\">",
"      Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 2003; 12:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/164\">",
"      Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA. Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 1999; 80:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/165\">",
"      Chan JM, Pietinen P, Virtanen M, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000; 11:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/166\">",
"      Clark LC. The epidemiology of selenium and cancer. Fed Proc 1985; 44:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/167\">",
"      Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr 2005; 135:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/168\">",
"      Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. Gastroenterology 2010; 138:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/169\">",
"      Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 2008; 168:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/170\">",
"      Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/171\">",
"      Bardia A, Tleyjeh IM, Cerhan JR, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc 2008; 83:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/172\">",
"      Myung SK, Kim Y, Ju W, et al. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. Ann Oncol 2010; 21:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/173\">",
"      Klein EA, Thompson IM, Lippman SM, et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis 2000; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/174\">",
"      Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/175\">",
"      Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/176\">",
"      Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/177\">",
"      Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009; 301:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/178\">",
"      Slattery ML, Potter JD, Samowitz W, et al. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999; 8:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/179\">",
"      Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 2006; 131:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/180\">",
"      Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993; 85:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/181\">",
"      Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998; 129:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/182\">",
"      Zhang SM, Moore SC, Lin J, et al. Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women. Am J Epidemiol 2006; 163:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/183\">",
"      Larsson SC, H&aring;kansson N, Giovannucci E, Wolk A. Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst 2006; 98:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/184\">",
"      Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Inst 2006; 98:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/185\">",
"      Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/186\">",
"      Ebbing M, B&oslash;naa KH, Nyg&aring;rd O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009; 302:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/187\">",
"      Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009; 101:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/188\">",
"      Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/189\">",
"      Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50000 individuals. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/190\">",
"      Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. JAMA 2010; 303:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/191\">",
"      Johansson M, Relton C, Ueland PM, et al. Serum B vitamin levels and risk of lung cancer. JAMA 2010; 303:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/192\">",
"      Giovannucci E, Rimm EB, Ascherio A, et al. Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 1995; 87:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/193\">",
"      Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/194\">",
"      Baglietto L, English DR, Gertig DM, et al. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. BMJ 2005; 331:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/195\">",
"      Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/196\">",
"      van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995; 24:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/197\">",
"      Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994; 56:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/198\">",
"      Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/199\">",
"      The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/200\">",
"      Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/201\">",
"      Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/202\">",
"      Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/203\">",
"      Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/204\">",
"      Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst 2009; 101:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/205\">",
"      Zhang SM, Lee IM, Manson JE, et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 2007; 165:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/206\">",
"      Chen WY, Rosner B, Hankinson SE, et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011; 306:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/207\">",
"      Sch&uuml;tze M, Boeing H, Pischon T, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011; 342:d1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/208\">",
"      Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/209\">",
"      Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997; 337:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/210\">",
"      Bagnardi V, Rota M, Botteri E, et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013; 24:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/211\">",
"      Theruvathu JA, Jaruga P, Nath RG, et al. Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde. Nucleic Acids Res 2005; 33:3513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/212\">",
"      Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     Mueller N. Infectious Agents. In: Cancer Prevention: The Causes and Prevention of Cancer, Colditz G, Hunter D (Eds), Springer, 2000. p.63.",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses, Lyon, France 1995. Vol 64.",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Hepatitis Viruses, Lyon, France 1994. Vol 59.",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Immunodeficiency Viruses and Human T-Cell Lumphotropic Viruses, Lyon, France 1996. Vol 67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/217\">",
"      Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228.",
"     </a>",
"    </li>",
"    <li>",
"     International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, Liver Flukes, and Helicobacter Pylori, Lyon, France 1994. Vol 61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/219\">",
"      Malnati MS, Dagna L, Ponzoni M, Lusso P. Human herpesvirus 8 (HHV-8/KSHV) and hematologic malignancies. Rev Clin Exp Hematol 2003; 7:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/220\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin. Cervical Cytology screening. Number 45, August 2003. Int J Gynaecol Obstet 2003; 83:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/221\">",
"      Little RF. AIDS-related non-Hodgkin's lymphoma: etiology, epidemiology, and impact of highly active antiretroviral therapy. Leuk Lymphoma 2003; 44 Suppl 3:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/222\">",
"      Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/223\">",
"      Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/224\">",
"      Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147.",
"     </a>",
"    </li>",
"    <li>",
"     International Agency for Research on Cacner (IARC). IARC Monographcs on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, Liver Flukes, and Helicobacter Pylori, Lyon, France 1994. Vol 61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/226\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/227\">",
"      Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007; 99:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/228\">",
"      Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003; 95:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/229\">",
"      Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/230\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/231\">",
"      Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/232\">",
"      Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361:296.",
"     </a>",
"    </li>",
"    <li>",
"     Gail Model tool  for breast cancer risk assessment available online at www.cancer.gov/bcrisktool/ (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/234\">",
"      Nelson HD, Fu R, Griffin JC, et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med 2009; 151:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/235\">",
"      U.S. Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 2002; 137:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/236\">",
"      Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/237\">",
"      Goss PE, Ingle JN, Al&eacute;s-Mart&iacute;nez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/238\">",
"      J&auml;nne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/239\">",
"      Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 2003; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/240\">",
"      Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/241\">",
"      Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/242\">",
"      Chan AT, Lippman SM. Aspirin and colorectal cancer prevention in Lynch syndrome. Lancet 2011; 378:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/243\">",
"      Sandler RS. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Important Adv Oncol 1996; :123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/244\">",
"      Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/245\">",
"      Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/246\">",
"      Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/247\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/248\">",
"      U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 146:361.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.org/docroot/CRI/content/CRI_2_4_2X_Can_colon_and_rectum_cancer_be_prevented.asp (Accessed on March 22, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/250\">",
"      Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/251\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/252\">",
"      Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/253\">",
"      Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/254\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/255\">",
"      Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/256\">",
"      Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5&alpha;-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011; 365:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/257\">",
"      Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/258\">",
"      Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/259\">",
"      Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/260\">",
"      Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/261\">",
"      Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7:e33411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/262\">",
"      Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012; 107:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/263\">",
"      Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/264\">",
"      Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009; 8:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/24/42378/abstract/265\">",
"      V&aacute;zquez-Mart&iacute;n A, Oliveras-Ferraros C, del Barco S, et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009; 11:455.",
"     </a>",
"    </li>",
"    <li>",
"     Metformin hydrochloride in treating patients with early-stage breast cancer. file://clinicaltrials.gov/ct2/show/NCT01101438?term=metformin+breast+cancer&amp;rank=4.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6893 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42378=[""].join("\n");
var outline_f41_24_42378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TOBACCO USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tobacco prevention and cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXCESS SUN EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendations for sun protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349227082\">",
"      PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349227125\">",
"      EXCESS WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Red meat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fruits and vegetables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dairy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fiber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Glycemic load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Omega-3 fatty acids and dietary fish",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VITAMINS AND MICRONUTRIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prostate and breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Total cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Selenium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34459741\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Folate and other B vitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Folate in alcohol users",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ALCOHOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6644636\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Aspirin and other anti-inflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Other cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      5-Alpha reductase inhibitors and prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28310607\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6893|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/34/16942\" title=\"figure 1\">",
"      RR breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23529?source=related_link\">",
"      Aspirin in the primary prevention of cardiovascular disease and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2791?source=related_link\">",
"      Pathobiology of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9610?source=related_link\">",
"      Risk factors for type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30138?source=related_link\">",
"      Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_24_42379="Clin Applications SPRMs";
var content_f41_24_42379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical applications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Short-term (usually single dose administration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Termination of first trimester pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Termination of second trimester pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menstrual regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early and late fetal demise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potential use in IVF programs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Long term administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irregular bleeding induced by progestin-only contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine myoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysfunctional uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-gynecological applications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoid antagonism (potential application in burns, glucocorticoid-dependent hypertension, arthritis, glaucoma, chorioretinopathy, viral diseases possibly including AIDS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Major depression with psychotic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bipolar disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steroid receptor containing tumors (meningiomas, gliomas, leiomyosarcomas, and carcinomas of the breast, ovary, and prostate)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42379=[""].join("\n");
var outline_f41_24_42379=null;
var title_f41_24_42380="Lab findings thalassemias";
var content_f41_24_42380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The thalassemias: Genetic, clinical, and laboratory findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        MCV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hb electrophoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Alpha thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silent carrier",
"       </td>",
"       <td>",
"        &alpha; &alpha; / &alpha; -",
"       </td>",
"       <td>",
"        NL",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        <p>",
"         Normal",
"        </p>",
"        <p>",
"         &lt;3 percent Hb Barts at birth",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trait",
"       </td>",
"       <td>",
"        <p>",
"         &alpha; &alpha; / - - or",
"        </p>",
"        <p>",
"         &alpha; - / &alpha; -",
"        </p>",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        <p>",
"         Normal",
"        </p>",
"        <p>",
"         3 to 8 percent Hb Barts at birth",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hb H disease (deletional)",
"       </td>",
"       <td>",
"        &alpha; - / - -",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        <p>",
"         5 to 30 percent Hb H present in adults",
"        </p>",
"        <p>",
"         20 to 40 percent Hb Barts at birth",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major (fetal hydrops)",
"       </td>",
"       <td>",
"        - - / - -",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Fatal",
"       </td>",
"       <td>",
"        <p>",
"         Hb Barts, Hb Portland, and Hb H present",
"        </p>",
"        <p>",
"         Hb A, Hb F, and Hb A2 are absent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Beta thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trait",
"       </td>",
"       <td>",
"        <sub>",
"         &beta;",
"        </sub>",
"        /",
"        <sub>",
"         &beta;",
"        </sub>",
"        &deg;",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Hb A2 increased (3.5 to 7 percent)",
"        </p>",
"        <p>",
"         Hb F increased in about 50 percent of patients",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermedia",
"       </td>",
"       <td>",
"        <sub>",
"         &beta;",
"        </sub>",
"        <sup>",
"         +",
"        </sup>",
"        /",
"        <sub>",
"         &beta;",
"        </sub>",
"        <sup>",
"         +",
"        </sup>",
"        and others*",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major",
"       </td>",
"       <td>",
"        <sub>",
"         &beta;",
"        </sub>",
"        &deg; /",
"        <sub>",
"         &beta;",
"        </sub>",
"        &deg;",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        <p>",
"         Hb A absent",
"        </p>",
"        <p>",
"         Only Hb A2 and Hb F are present",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCV: mean corpuscular volume; Hb: hemoglobin; NL: normal;",
"     <sub>",
"      &beta;",
"     </sub>",
"     <sup>",
"      +",
"     </sup>",
"     : thalassemic gene producing some",
"     <sub>",
"      &beta;",
"     </sub>",
"     -chain;",
"     <sub>",
"      &beta;",
"     </sub>",
"     &deg;: thalassemic gene producing no",
"     <sub>",
"      &beta;",
"     </sub>",
"     -chain.",
"     <br>",
"      * See text for multiple other genotypes.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen A Landaw, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42380=[""].join("\n");
var outline_f41_24_42380=null;
var title_f41_24_42381="Contents: Psychiatry";
var content_f41_24_42381=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Psychiatry",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Psychiatry",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"mobipreview.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?21/60/22478\">",
"         Anxiety disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?13/24/13710\">",
"         Bipolar disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?0/7/122\">",
"         Child and adolescent mental disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?3/42/3759\">",
"         Depressive disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?30/60/31693\">",
"         Dissociative disorders",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?2/31/2558\">",
"         Eating disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?26/47/27389\">",
"         Impulse control disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?5/7/5246\">",
"         Mental and medical disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?34/50/35629\">",
"         Personality disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?4/1/4126\">",
"         Psychotic disorders",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27053\">",
"         Sexual and gender identity disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?32/17/33053\">",
"         Somatoform disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?16/56/17294\">",
"         Substance use disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?12/5/12372\">",
"         What's new in psychiatry",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-95ED13809F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_24_42381=[""].join("\n");
var outline_f41_24_42381=null;
var title_f41_24_42382="Gram stain CSF 3 with answer";
var content_f41_24_42382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and small, pleomorphic, gram-negative coccobacilli.",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42382=[""].join("\n");
var outline_f41_24_42382=null;
var title_f41_24_42383="Standard cricothyrotomy step five";
var content_f41_24_42383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step five",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <font class=\"red\">",
"     <font color=\"black\">",
"      Insert the Trousseau dilator and open to expand the incision vertically.",
"     </font>",
"    </font>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_24_42383=[""].join("\n");
var outline_f41_24_42383=null;
